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Abstract 
Systemic neuromodulatory medications (NMs) are the conventional 
management modality of neuropathic orofacial pain (NOP). Topical 
administration of NMs such as amitriptyline, carbamazepine and gabapentin 
have been reported to show promising results when used with NOP, however, 
the effect of exposure of oral mucosa and skin to topical NMs has not been 
examined and is therefore unlicensed. The aims of the research contained 
within this thesis were to: a) investigate the effects of the aforementioned NMs 
on cell lines and 3D tissue relevant to the orofacial tissue in vitro; b) conduct a 
preliminary study using RNA extracted from human gingival tissue to investigate 
whether the potential therapeutic targets for these NMs were expressed.  
Cellular viability was measured using alamarBlue®, testing the effects of NMs 
on monolayer cell culture (2D): human skin and oral keratinocytes and mouse 
fibroblasts. Effects on cell counts were investigated by a CCK-8 assay. 
Morphological changes and cytokine expression were investigated using 
scanning electron microscopy and antibody array, respectively. Human gingival 
tissue biopsy was used to investigate the expression of receptors at the mRNA 
level using PCR. 
Amitriptyline exposure was found to decrease cellular viability and count, along 
with morphological changes as opposed to carbamazepine and gabapentin 
which had little demonstrable effects. Amitriptyline’s cytotoxic effect was 
confirmed using 3D oral mucosa models. Amitriptyline’s effect on 3D models 
was then further examined using immunohistochemistry (H&E, anti-caspase 3 
antibodies) and immunofluorescence (anti-amitriptyline antibody). In the 3D 
model, amitriptyline caused apoptosis after repeated exposure, but was able to 
traverse tissue barriers, which was also confirmed by High Performance Liquid 
Chromatography (HPLC). 
The results of preliminary genetic investigations suggested the expression of 
the most receptors analysed, this suggests that further studies are required to 
investigate the efficacy of the topical route as a treatment for NOP. 
The overall results demonstrate amitriptyline toxicity and avoiding topical 
amitriptyline is therefore likely to be advisable. Carbamazepine and gabapentin 
exposure were less harmful and possibly more suitable topical choices, but 
further studies need to be conducted.  
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Chapter: 1 Review of literature 
1.1 Pain   
Pain is a complicated biopsychosocial experience, starts as a noxious stimulus, 
transduced and transmitted to the sensory cortex (nociception). The sensation 
and recognition of pain in the sensory cortex is then processed and reported as 
the pain experience (Renton, 2015).  
The perceptual biological activity of pain, is managed by peripheral and central 
complex network of neurons and transmitters (Basbaum and Woolf, 1999; 
Basbaum et al., 2009). Noxious stimuli transduction starts as molecular and 
signalling interaction at the peripheral nerve endings. These nerve endings 
express various receptors and ion channels with major role in pain 
pathophysiology. With increased understanding of these peripheral activities, 
peripheral receptors and ion channels have been raised as possible targets for 
topical treatment in chronic pain management such as neuropathic pain (NP). 
The topical modality was found feasible and promising as a treatment of NP, 
with fast action and low side effect profile (Heir et al., 2008; Nasri-Heir et al., 
2013; Zur, 2014). 
This chapter describes the various types and mechanisms of pain in the 
orofacial region with a more in-depth discussion of neuropathic pain (NP) and 
the potential mechanisms and role of topical treatment in this type of orofacial 
pain.  
1.1.1 Pain definition and types 
Pain is a subjective experience, which impairs the patient’s life through 
emotional, sensory and behavioural impacts. It is defined by The International 
Association for the Study of Pain (IASP) as “an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage” (Merskey and Bogduk, 2012). 
According to the duration of pain it can either be defined as acute or chronic. 
Acute pain begins quickly as seen after injury or surgery and lasts for short 
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duration. It is considered an adaptive, protective, mechanism until healing is 
completed (De Leeuw and Klasser, 2013). Chronic pain according to IASP is 
pain persisting for 3 months or more, that is beyond the normal healing period. 
Persistent pain may cause neuroplastic and behavioural changes, which may 
then make the pain more difficult to manage (Flor, 2003; Merskey and Bogduk, 
2012; De Leeuw and Klasser, 2013).  
Pain may be classified according to aetiology and sequelae into three main 
types (Costigan et al., 2009; Woolf, 2010): 
 
1. Nociceptive pain: acting as a protective system, which begins operating 
in response to primary sensory neurons’ exposure to different noxious 
stimuli. 
2. Adaptive pain sensation: develops in the healing period following tissue 
injury during which even innocuous stimuli produce pain as a protective 
mechanism from further damage. 
3. Maladaptation or dysfunction of nervous system for example neuropathic 
pain. 
1.1.2 Mechanism and pathway of pain in the orofacial region 
The trigeminal nerve, through its three divisions the ophthalmic, maxillary and 
mandibular, represents the main conduit for the pain signal conduction in the 
orofacial region Figure 1.1, (Sessle, 2000). The very first aspect of pain is 
nociception where external noxious stimulation of the specialized nerve endings 
of primary afferent neurons (nociceptors) in the trigeminal system induces 
depolarization and action potentials in the nociceptors (the afferent nerve fibres 
ending). The impulse then propagates to the trigeminal ganglia where the cell 
bodies of primary afferent neurons are located (Basbaum and Woolf, 1999; 
Julius and Basbaum, 2001; De Leeuw and Klasser, 2013). 
Nociceptors are defined by IASP as “a high-threshold sensory receptor of the 
peripheral somatosensory nervous system that is capable of transducing and 
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encoding noxious stimuli” (Merskey and Bogduk, 2012). There are two types of 
nociceptors responsible for pain transduction: the medium diameter lightly 
myelinated A (A-delta) fibres which rapidly conduct impulses and are 
responsible for the first pain response. The second type of nociceptors are 
unmyelinated small diameter C-fibres which are characterized by slow 
conduction of impulses and responsible for second pain response (Julius and 
Basbaum, 2001). Both C-fibres and A fibres respond with high threshold to the 
noxious stimuli provoking nociceptive pain dull and sharp respectively (harmful 
sensation). The C-fibres are polymodal, therefore responding to a range of 
stimuli including chemical, thermal and mechanical. The A fibres, however, 
mainly respond to thermal and mechanical stimuli (Julius and Basbaum, 2001; 
Woolf and Ma, 2007; Dubin and Patapoutian, 2010). Different tissues  
receptors may respond differently for example  in teeth where any stimulus to 
pulp is considered noxious and provokes pain (Julius and Basbaum, 2001). The 
primary afferent neurons travel into and through the trigeminal ganglion with 
very little crossover entering into the brainstem and the Trigeminal Nuclear 
Complex (TNC) through the sensory nerve root from the trigeminal ganglion.  
Within the TNC, they synapse with second-order neurons in the sub nucleus 
caudalis (SN caudalis). Along with SN oralis and SN interpolaris, the SN 
caudalis forms the spinal sensory nucleus of the trigeminal nuclear complex. 
The two types of second-order neurons: nociceptive–specific (NS) and wide 
dynamic range neurons (WDR) transfer pain impulses to the higher brain 
centres through the antero-lateral spinothalamic tract, feeding back to the other 
two trigeminal sensory nuclei, the Mesencephalic and Principal nuclei, which 
have a major role in proprioception.  
SN caudalis transfers pain impulses to the higher brain centres for perception 
and response by one of two pathways according to the pain type. Sharp and 
fast pain impulses transfer by ascending WDR neurons through the 
neospinothalamic tract directly to the thalamus and then to the cortex. A 
descending impulse is then immediately produced to the motor neurons 
presenting as muscle contraction as in flinch response and blinking. 
Dull pain transfers by NS neurons through the paleospinothalamic tract and 
trough reticular formation before it reaches thalamus, cortex, limbic structure 
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and hypothalamus for perception and response (Okeson, 2005; De Leeuw and 
Klasser, 2013). 
 
 
 
 
Figure 1.1: Major pain pathway in orofacial region through trigeminal nerve. 
Reproduced from Sessle (2000) with permission, Appendix A. 1. 
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1.1.3 Sensitization and neuroplasticity 
Inflammation following trauma or surgery in the orofacial region causes the 
release of inflammatory mediators, creating the so-called “inflammatory soup” 
which includes inflammatory mediators such as prostaglandins and bradykinin 
(Verdu et al., 2008). These mediators induce changes in the nociceptors 
characteristics and can increase nociceptive transmission centrally by a number 
of mechanisms including: lowering the stimulation threshold, increasing the 
likelihood of spontaneous activity, and recruitment of silent nociceptors. This 
process is known as peripheral sensitization and it is defined by IASP as an 
“increased responsiveness and reduced threshold of nociceptive neurons in the 
periphery to the stimulation of their receptive fields” (Merskey and Bogduk, 
2012).  
Due to the amplified input from peripheral nociceptors central neurons become 
more active and sensitive with modulation of synaptic excitability and transmitter 
production/ release in the brain stem. Long lasting excitability and inflammation 
induce changes in receptors and cytokine expression in addition to the mutation 
of receptors’ genes  (Ji and Strichartz, 2004). IASP defined central sensitization 
as “Increased responsiveness of nociceptive neurons in the central nervous 
system to their normal or subthreshold afferent input” (Petersen-Felix and 
Curatolo, 2002; Merskey and Bogduk, 2012). 
The previously described augmentations in the detection and perception of 
noxious stimuli and the associated chain of peripheral and central modulation of 
nociception begins as reversible changes but may become permanent over time 
and thereby cause chronic pain. Concomitant to the previously described 
changes, glia and microglia cells have also been implicated (Scholz and Woolf, 
2007), both peripherally and centrally, in central sensitisation through synthesis 
and release of various cytokines and mediators that induce or maintain the 
sensitised state.  
The changes explained in the previous paragraphs are part of what is known as 
neuroplasticity which relates to the ability of nervous tissue to produce different 
changes in its structure and function in response to both internal and external 
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stimuli (Petersen-Felix and Curatolo, 2002; Chiang et al., 2011; De Leeuw and 
Klasser, 2013). 
1.2 Neuropathic pain 
The IASP has introduced a revised definition of (NP) as “Pain caused by a 
lesion or disease of the somatosensory nervous system” (Treede et al., 2008; 
Merskey and Bogduk, 2012). Clinically, patients with NP present with one or 
more types of pain and sensory disturbances:  
1. Spontaneous pain (stimulus independent): which occurs either as a 
paroxysmal shooting, electrical shock like pain or constant continuous 
burning sensation. 
2. Stimulus dependent pain: including allodynia, pain in response to 
innocuous stimuli, and hyperalgesia which is increased response to 
noxious stimuli (Jensen et al., 2001; Jensen and Baron, 2003).  
Different negative sensations can also present with the pain including 
paresthesias, hypoesthesia and hypoalgesia; some of which predominate in 
peripheral or central NP or both (Woolf and Mannion, 1999; Jensen et al., 2001; 
Jensen and Baron, 2003). 
Clinical examination is the key step in diagnosis and assessment of NP. 
Sensory assessment including: thermal, cold, pinprick and touch, is convenient 
method for initial diagnosis in chairside examination. The further 
psychophysiological and more sophisticated assessment could be applied for 
further confirmation and research purposes (Haanpää et al., 2011). Recently, 
Finnerup et al. (2016) introduced a grading system with sophisticated methods 
such as QST, and biopsy to give definitive NP diagnosis, however, that is may 
be acceptable for research centres with available budget and facility but it is 
rather difficult to apply for every clinical examination and decision including 
NOP. 
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1.2.1 Neuropathic pain Types 
Neuropathic pain can be subdivided into peripheral and central NP according to 
the site of the causative disease or lesion. 
Central neuropathic pain 
IASP defined central neuropathic pain (CNP) as “Pain caused by a lesion or 
disease of the central somatosensory nervous system“, associated with central 
nervous system (CNS) trauma and neurological conditions such as stroke and 
multiple sclerosis.  
Peripheral neuropathic pain  
Peripheral neuropathic pain (PNP) can be the result of infection, trauma or toxic 
chemicals and is defined by IASP as “pain caused by a lesion or disease of the 
peripheral somatosensory nervous” (Dworkin et al., 2003; Costigan et al., 
2009). Baron et al. (2010) proposed a further subdivision of PNP to into: focal 
/multifocal neuropathic pain as in post-traumatic neuralgia, postherpetic 
neuralgia and phantom pain; generalized peripheral neuropathic pain as in drug 
toxicity and diabetes polyneuropathy.  
Focal and multifocal PNP is a more localized entity which appears to have 
better management results with topical treatment such as lidocaine patches.  
Localized neuropathic pain 
The term “localized neuropathic pain” (LNP) came into use in response to 
clinical findings of localized and well circumscribed areas of PNP which were 
responsive to topical treatment (Dworkin et al., 2007; De Moulin et al., 2014). 
LNP is defined as a “type of neuropathic pain that is characterized by consistent 
and circumscribed area(s) of maximum pain associated with negative or 
positive sensory signs and/or spontaneous symptoms characteristic of 
neuropathic pain” (Mick et al., 2011).  
LNP is thought to be present in more than 60% of all neuropathic pain patients 
(Mick et al., 2011) and it presents as a part of PNP for example postherpetic 
neuralgia and diabetic neuropathy with an association with central plasticity 
(Casale et al., 2014; Casale and Mattia, 2014). LNP is not, however, officially 
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classified, but is often mentioned whenever topical treatment is suggested in the 
NP management guidelines (Dworkin et al., 2007; NICE, 2013; De Moulin et al., 
2014) or as Finnerup et al. (2015) termed LNP the presence of a “local pain 
generator”. 
1.2.2 Mechanisms of neuropathic pain 
Different types of NP share similar signs and symptoms of pain independent of 
their underlying causes and mechanisms. NP mechanisms include multiple 
changes and modulations, which may contribute peripherally and centrally to 
NP’s intensity and clinical picture (Finnerup et al., 2007; Baron et al., 2010).  
At the peripheral level, a lesion in the primary afferent nerve fibres is considered  
essential to initiate NP (Baron, 2006). Following this a series of mechanisms will 
develop peripheral sensitivity and give rise to spontaneous or ectopic pain. The 
spontaneous pain may be related to increase in expression of voltage-gated 
sodium channels on both injured and undamaged nerve fibres and at the same 
time lowering of the action potential threshold of these afferents (Hunt and 
Mantyh, 2001). Other ion channels, including voltage-gated potassium channels 
also undergo alteration and lead to increased excitability in primary afferents. 
Specific receptors, such as the transient receptor potential V1 (TRPV1), 
respond to thermal stimuli about 41° C under normal physiological conditions 
(Scholz and Woolf, 2002; Baron et al., 2010). Following injury these thermally 
responsive receptors tend to become downregulated on the affected neurons 
and upregulated on unaffected ones. This phenomenon explains the heat 
allodynia in which burning sensations may occur in response to normal body 
temperature and/or endogenous signalling. Cold allodynia has also, however, 
been reported in specific cases of NP which may result from upregulation of 
definite cold receptors (TRPM8) (Finnerup et al., 2007; Zagury et al., 2011). The 
inflammatory process following nerve injury and activation of microglia also 
contribute to the chronicity of NP by releasing inflammatory mediators and 
increasing sensitivity at both central and peripheral levels (Finnerup et al., 2007; 
Baron et al., 2010). 
Several changes may develop centrally as a normal consequence of 
exaggerated peripheral afferent input thereby leading to central sensitization. 
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These changes at central level may start as secondary hyperalgesia and 
allodynia are transduced by mechanosensitive receptors (A fibres and A 
fibres). The central changes may also lead to increase of synaptic strength 
through synaptic changes. At the presynaptic level there are modulations in 
synthesis of neurotransmitters and neuromodulators, and increase in calcium 
channel expression. At the postsynaptic connection there are increases in ion 
channel production, enhancing receptor density and phosphorylation of N-
methyl-D-aspartate (NMDA) subunits. Increased input from peripheral sensitivity 
may induce serial events within inhibitory pathways such as degeneration of the 
inhibitory interneurons in medullary (spinal trigeminal nucleus caudalis) and/or 
dorsal horn regions, resulting in exaggeration of postsynaptic sensitivity. The 
inhibitory transmitters accompanying the descending pathway from the cortex 
and/or hypothalamus may be also shifted from expected inhibitory action to 
more facilitation action (Campbell and Meyer, 2006; Costigan et al., 2009). 
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1.3 Orofacial pain 
Orofacial pain (OFP) is “pain associated with the hard and soft tissue of the 
head, face and neck” (De Leeuw and Klasser, 2013). It therefore occurs within 
the distribution of the trigeminal nerve sensory supply (Lavigne et al., 2005). 
Several studies investigating orofacial pain recognise its multidimensional 
nature and consider it a biopsychosocial phenomenon (Robert et al., 2008; 
Hargreaves, 2011). Many studies have attempted to identify the prevalence of 
OFP in the general population with estimates varying between 7% and 25% in 
different study populations (Macfarlane et al., 2002; Aggarwal et al., 2006; 
Benoliel et al., 2008).  
The diagnosis of OFP can present difficulties to the specialist and generalist 
alike as many disorders share similar signs and symptoms with comorbidities to 
psychological profiles which can contribute, and add, to the complexity of the 
presenting pain (Durham et al., 2007; Aggarwal et al., 2011; Hargreaves, 2011; 
De Leeuw and Klasser, 2013). Some of the diagnostic challenges can be 
related to the complex innervation of orofacial region and different, highly 
specialized, tissues that can make it difficult sometimes to identify the origin of 
the pain in addition to any comorbid psychosocial factors that may complicate 
the presenting picture further (Benoliel et al., 2008; Renton et al., 2012a). 
1.3.1 Classification of orofacial pain 
The complex nature of OFP conditions makes an easily applicable classification 
difficult. Several attempts have been made to develop a robust and applicable 
classification for OFP based on aetiology, anatomy and duration of pain, but 
with less professional satisfaction regarding research and or clinical applications 
of the resultant classification or criteria (Renton et al., 2012a). The main three 
classifications: the International Headache Society’s classification of headache 
disorders  (IHS) in 2013 (Silberstein et al., 2005; De Leeuw and Klasser, 2013; 
IHS, 2013); the disorder-specific Research Diagnostic Criteria for 
Temporomandibular Disorders (RDC/TMD) in 2013; the more generic IASP 
classification in 1994 (Dworkin and LeResche, 1992; Okeson, 2008; Merskey 
and Bogduk, 2012; Renton et al., 2012a; De Leeuw and Klasser, 2013; 
Schiffman et al., 2014). The American Academy of Orofacial Pain’s (AAOP) 
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classification tries to utilise the other preceding classifications to some extent 
and present an amalgamation of them (De Leeuw and Klasser, 2013) 
The AAOP guidelines for orofacial pain diagnosis and management  (De Leeuw 
and Klasser, 2013) subdivides OFP into the following main categories:   
1. Vascular and nonvascular Intracranial pain disorders: many of these are 
associated with life-threatening conditions such as neoplasm, hematoma.  
2. Primary headache disorders: common presentations include migraine 
and tension headache.  
3. Neuropathic pain disorders: including the episodic and continuous types. 
4. Intraoral pain disorders: the commonest form of orofacial pain. 
5. Temporomandibular disorders: main non dental cause of pain  
6. Cervical pain disorders: mostly related to the cervical spine. 
7. Extracranial and systemic causes of orofacial pain: mostly referred pains 
from associated structures such as the ears, nose and salivary glands.  
The most frequently presenting pain conditions in primary care are intraoral 
disorders, musculoskeletal disorders and NP (Scully and Felix, 2006; Bell et al., 
2008; Aggarwal et al., 2011). 
The most common orofacial pain category is intraoral disorders which includes 
odontogenic and non-odontogenic diseases affecting oral hard tissue including 
bone and tooth structure and/or oral soft tissues including the dental pulp, 
gingivae, lining mucosa, periodontal tissues, tongue and salivary glands (McNeil 
et al., 2008). After intraoral pain, temporomandibular disorders (TMD) are the 
next common category of chronic orofacial pain. Temporomandibular disorders 
(TMDs) term is defined by the AAOP as  “encompass a group of 
musculoskeletal and neuromuscular conditions  that involve the TMJs, 
masticatory muscles and all associated tissues” (De Leeuw and Klasser, 2013) 
The previous two types of pain are recognised by nervous system nociceptors 
and categorized into protective and adaptive pain types, with TMDs having the 
potential to become a maladaptive persisting sensation through a process of 
central sensitisation (Sarlani and Greenspan, 2003). One maladaptive 
sensation that is likely to be maladaptive from its inception is NP. This 
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“neuropathic pain” can impact on almost all aspects of the patients life (Treede 
et al., 2008; Costigan et al., 2009). 
1.3.2 Types of neuropathic orofacial pain 
Among various types of NOP, the following groups of NOP have been found to 
be treatable by topical neuromodulatory medications (NMs): trigeminal 
neuralgia (TN), glossopharyngeal neuralgia, postherpetic neuralgia (PHN), 
burning mouth syndrome (BMS), atypical facial pain, persistent dento alveolar 
pain (PDAP) and complex regional pain syndrome (CRPS), (Argoff, 2003; 
Bennett, 2004; Zakrzewska, 2010; Nixdorf et al., 2012a; De Leeuw and Klasser, 
2013). 
a- Trigeminal neuralgia 
Trigeminal neuralgia presents as a recurrent, severe, stabbing, mostly unilateral 
pain within the distribution of the trigeminal nerve often initiated by contact with 
a trigger zone (Durham, 2011). Recently, IHS classification has divided TN 
according to its aetiology and clinical picture into “classical trigeminal neuralgia, 
purely paroxysmal and Classical trigeminal neuralgia with concomitant 
persistent facial pain”, (IHS, 2013). Trigeminal neuralgia is mostly diagnosed as 
unilateral paroxysmal pain associated with either the 2nd or 3rd divisions of the 
trigeminal nerve, often affecting females in their seventh decade without 
identifiable cause (Lopes et al., 2002; Zakrzewska, 2010; De Leeuw and 
Klasser, 2013). It is a rare disease as reported by different epidemiological 
studies with prevalence range about 4 – 6 per 100,000 of population. However, 
higher results reported in United Kingdom and Netherlands studies, about 26 -
28 incidences per 100,000 of population. These wide variations in prevalence 
may be related to the criteria have been used in the diagnosis (Katusic et al., 
1990; Hall et al., 2006; Dieleman et al., 2008; Zakrzewska, 2010). 
b- Glossopharyngeal neuralgia  
Glossopharyngeal neuralgia is defined by the IASP as a “sudden severe brief 
stabbing recurrent pains in the distribution of the glossopharyngeal nerve” 
(Merskey and Bogduk, 2012). It is a rare condition affecting the 9th cranial nerve 
with severe, stabbing episodic pain presenting in the ear, base of tongue and 
beneath the angle of the mandible. Similar to TN, it predominantly presents in 
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elderly females but is reportedly less prevalent than TN presenting in 0.8 per 
100,000 of population (Katusic et al., 1991; Zakrzewska, 2010).  
c- Postherpetic neuralgia 
Postherpetic neuralgia (PHN) is a constant burning pain which can also present 
with stabbing sensation. These symptoms result from neuronal destruction both 
peripherally and centrally (at dorsal horn) as a complication of latent varicella-
zoster virus (shingles). After the thoracic region, the orofacial region is the next 
most frequently affected region, especially the region innervated by ophthalmic 
division of the trigeminal nerve (Sayanlar et al., 2012). PHN commonly affects 
elderly people (≥ 65), in which 50% of elderly may be affected especially 
females (Bennett, 2004; Merskey and Bogduk, 2012; De Leeuw and Klasser, 
2013) 
d- Burning mouth syndrome (BMS) 
BMS is subdivided into primary and secondary BMS. Sardella et al. (2006) 
defined primary BMS as “a common dysesthesia described as burning 
sensation in the oral mucosa occurring in the absence of clinically apparent 
mucosal abnormality or laboratory finding and often perceived as painful”. 
Secondary BMS is a burning sensation secondary to precipitating disorders 
such as anaemia, diabetes, specific medications (Jääskeläinen, 2012). BMS 
patients commonly present complaining of pain in the anterior tongue, hard 
palate and lower lip, and occasionally the whole mouth is involved (Grushka et 
al., 2003). Concomitant symptoms of xerostomia and taste disturbance 
(dysgeusia), especially bitter and metallic tastes are also commonly reported in 
BMS (Grushka et al., 2003; Amos et al., 2011). Epidemiological studies report a 
wide variation in the prevalence of BMS ranging from 0.7% to 15% (Zakrzewska 
et al., 2005; López-Jornet et al., 2010). This is likely due to the lack of accepted 
diagnostic criteria and other variations in method between the studies (Bergdahl 
and Bergdahl, 1999; Scala et al., 2003; Zakrzewska et al., 2005). Like most 
other NOP, BMS predominantly presents in older, postmenopausal females 
(Lavigne et al., 2005; Ko et al., 2012). There is uncertainty over the 
pathophysiology of primary BMS, however, the human studies and treatment 
trials suggest it is most likely to neuropathic in origin (Lauria et al., 2005; Eliav 
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et al., 2007; Yilmaz et al., 2007; Zakrzewska, 2010; de Tommaso et al., 2011; 
De Leeuw and Klasser, 2013).  
e- Persistent dento-alveolar pain 
Chronic idiopathic intraoral pain without definitive pathology has been 
explained, described and classified as different entities or as pseudonyms such 
as: phantom tooth pain, atypical facial pain, atypical odontalgia, atypical 
trigeminal neuropathic pain or idiopathic continuous neuropathic pain (Marbach, 
1978; Woda et al., 2005; Baad-Hansen, 2008; De Leeuw and Klasser, 2013). 
One of the classifications introduced by Woda et al. (2005) sought to 
differentiate orofacial  idiopathic pains into atypical facial pain (AFP), atypical 
odontalgia (AO), BMS and TMD. According to anatomical division AFP is a term 
generally used to describe a group of idiopathic facial pain complaints which are 
persistent and may be confusing to classify and manage, whilst atypical 
odontalgia (AO) is a potentially related condition that is usually described as 
persistent tooth pain often without any objective signs of clinical and/or 
radiological pathology or known cause (De Leeuw and Klasser, 2013). More 
recently Nixdorf et al. (2012a) reclassified AO as persistent dento- alveolar pain 
disorder (PDAP). Benoliel et al. (2012b) introduced a broad nomenclature for 
orofacial neuropathy as “painful posttraumatic trigeminal neuropathy” including 
both facial and oral constant pain and sensation discrepancy. Benoliel’s 
proposed criteria was adopted in IHS classification (IHS, 2013), while atypical 
odontalgia description for continuous idiopathic trigeminal pain within dental 
region, was listed in AAOP classification (De Leeuw and Klasser, 2013). 
The reclassification of AO into PDAP aimed to simplify the diagnosis of this 
chronic orofacial pain and allow it to be categorised in an ontological fashion 
with the ultimate aim of advancing the management of this subtype of NOP.  
The prevalence of PDAP is reported to range from 2 to 6% (Rodríguez-Lozano 
et al., 2010). PADP may arise after dental intervention involving deafferentation 
injuries such as endodontic treatment, extraction and even following local 
anaesthetic injection. Other studies provide information on the incidence of 
PDAP after implant surgery, surgical endodontic treatment and 3rd molar 
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extraction (Vickers and Cousins, 2000; Melis et al., 2003; Bennett, 2004; 
Epstein et al., 2007; Rodríguez-Lozano et al., 2010). 
f- Complex regional pain syndrome (CRPS) 
CRPS is a continuous burning NP, characterised by swelling and changes in 
blood flow in addition to allodynia and hyperalgesia of the affected area 
(Merskey and Bogduk, 2012). The pathophysiology is still unclear but central 
and peripheral NP mechanisms in addition to immunological, inflammatory 
causes subdivide the CPRS into I and II types (De Leeuw and Klasser, 2013). 
Reported cases in the orofacial region are fewer than elsewhere in the body (de 
Mos et al., 2007; Nixdorf et al., 2012b). 
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1.4 Treatment of neuropathic orofacial pain 
Apart from diversity in diagnosis, treatment with such neuronal system 
complexity and serial cascading pathophysiology is difficult and challenging all 
over the body not only in orofacial region (O'Connor, 2009). This is especially 
true when the patient cohort presenting can be elderly with many comorbid 
health problems. NP presenting in the orofacial region, as opposed to 
elsewhere in the body, can be more complex to diagnose due to the need to 
exclude many more cofactors in order to make a diagnosis and there are limited 
criteria and tools to facilitate this process (Truelove, 2004; McDermott et al., 
2006). Absence of clinical and or radiological lesions limits current treatment to 
choosing between pharmacological options, except in trigeminal neuralgia and 
surgical trauma cases. These pharmacological options are characterized by a 
limited evidence-base for their use in NOP and generally are subject to 
decreased patient adherence to prescribed regimens due to the medication 
side-effect profile (Finnerup et al., 2015).  
1.4.1 Types of treatment 
The treatment of NOP can be difficult for two main reasons: 1) the conflicting 
evidence base on its management; 2) the pain can be resistant to the usual 
methods of pain relief (Gilron et al., 2006; de Leon-Casasola, 2007; O'Connor, 
2009).  
The treatment modalities for NOP relate to the type and site of the lesion and/or 
the disease or disorder affecting the somatosensory nervous tissue. 
1.4.2 Surgical management 
Surgical management is predominately for the various macroscopic injuries 
caused to the trigeminal nerve such as those caused through trauma, wisdom 
tooth removal and vascular compression in TN. It is not a compulsory choice for 
all cases and depends on careful assessment and examination of the patient, 
the cause of their injury, the duration of their injury, their response to medication 
and their perspectives on surgery (Lopez et al., 2004; Robinson et al., 2004; 
Renton et al., 2012b). In case of trigeminal neuralgia, the best results were 
found by either nerve decompression or palliative care destruction procedures, 
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with chance of recurrence and side effect such as numbness as in palliative 
care destruction (Zakrzewska and Linskey, 2014).  
1.4.3 Pharmacological management 
Pharmacological management is often the treatment of choice currently in NOP. 
Several types of microscopic nerve ending damage can occur following 
infection, systemic disease and deafferentation; and attempts have been made 
to manage this type of pain with different types, routes, and dosages of 
medications (Lewis et al., 2007; Woda and Salter, 2008) which mostly attempt 
neuromodulation. 
A reference guide (Figure 1.2) for NP treatment has been introduced by the 
National Institute for health and Care Excellence (NICE). In this guideline, first 
line of treatment are tricyclic antidepressants (eg: amitriptyline) and 
anticonvulsants (eg: pregabalin). The second choice would be interchange 
between previous two groups when intolerance of side effect or low effectivity is 
reported. A third line of opioid and topical capsaicin is also advised in specific 
conditions (NICE, 2013). Other studies have investigated different systemic 
medications including N-methyl-D-aspartate (NMDA) antagonist such as 
ketamine, and anticonvulsants such as carbamazepine in TN (Attal et al., 2010; 
Zakrzewska, 2010). Due to the side effect profile of most drugs used 
systemically in management of NOP recent evidence has begun to emerge 
about the efficacy of topical NMs either alone or in conjunction with other 
systemic medications (Lewis et al., 2007; Heir et al., 2008). 
The side effects of systemic medications and the mechanism of action are listed 
in Table 1.1. The recommended type of treatment always has been judged by 
side effect profile alongside level of pain relief. The side effects of systemic 
medications and the rapid onset of action of topical medications have 
encouraged many researchers to trial the topical administration of 
neuromodulatory agents for the management of NP in the orofacial region and 
elsewhere in the body.  
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Figure 1.2: NICE guidelines for NP treatment including three main lines of 
pharmacological treatment (NICE, 2013). 
 
Following diagnosis of NP 
Other NP categories Trigeminal Neuralgia 
1st line of treatment: amitriptyline, 
duloxetine, gabapentin or pregabalin as 
initial treatment for neuropathic pain 
 
1st line of treatment: carbamazepine. 
2nd line of treatment: 
If the initial treatment (amitriptyline) is not 
effective or is not tolerated, offer one of 
the remaining 3 drugs (duloxetine, 
gabapentin or pregabalin), and consider 
switching again if the second and third 
drugs tried are also not effective or not 
tolerated. 
Tramadol only if acute rescue therapy is 
needed. Capsaicin cream for people 
with localised neuropathic pain who 
wish to avoid, or who cannot tolerate 
oral treatments. 
2nd line of treatment: 
If the first line treatments not effective, is 
not tolerated or is contraindicated, 
consider seeking expert advice from a 
specialist and consider early referral to a 
specialist pain service or a condition-
specific service. 
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Medications Mode of action Major side effects Precautions 
Tricyclic antidepressants (TCA) 
Amitriptyline 
Nortriptyline 
Desipramine 
Inhibition of reuptake of serotonin and/or 
noradrenaline, block of sodium, calcium, 
and potassium channels, anticholinergic, 
weak NMDA antagonism. 
Sedation, dry mouth, 
blurred vision, urinary 
retention, weight gain. 
Cardiac disease, 
glaucoma, seizure, suicide 
risk, concomitant use of 
tramadol. 
Selective serotonin and noradrenaline reuptake inhibitors (SSNRIs) 
Duloxetine 
 
 
Venlafaxine 
Inhibition of both serotonin and 
noradrenaline reuptake 
 
Inhibition of both serotonin and 
noradrenaline reuptake 
Nausea 
 
 
Nausea 
Hepatic dysfunction, renal 
insufficiency, alcohol 
abuse, concomitant use of 
tramadol 
Cardiac disease, 
concomitant use of 
tramadol, withdrawal 
syndrome with abrupt 
discontinuation. 
Calcium channel α2- ligands 
Gabapentin 
Pregabalin 
 
Decrease release of glutamate, 
noradrenaline and substance P, with ligand 
on α2- sub unit of voltage gated calcium 
channel. Still some uncertainty about their 
exact mechanism of action. 
Sedation, dizziness, 
peripheral oedema. 
Renal insufficiency 
Opioid agonists 
Morphine 
Oxycodone 
Methadone 
Levorphanol 
 
Tramadol 
-receptor agonism(oxycodone also causes 
-receptor antagonism) 
 
 
 
-receptor agonism, inhibition of 
noradrenaline and serotonin reuptake 
Nausea/vomiting, 
constipation, dizziness 
 
 
 
Nausea/vomiting, 
constipation, dizziness 
History of substance 
abuse, suicide risk, driving 
impairment 
 
 
History of substance 
abuse, suicide risk, driving 
impairment, concomitant 
use of SSNRI, TCA 
Table 1.1: List of systemic medications, mode of action and side effects 
administered in NP treatment, adapted from Baron et al. (2010), Appendix A.2. 
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1.4.4 Topical treatment  
Bar Lignocaine and Capsaicin, low power, uncontrolled, clinical trials and case 
reports form the main source of evidence regarding the efficacy of topical 
treatment in NP. This lack of high-quality evidence is the reason why most 
management guidelines for NP, exclude these compounded topical 
medications. Compounded topical treatment is, however, increasingly  used as 
an off-label treatment, prescribed and prepared all over the world using various 
concentrations and types of neuromodulatory agents used as systemic 
treatments of NP.  
Management of NP is in itself a process of trial and error as guidelines contain 
several different suggestions of systemic antidepressant, anticonvulsant and 
opioid medications in addition to topical and non-pharmacological treatments 
(Breivik et al., 2006; NICE, 2013). In McDermott et al. (2006) cross sectional 
study of NP, they found that over a third of patients used topical treatment, with 
the majority (65 %) of those patients using it for over a year. This may be due to 
the fact that topical administration of neuromodulatory agents often results in a 
lessened side effect profile than the same systemically administered 
medication.  
The PNP site, both focal and multifocal sites were found to be more responsive 
in patients using these types of topical compounding, with relieving of various 
forms of pain and altered sensations associated with NOP (Padilla et al., 2000; 
Sawynok, 2003; Heir et al., 2008). Except Lignocaine and Capsaicin, which are 
already approved for topical use in NP (NICE, 2013), most clinical trials of other 
topical treatment for NP are preliminary, low power, and uncontrolled studies 
(De Leeuw and Klasser, 2013; Thompson and Brooks, 2015), however, the 
clinical trials of other possible pharmacological management strategies and 
agents keep evolving and an accepted trend for prescription and compounding 
topical therapies has been established as off-label treatment of NOP, Table 1.2, 
(Padilla et al., 2000; Bramwell, 2010). Topical treatment for NOP includes 
patches, creams, mouth wash and other carrier mediums and excipients 
(Watson, 2004; Benoliel et al., 2012a). 
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The way these topical treatments are applied depends mainly on site of 
application,  
Table 1.3. For extraoral application, topical treatments are applied using gel, 
cream and for lidocaine and capsaicin there are commercial plaster and 
patches (Gilron et al., 2006; Maihofner and Heskamp, 2013). Intra oral 
application depends on the affected site and size; for localised area, gel or 
Orabase paste can be applied directly or within custom fabricated stent 
(Haribabu et al., 2013). In case of multifocal site or difficulty in applying the 
paste as in burning mouth syndrome or when the tongue is affected, mouth 
wash of a designed treatment can be used. There is no typical or recognised 
prescription guideline, these topical treatment are prescribed regarding type, 
concentrations, and frequency depending on the pain severity, type of drug and 
clinician experience. 
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Topical 
treatment 
Type of 
treatment 
Site of action References 
Topical 
anaesthetic 
Lidocaine, EMLA, 
Benzocaine 
Sodium channels (Padilla et al., 2000; 
Rogers et al., 2006; Jorge 
et al., 2011)  
Vanilloid 
compound 
 
Capsaicin TRPV1 channels (Jackson, 2006; Moore et 
al., 2010; Jorge et al., 
2011) 
Antidepressant 
 
Amitriptyline, 
Doxepin 
Sodium channels, 
NMDA and adenosine 
receptors 
(Epstein et al., 2008; 
Liebregts, 2011; Kopsky 
and Keppel Hesselink, 
2012)  
Sympathomimetic 
agent 
Clonidine α1- adrenergic 
receptors 
(Merrill, 2004; Jorge et al., 
2011) 
Anxiolytic Clonazepam GABAA (Type-A γ-
aminobutyric acid )  
receptor 
(Gremeau-Richard et al., 
2004) 
NMDA blocking 
agent 
Ketamine NMDA receptors (Lynch et al., 2005b; Ryan 
et al., 2009) 
NSAIDs Ketoprofen Interference with 
prostaglandin 
production 
(Heir et al., 2008) 
Anti-convulsant Gabapentin   
 
Calcium channels 
subunit (α2δ-1) 
(Heir et al., 2008; Hiom et 
al., 2015) 
Carbamazepine Sodium channels (Padilla et al., 2000; Heir et 
al., 2008) 
Anti-spasmodic 
drugs 
Baclofen GABA receptor  (Padilla et al., 2000) 
 
Table 1.2: This table showing a list of possible topical treatments for 
neuropathic orofacial pain with possible target receptors and ion channels.  
 
 
 
 
 
23 
 
 
Table 1.3: This table showing the concentrations, carrier medium and 
application methods of commonly used topical treatments in management of 
NP. 
 
 
Medications Concentrations Carrier media  References 
Capsaicin 0.02 % 
0.075 % 
8 % 
Mouth wash 
Cream 
Patch 
(Silvestre et al., 2012) 
(Lewis et al., 2007) 
(Maihofner and Heskamp, 2013) 
Amitriptyline 2% 
5 %,10 % 
Cream 
Cream 
(Lynch et al., 2005a) 
(Kopsky and Keppel Hesselink, 
2012) 
Gabapentin 4% Lecithin organo 
gel 
(Heir et al., 2008) 
Carbamazepine 4% Lecithin organo 
gel 
(Heir et al., 2008) 
Doxepin 3.3% 
5 mg/ml (0.5%) 
Aqueous  cream 
Mouth wash 
(McCleane, 2000) 
(Epstein et al., 2006) 
Clonidine 0.2 mg/g (0.02 %) 
4% 
Cream 
Gel 
(Epstein et al., 1997) 
(Graff-Radford and Evans, 2003) 
Clonazepam 1 mg 
0.5 mg 
Tab 
Tab 
(Gremeau-Richard et al., 2004) 
(Amos et al., 2011) 
Ketamine 4%, 
1% 
0.4 %  
Lecithin organo 
gel 
Gel 
Mouth wash 
(Heir et al., 2008) 
(Gammaitoni et al., 2000) 
(Slatkin and Rhiner, 2003) 
Lidocaine 4% 
5% 
Gel 
Patch 
(Graff-Radford and Evans, 2003) 
(Gilron et al., 2006) 
Ketoprofen 4% Lecithin organo 
gel 
(Heir et al., 2008) 
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a. Topical anaesthetic 
Topical anaesthetic such as lidocaine is frequently used as topical medication to 
manage NP, by blocking voltage gated sodium channels on nociceptors (Padilla 
et al., 2000; Rogers et al., 2006; Jorge et al., 2011). Lidocaine is an amide local 
anaesthetic usually used as an injection, but can also applied as cream, gel, 
mouth wash or patches to relieve NOP. Specifically it has been used in PDAP, 
BMS, cancer NP and PHN with range of concentrations 2%-10% (Padilla et al., 
2000; Gilron et al., 2006; Torgerson, 2010; Pachman et al., 2011; Sankar et al., 
2011). An Eutectic Mixture of Local Anaesthetics (EMLA) obtained by 
combining lidocaine 2.5% and prilocaine 2.5% has also been trialled with 
PDAP, and it is considered safe and effective for pain relief (Vickers et al., 
1997; Vickers et al., 1998; McGeeney, 2009). An ester local anaesthetic, 
Benzocaine, has also been used for treating NOP when incorporated into 
orabase as a carrier medium in order to treat intraoral pain (Padilla et al., 2000). 
b. Vanilloid compound 
Capsaicin is the main component in chilli peppers responsible for the hot 
sensation derived from genus Capsicum. It acts on unmyelinated C-fibres 
peripheral nerve ending and on vanilloid receptors (TRPV1). After repeated 
application of capsaicin, a constant pain relief may occur as result of: depletion 
of substance P, defunctionalisation of TRPV1 receptors and potentially nerve 
degeneration (Jackson, 2006; Moore et al., 2010; Jorge et al., 2011). Although 
the first contact burning sensation can limit capsaicin application by the patient, 
it is utilized to manage various NOP like PHN, BMS and macroscopic trigeminal 
nerve injury. Different concentrations and methods have been used to deliver it 
as intraoral topical medication such as cream, patches, mouth wash and even 
chewing gum or hot tabasco sauce to supply the patient with capsaicin and 
achieve desensitization (Epstein and Marcoe, 1994; Merrill, 2004; Renton and 
Yilmaz, 2012; Silvestre et al., 2012). Capsaicin is now one of documented 
management strategies not only for chronic NP pain but also various 
musculoskeletal diseases (Lorna et al., 2004; McGeeney, 2009). The chilli 
characteristic of Capsaicin made it less preferable especially in facial area with 
NP, however, a few studies have demonstrated promising results with minimal 
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side effects in case of resistant cases and patients who failed to adhere to 
systemic treatment (Sayanlar et al., 2012; Gaul and Resch, 2015). 
c. Antidepressants 
Tricyclic antidepressants (TCA) are the most commonly used systemic 
treatment for managing NP and amitriptyline is the traditional first choice 
(Namaka et al., 2004). Amitriptyline’s effect on pain when used topically is 
mediated by several different mechanisms including: inhibition of  serotonin and 
noradrenaline reuptake and blockage of sodium channels (de Leon-Casasola, 
2007). In low concentrations amitriptyline provides pain relief and patient 
satisfaction in peripheral NP (Lynch et al., 2005a), but higher concentrations of 
amitriptyline containing cream can provide more rapid relief of pain (Liebregts, 
2011; Kopsky and Keppel Hesselink, 2012). The antidepressant drug Doxepin 
is also used to manage different NOPs as a singular drug or in combination with 
capsaicin (McCleane, 2000). Doxepin is also used as a mouth wash in 
managing BMS (Epstein et al., 2006; Epstein et al., 2008; Torgerson, 2010). 
d. Sympathomimetic agent 
Several studies explained that the sympathomimetic agent clonidine is a 
powerful topical modality in treatment of NP. It blocks sympathetically mediated 
NP (Padilla et al., 2000) and its mechanism of action is to inhibit noradrenaline 
release and prevent stimulation of α1- receptors on C-fibres (Merrill, 2004; 
Jorge et al., 2011). It is applied in management of lingual nerve injury, PDAP 
and in different causes of NP. It is available as patches, cream or gel (Epstein 
et al., 1997; Graff-Radford and Evans, 2003; Merrill, 2004; Jorge et al., 2011). 
e. Clonazepam 
Topical clonazepam is now one of the first choice drugs in BMS management 
(Buchanan and Zakrzewska, 2004; Lavigne et al., 2005; Zakrzewska, 2010; 
Sankar et al., 2011). Systemic treatment of BMS with clonazepam showed 
promising results even with low doses (Grushka et al., 1998). In another trial 
clonazepam has been topically applied through double blind randomized study 
by Gremeau-Richard et al. (2004). They demonstrated that dissolving 1 mg tab 
of clonazepam orally and wash around the mouth and then expectorating can 
relieve the burning sensation of BMS with few side effects. Another study 
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combined the topical mechanism of Gremeau-Richard et al. (2004) alongside 
swallowing the saliva after mouth washing the tablet around the oral cavity 
(Amos et al., 2011). The disadvantage of this was that side effects have been 
reported in about 33% of the patients. 
f. NMDA- blocking agent 
Ketamine is a general anaesthetic drug which has been used widely as an 
intravenous or intramuscular analgesic for chronic pain conditions including 
NOP, cancer and non-cancer pain (Mathisen et al., 1995; Bell, 2009; Noppers 
et al., 2010). It is an NMDA antagonist which can be applied topically to various 
types of NP as a gel, mouth wash or cream (Lynch et al., 2005b; Ryan et al., 
2009). It has shown promising results in pilot study on NOP by Heir et al. 
(2008). They suggested that topical treatment may be beneficial in mild or 
moderate pain and could be used as combined therapy with systemic 
prescription. Two reviews on the management of NOP (Padilla et al., 2000; 
Merrill, 2004), suggested that using ketamine in conjugation with a stent with or 
without other medications demonstrated accepted results on intraoral pain. 
However, the chronic use of ketamine should be under taken with caution 
because of high dose toxicity and drug abuse. 
g. Topical NSAIDs 
The major benefits of using topical administration of drugs are avoiding first 
pass metabolism, associated systemic toxicity and side-effects. This is of 
significant benefit when using NSAIDs as a topical treatment because gastric 
upset is the main complication of systemic NSAIDS. The NSAIDs mainly inhibit 
inflammatory cascade through their interference with prostaglandin production 
and therefore, perhaps unsurprisingly, there are only a few studies investigating 
their use in NP. Heir et al. (2008) applied Ketoprofen with other medications to 
improve symptoms in patient with different NOP. He reported successful pain 
relief with topical medications in mild and moderate cases. Epstein et al. (2001) 
declared that using benzydamine hydrochloride mouth wash by patients with 
mucositis may be helpful in relieving pain related to cancer and cancer 
treatment, however, Sardella et al. (1999) show that benzydamine mouth wash 
was not more effective than placebo in managing BMS. 
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h. Anti convulsant and anti-spasmodic drugs 
In addition to the previous drugs, anti convulsants and anti-spasmodic 
medications are also applied topically to manage NOP. Gabapentin is 
anticonvulsant medication which is a systemic medication prescribed in epilepsy 
and NP. It is a gamma amino-butyric acid (GABA) analogue, acting at the 
central and peripheral nervous system by blocking calcium channels and 
increasing GABA synthesis. Another anticonvulsant is carbamazepine, which is 
the drug of choice in TN management. The mechanism of action of 
Carbamazepine is by blocking sodium channels. The anti-spasmodic drug, 
baclofen, is GABA receptor agonist mainly used to treat spasticity. Several 
studies have trialled these three medications topically to manage NOP. They 
demonstrated that pain relief could be achieved when using these medications 
as a single drug or in combination with other topical ones (Padilla et al., 2000; 
Merrill, 2004; Lavigne et al., 2005; Heir et al., 2008).   
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1.5 Neuromodulatory medications 
The types and concentrations of NMs included in this research were decided 
after literature search regarding NOP treatment (Padilla et al., 2000; Sawynok, 
2003; Argoff, 2004; Lynch et al., 2005b; Sawynok, 2005; Heir et al., 2008; 
McCleane, 2008; Bramwell, 2010; Haribabu et al., 2013), and an informal 
survey of the international members of the University of California, Los Angeles 
(UCLA) OFP list-serve about the more common compounded medications used 
in NOP (Vahedifar, 2010). Among types and concentrations, the three types of 
NMs found frequently employed in the clinical trials are: amitriptyline, 
carbamazepine and gabapentin. As these were the neuromodulatory agents 
chosen as the test medications for this thesis, their pharmacology will now be 
described in depth. 
1.5.1 Amitriptyline 
Amitriptyline is a tertiary amine tricyclic antidepressant drug (Figure 1.3), (Viola 
et al., 2000). Amitriptyline antidepressant characteristics arise from its dual 
activity as a serotonin, and noradrenaline, reuptake inhibitor at the presynaptic 
site. This accomplished by blocking the transporters, resulting in an increase of 
the synaptic level of serotonin and noradrenaline (Fishbain, 2000; Fangmann et 
al., 2008; Richard et al., 2008).  
 
 
Figure 1.3: Chemical structure of amitriptyline. Reproduced from Viola et al. 
(2000) with permission, Appendix A.3. 
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The anti-depressive characteristic of amitriptyline is part of its chronic pain 
management mechanism, in addition to the peripheral activity on range of 
receptors and ion channels such as sodium channels, NMDA, adenosine 
receptors. In NP treatment guidelines, amitriptyline is considered as the first line 
treatment for NP like diabetic neuropathy and post-herpetic neuralgia (Breivik et 
al., 2006; McDermott et al., 2006; Micó et al., 2006; NICE, 2013) 
Pharmacokinetics 
Amitriptyline bioavailability is between 31 to 61 % after fast, but incomplete 
absorption from gastrointestinal tract. The active metabolite of amitriptyline is 
nortriptyline. Amitriptyline is characterized by high lipid solubility and protein 
binding affinity (82-96%), which is vital in increasing tissue distribution. The 
plasma therapeutic concentration of amitriptyline is 80-200 ng/ml in doses of 75 
mg to 100 mg taken orally (Waller and Renwick, 1994a). 
Mechanism of action  
Amitriptyline as a tricyclic antidepressant inhibits reuptake of the serotonin and 
noradrenaline by blocking monoamine transporter there by increasing both the 
amount of amines (serotonin and noradrenaline) in the intrasynaptic space and 
the time these amines are present in the presynaptic space. All of these actions 
improve serotonin transmission through post synaptic space (Richard et al., 
2008).  
The analgesic effect of amitriptyline in NP largely mirrors its mechanism of 
action in depression in addition to its peripheral action of blocking a series of 
pain receptors (adenosine receptors, glutamate receptors) and ion channels 
(sodium channels, potassium channel). The analgesic capability of amitriptyline 
as systemic medication, has also been suggested to be mediated through the 
descending inhibitory pathway in which serotonin and noradrenaline are 
considered as endogenous analgesics (Micó et al., 2006; Marks et al., 2009). 
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Clinical pharmacology 
The main indication for systemic amitriptyline is a major depression episode, 
treated with a daily dose between 75 and 200 mg with a maximum dose of 300 
mg. In the case of NP, the starting dose is 10 mg at night up to 75 mg with 
maximum range 25-150 mg daily (McQuay et al., 1993; NHS, 2015a). PNP 
such as diabetic neuropathy and post herpetic neuralgia are amongst those 
PNPs managed by amitriptyline (Waller and Renwick, 1994a; NICE, 2013). 
Several clinical studies have applied amitriptyline topically in a range of 
concentrations to relieve various types of PNP conditions (Lynch et al., 2005b; 
Kopsky and Keppel Hesselink, 2012; Mercadante, 2015). There are different 
analgesic mechanisms suggested for the topical amitriptyline including the 
blocking of ion-gated channels such as sodium and calcium channels. 
Amitriptyline also blocks NMDA receptors and affects adenosine receptors 
helping in developing analgesic action (Sawynok et al., 1999; Cummins, 2009; 
Sawynok, 2009). The reported doses applied topically in orofacial pain range 
from 2% (20 mg/ml) to 10 % (100 mg/ml) using various methods to help retain 
the agent near the target tissue such as orabase paste or pluronic lecithin 
organogel with or without a stent to help prevent the “washing away” of the 
medicament (Padilla et al., 2000; Lynch et al., 2005a; Heir et al., 2008; Kopsky 
and Keppel Hesselink, 2012; Scheinfeld, 2014). 
Side effects 
When using amitriptyline as a systemic medication for NP, vigilance is required 
as NP patients are often likely to be older and may therefore have multiple 
comorbidities (Gore et al., 2006). This is not always the case with topical 
treatment of NOP, but a similar degree of vigilance is required given the 
medication is used “off-label”. 
According to the General Medical Council (GMC), there are several aspects 
should be followed in case of the need for off-label prescription: the sufficient 
knowledge of safety and efficacy of the prescribed drugs, the medical 
documentation explaining the need for such prescription and the necessary 
follow up of the patient (GMC, 2015). 
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Amitriptyline’s antagonism of histamine H1, muscarinic and α-adrenergic 
receptors, causes a group of side effects such as sleepiness, tremor, blurred 
vision, orthostatic hypotension, arrhythmia, withdrawal syndrome, seizure, 
weight gain and sexual disturbance (Waller and Renwick, 1994a; Richard et al., 
2008; O’Donnell and Shelton, 2011). These side effects can significantly affect 
patient adherence to treatment especially in a more elderly patient group where 
side effects can be more pronounced. Topical treatment as alternative route of 
administration has not been associated with major side effects except those 
related to a minimal systemic absorption of topical treatment causing mild 
symptoms such drowsiness, but this study had methodological issues (Kopsky 
and Keppel Hesselink, 2012).  
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1.5.2 Carbamazepine 
Carbamazepine was first approved by the FDA in 1986 as initial or adjunctive 
treatment for epilepsy. Carbamazepine’s chemical structure and characteristics 
are very similar to that of antiepileptic phenytoin (Figure 1.4), (McMillin et al., 
2010). Since its approval, carbamazepine has been established as effective 
treatment of epilepsy, bipolar syndrome, and as the drug of choice in trigeminal 
neuralgia (Porter and Meldrum, 2007; Leduc, 2008). 
 
 
Figure 1.4: Chemical Structure of carbamazepine. Reproduced from McMillin et 
al. (2010) with permission, Appendix A.4. 
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Mechanism of action  
The main anti-convulsant action of carbamazepine is related to blocking the 
voltage gated sodium channel and preventing the spread of the action 
potentials of a seizure. Some evidence also suggests that carbamazepine 
exerts an antagonistic effect against adenosine receptors and NMDA receptors 
(Hough et al., 1996; Porter and Meldrum, 2007; Lee and Abrahams, 2008). 
 
Pharmacokinetics 
Carbamazepine is slowly, but completely, absorbed after oral administration. 
Carbamazepine’s peak plasma concentration depends mainly on tablet type. In 
the extended release tablet it takes 3-12 hours while in the in the immediate 
release tablet it attains peak plasma concentration after 4-5 hours. 
Carbamazepine is distributed with 70 % bound to plasma protein with 
therapeutic plasma concentrations of 4-12 g/ml (Porter and Meldrum, 2007; 
Leduc, 2008). 
Clinical pharmacology 
Carbamazepine is approved for use in both partial and generalized seizure 
disorders. In case of NP such as trigeminal neuralgia and diabetic neuropathy, 
the starting dose is  100 mg 1-2/ daily, then changed according to response up 
to 1.6 g/ day, the usual dose is 200 mg 3-4/day (NHS, 2015b).  
Carbamazepine’s sodium channel blocking action, alongside a possible 
antagonism  on adenosine and NMDA receptors has resulted in it being applied 
as an adjunctive analgesic in compounded topical treatment (Vučković et al., 
2006; Cummins, 2009). The inclusion of carbamazepine in topical treatment 
produced promising results when trials were conducted to treat NOP with a 4 % 
(40 mg/ml) prescribed dose (Padilla et al., 2000; Heir et al., 2008). 
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Side effects 
No reported side effects were found in the literature following topical treatment 
prescription. All the side effects mentioned in the literature related to systemic 
treatment. 
Diplopia and ataxia are the main side effects which can be managed by dose 
adjustment. In case of higher doses drowsiness, hyponatremia and water 
intoxication may occur. In the case of prolonged systemic treatment for example 
in trigeminal neuralgia patients, idiosyncratic blood dyscrasias including fatal 
cases of aplastic anaemia have been reported in the first four months of 
treatment. The most common idiosyncratic reaction is erythematous skin rush. 
Mild persistent leukopenia has also been reported in some patients which 
needs careful monitoring and or cessation of the drug (Porter and Meldrum, 
2007; Leduc, 2008; Lee and Abrahams, 2008). 
Carbamazepine has also been found to trigger Steven Johnson’s syndrome, a  
life threating reaction that may be related to the immune reaction to one of its 
metabolite (Porter and Meldrum, 2007; Leduc, 2008). 
 
 
 
 
 
 
 
 
 
 
35 
 
1.5.3 Gabapentin 
Gabapentin was designed with a chemical structure similar to the Gama Amino-
butyric acid structure allowing it to easily penetrating the blood brain barriers 
Figure 1.5), (Rose and Kam, 2002). Gabapentin is a water soluble amino acid 
used mainly in the management of epilepsy and more recently in chronic pain 
management especially in postherpetic neuralgia (Porter and Meldrum, 2007; 
Leduc, 2008; NICE, 2013). 
 
 
Figure 1.5: Chemical structure of gabapentin. Reproduced from Rose and Kam 
(2002) with permission, Appendix A.5. 
 
Pharmacokinetics  
High plasma levels of gabapentin are reached after 2-3 hours of oral 
administration of gabapentin with bioavailability of 60% achieved after 300 mg 
tablet ingestion. Gabapentin’s bioavailability is subject however to L-amino acid 
transporter saturation  and may therefore significantly decrease with higher oral 
doses  (Porter and Meldrum, 2007).  
Mechanism of action 
Gabapentin’s main mechanism of action is through voltage gated calcium 
channels by binding to 2-subunit and blocking calcium ion influx. This 
decreases action potentials related to excitatory stimuli thereby decreasing the 
potential for seizures. Its therapeutic efficacy may also be amplified by 
decreasing glutamate release from presynaptic reservoir and increasing the 
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plasma level of gamma amino butyric acid (Porter and Meldrum, 2007; Taylor, 
2009). The 2-subunit ligand mechanism also justifies the analgesic effect of 
gabapentin both peripherally and centrally in management of NP. 
Clinical pharmacology 
Gabapentin is prescribed in case of partial and generalized seizure with daily 
dose up to 4800 mg in three divided doses. NICE guidelines put gabapentin in 
the first line of NP management especially postherpetic neuralgia. Adult dose 
started with 300 mg there times daily and increased according to response up 
to 3.6 g/day (Porter and Meldrum, 2007; Leduc, 2008; NICE, 2013; NHS, 
2015c).  
The topical gabapentin dose of 4 % (40 mg/ml) was found helpful in treatment 
of NOP. The pathway of topical analgesic is ligand to the ability of gabapentin to 
block the Ca 2-1 subunit, in addition to gabapentin’s role in blocking excited 
synapse formation (synaptogenesis) that was found associated with NOP 
pathophysiology (Luo et al., 2002; Gordh et al., 2008; Bauer et al., 2009; Eroglu 
et al., 2009; Li et al., 2014; Hiom et al., 2015). 
Side effects 
Gabapentin is generally considered a safe treatment for chronic pain conditions 
with side effects mainly related to dizziness, peripheral oedema and gait 
impairment all of which that can be controlled by dose titration. The topical use 
of gabapentin was not associated with any reported side effects or toxicity when 
applied intra or extra orally in the literature (Heir et al., 2008; Hiom et al., 2015). 
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1.6 Peripheral receptors 
The biological part of pain is related to the neuron in both peripheral and central 
nervous system. The nociceptor part of the neuron body in PNP, expresses a 
group of receptors and ion channels that found essential for both pain and 
analgesic process (Basbaum and Woolf, 1999). The increased knowledge of 
molecular and signalling mechanism of pain transduction at nociceptors side, 
helped in raise new targets and methods of pain management including NOP. 
Peripheral pathophysiology of NOP as in deafferentation pain and post herpetic 
neuralgia suggests that there is likely to be a role for neurotransmitter receptors 
and excitability of ion channels in starting pain experience. The previous 
assuming was what the efficacy and specificity of these topical agents depend 
on in peripheral tissue to perform analgesic action (Henry and Hargreaves, 
2007; McDougall, 2011).  
The analgesic action of the three neuromodulators in this study was justified but 
not completely confirmed regarding expression of their main targets on nerve 
endings (nociceptors) in the skin or oral mucosa where the drug action and 
potential damage might be. In the literature, there are a group of expected 
targets for these NMs as peripheral analgesics will be discussed. The receptors 
and ion channels mentioned here are not the final and/or the exclusive pathway 
of peripheral analgesics but thought as the main pathway of pain analgesia: 
1.6.1 Adenosine receptors 
Adenosine is an endogenous nucleoside molecule with wide physiological 
functions. Adenosine has a neuromodulator function through four extracellular 
receptors: A1, A2A, A2B and A3 (Figure 1.6), (Landolt et al., 2012). Their main 
action is through G-protein and cyclic adenosine 5-monophosphate cAMP 
(Doak and Sawynok, 1995). In addition to neurophysiology, these metabotropic 
receptors are distributed in various organs exerting numerous physiological 
roles in cardiac, CNS and immune system function (Jacobson, 2002). 
The adenosine endogenous system has a role in anti-nociception through 
blocking of calcium channel excitation and inhibition of trans-synaptic 
transmission (Dolphin et al., 1986). The same endogenous system is thought to 
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play the pathway of amitriptyline’s analgesic mechanism, mainly by decreasing 
uptake of peripheral adenosine (Sawynok et al., 1999). 
Neuronal culture and immunohistochemical studies have reported the 
expression of A1 and A2A receptors in the sensory neurons of PNS (Sawynok, 
2009).  The anti–nociception resulting from stimulating A1 receptors leads to a 
decrease in cAMP production, the release of calcitonin gene related peptide 
and the influx of calcium ions, all of which contribute to the analgesic effects of 
A1 agonists. Hyperalgesia resulting from agonist stimulation of A2A receptors,  
results from an increase in cAMP production resulting in the synthesis of protein 
kinase-A, phosphorylation of sodium channels and increased in ward Na+ 
current (Burnstock and Sawynok, 2010). The A2B and A3 receptors may affect 
pain nociception indirectly, through the stimulation of immune and inflammatory 
cells such as mast cells where A3 receptors are expressed thereby influencing 
the release of inflammatory mediators (Carruthers et al., 2001; Fredholm et al., 
2001; Gessi et al., 2008; Sawynok, 2009). 
 
 
 
Figure 1.6: Adenosine receptors. Reproduced from Landolt et al. (2012), this is 
an open-access article.  
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1.6.2 Sodium channels 
Sodium channels are the main voltage gated ion channels involved in pain 
transduction and propagation through the nervous system. The sodium 
channel’s structure is a trans-membrane domain with a central ion-conducting 
pore (Figure 1.7), (Catterall, 2000). Sodium channels are composed of two main 
subunits:  and  subunits, the -subunit is integral membrane protein, it 
represents the main functional part of sodium channel. The -subunits are a 
transmembrane protein and act as a controller and a stabilizer of the -subunit 
(Cummins, 2009). Sodium channels are subdivided according to their sensitivity 
to tetrodotoxin (TTX) into sensitive and resistant sodium channels (Lee et al., 
2005). The pain sensation starts peripherally when a noxious stimulus 
stimulates depolarization of the cell membrane and causes the sodium 
channels to open causing the start of the action potential and its propagation. 
These processes last milliseconds before the cell membrane is repolarized 
through the closure of the sodium channel and concomitant opening of 
potassium channels to allow for outflow current for repolarization (Devor, 2006; 
Cummins and Rush, 2007; Cummins, 2009). 
The mechanism of NP is associated with various physiological changes 
including the excitability and distribution of sodium channels. Among these 
changes, there are evidence of mutation and upregulation of a group of sodium 
channels on myelinated and unmyelinated peripheral nociceptors in diabetic 
neuropathy (Faber et al., 2012a; Faber et al., 2012b). 
Types of Sodium channels 
According to the genomic sequence of a α-subunit, nine types of the sodium 
channel were identified: Nav 1.1 to Nav 1.9. The variants Nav 1.1 to Nav 1.6 are 
distributed in the nervous system, skeletal system and in the heart muscle 
without strong evidence about their role in pain processing or in the mechanism 
of analgesia except Nav 1.3, as opposed to Nav1.7 to Nav1.9 which are the best 
target for analgesia (Planells-Cases et al., 2000; Yu et al., 2006; Cummins, 
2009).  
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Nav 1.3  
There is some controversy regarding the Nav 1.3 TTX sensitive channel’s role in 
pain nociception and analgesia. The expression of Nav 1.3 normally subsides 
after nerve maturation, however, animal studies suggest that there is over 
expression of Nav 1.3 TTX sensitive channels in the nerve injuries and NP role 
and that they play a role in ectopic pain firing and pain behaviour in neuropathic 
pain pathophysiology (Rogers et al., 2006). 
Nav 1.7 
These types of sodium channels represent the main channels involved in pain 
transduction and represent the optimum target for peripherally acting 
analgesics. Nav 1.7 channels are TTX-sensitive channels and are exclusively 
only present peripherally. They are expressed in the nociceptive nerve endings 
of mainly C-fibres with less expression on Aδ fibres. They play a major role in 
normal, inflammatory and NP transduction; the latter is particularly true in 
diabetic neuropathy. The mutation of Nav 1.7 channels found in recent studies of 
diabetic patients with PNP as a major factor in NP pathophysiology (Cummins, 
2009; Faber et al., 2012a). 
Nav 1.8  
Nav 1.8 TTX-resistant channels are mainly implicated in the normal pain 
perception in the peripheral nerve endings with controversy regarding their role 
in neuropathic pain pathophysiology and chronicity. It is believed that the type of 
nerve injury is crucial in determining the under-, or over-, expression of Nav 1.8 
channels. Mutation, redistribution on uninjured nerve with up regulation of 
immune-reactivity may be illustrating the Nav 1.8 channel’s role in NP 
pathophysiology (Gold et al., 2003; Faber et al., 2012b). 
Nav 1.9  
Nav 1.9 is a TTX-resistant sodium channel mainly expressed in dorsal root 
ganglia, but it is also expressed on C-fibres and middle and large myelinated 
fibres. Nav 1.9 has a significant role in peripheral nociceptive and hyperalgesia 
associated with inflammatory pain. Its role in NP is less obvious given it is under 
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expressed following nerve injury and NP pathophysiology (Klugbauer et al., 
1995; Fang et al., 2002; Djouhri et al., 2003; Cummins, 2009). 
 
 
 
 
 
Figure 1.7: Structure of sodium channels. Reproduced from Catterall (2000) 
with permission, Appendix A.6. 
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1.6.3 Calcium channels 
Calcium channels are a group of voltage-gated ion channels expressed in 
various tissue cells and implicated in different physiological functions. In 
neuronal cells, the primary function of calcium channels is to promote and 
propagate depolarization. Calcium channels are activated through either the 
binding of chemical substances or by membrane depolarization propagation 
(McGivern, 2009).  
Calcium channels consist mainly of transmembrane pore 1-subunits, and they 
are the main route for calcium ion influx through the plasma membrane (Figure 
1.8), (Walker and De Waard, 1998). The transmembrane pore 1-subunits 
contain receptors for both the activation and blocking of their pore by means of 
pharmacological agents. Other coalescing subunits within the calcium channel 
complex are the 2 membrane ligand subunit,  cytoplasmic subunit and  
transmembrane subunit. These subunits usually modulate the kinetic of voltage 
gating α1 subunit in addition to membrane insertion and voltage dependence. 
Usually α1 subunit unites with one or two of the aforementioned subunits in 
channel formation. 
Calcium channels are divided into high voltage activated and low voltage 
activated according to their activating voltage. The high voltage calcium 
channels include L, N, P/Q and R types and the low voltage activated are 
mainly T type (Ertel et al., 2000; Catterall et al., 2003; McGivern, 2006). The 
main calcium channels associated with nociception and thereby representing 
therapeutic targets for peripherally acting analgesia are the N, T types and 
auxiliary subunits (α2δ subunits), (McGivern and McDonough, 2004; McGivern, 
2006; McGivern, 2009). 
N-channels  
N-channels are mostly found expressed on presynaptic nerve terminals in 
peripheral and central nervous system. N-channels are expressed as a main 
α1-subunit with α2δ and  subunits. Animal studies using nerve injury, ligation, 
or experimentally induced inflammatory states have shown that upregulation of 
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N-channels occurs with the chronic pain resulting from the experimentally 
induced injury. N-channel blocking agents such as Ziconotide have produced 
promising results in chronic pain management such as cancer pain (Matthews 
and Dickenson, 2001; Saegusa et al., 2001; McGivern, 2009). 
T-channels  
T-channels are mostly situated centrally in the brain and spinal cord with some 
present peripherally in neuronal cell bodies and associated dendrites and have 
an excitatory role. T-channels are blocked by varying medications including 
anaesthetic and anti-psychotic drugs but there is still no potent and highly 
selective blocker available for them (Scroggs and Fox, 1992; McGivern, 2009). 
Auxiliary subunits ligands 
There is a wealth of evidence, mainly from animal studies, demonstrating the 
important role of the calcium channel subunit α2δ-1 in the analgesic pathway of 
anti convulsants medications (gabapentin and pregabalin). It is perhaps, 
therefore, unsurprising that α2δ ligands are named as a drug of choice in PNP 
(Maneuf et al., 2006; McGivern, 2009; Dolphin, 2013). Over expression of the 
2-1 subunit at peripheral nerve endings is associated with an increased 
incidence of NP. Further pharmacological evidence of the importance of the 
2-1 subunit’s role in maintaining and propagating PNP is found in the action 
of gabapentin which through binding to the 2-1 subunit in the presynaptic 
neuron, inhibits neurotransmitter release and the influx of calcium ion currents 
thereby reducing peripheral nociceptive impulses (Stefani et al., 1998; Newton 
et al., 2001; Maneuf et al., 2006; Taylor, 2009). 
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Figure 1.8: Structure of calcium channel. Reproduced from Walker and De 
Waard (1998) with permission, Appendix A.7. 
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1.6.4 NMDA receptors 
The N-methyl D-aspartate (NMDA) receptors are one of the ionotropic 
neurotransmitter receptors, where glutamate, a principal neuro-excitatory amino 
acid, binds to exert its excitatory effect both in the central and peripheral 
nervous system. Glutamate is released peripherally following tissue injury and 
inflammation, and is therefore identified both in acute and chronic pain states as 
one contributory factor to maintenance of nervous system excitation.  
When glutamate is released peripherally from afferent nerve endings it 
stimulates various inflammatory and pain proactive receptors like NMDA (Miller 
et al., 2011). NMDA receptor is multi-ionic channel that is permeable for 
sodium, calcium and potassium ions following glutamate depolarization stage. 
The channel consists of three types of subunits: NMDA1, NMDA2 (A, B, C, D) 
and NMDA3 (A, B), (Figure 1.9), (Lakhan et al., 2013). The channel structure is 
largely made up of NMDA1/NMDA2 subunits; however, NMDA3 may replace 
NMDA2 subunits resulting in a channel with less permeability for Ca++. In 
peripheral tissue, the dominate expression of NMDA receptor is owned mainly 
by NMDA1/NMDA2B and NMDA1/NMDA2D subunits. 
The expression of NMDA receptors in the dorsal root ganglia and trigeminal 
ganglia along with peripheral expression has been reported in animal studies 
(Coggeshall and Carlton, 1998; Li et al., 2004). Topical treatment with drugs 
possessing NMDA-antagonist properties such as amitriptyline, carbamazepine 
and ketamine has been found helpful in relieving nociceptive impulses and NP. 
(Mathisen et al., 1995; Lynch et al., 2005a; Cairns, 2009a).  
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Figure 1.9: NMDA receptor. Reproduced from Lakhan et al. (2013), this an 
open-access article. 
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1.7 Compounded drugs and Drug approval process 
Patient satisfaction and wellbeing is the primary goal of clinicians and their 
treatment plans. Compounded drugs are a good example of clinicians trying to 
achieve this aim through treatment modification to alleviate patient’s suffering 
and increase their satisfaction by decreasing side effects. The United State food 
and drug administration (FDA) defined compounding as “a practice in which a 
licensed pharmacist, a licensed physician, or, in the case of an outsourcing 
facility, a person under the supervision of a licensed pharmacist, combines, 
mixes, or alters ingredients of a drug to create a medication tailored to the 
needs of an individual patient” (FDA, 2015a). Recently, concerns were raised 
regarding the potency and purity of compounded medications with increased 
marketing of these pharmaceutical products with less control and monitoring 
especially in Europe (FDA, 2006; Gudeman et al., 2013; Minghetti et al., 2014; 
Phillips et al., 2015).  
The treatment of NOP can be frustrating for the patient and clinician alike as 
finding agents to alleviate the suffering can be benefits from the patient’s point 
of view (Durham and Nixdorf, 2014). It is perhaps this challenge that has driven 
the desire to compound topical formulations of agents known to be effective 
systemically for NOP. The issue of topical treatment toxicity is less well 
addressed and reported as there are only low power and uncontrolled clinical 
studies examining the topical application of neuromodulatory medications in 
NOP. 
The programme of research in this thesis came about due to the concerns of 
the research team about the safety of compounded topical treatment, because 
of the lack of evidence that this administration route had been sufficiently 
examine to be approved for use. The standard drug approval process 
comprises long and expensive steps of drug design, efficacy and safety 
procedures, and can result in a high percentage of drugs being rejected after 
the process is complete because of safety or toxicity problems (Hopkins, 2008).  
The drug approval process contains three main steps: Discovery and design, 
preclinical and clinical stage, in addition to the post authorization monitoring 
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(FDA, 2015b). The cytotoxicity of a new drug is tested by what is defined as the 
pre-clinical investigations and guidelines, these investigations can be simply 
summarised as: Single and repeated dose safety, genotoxicity, carcinogenicity, 
reproductive and developmental toxicity, photo-toxicity, hepatotoxicity, 
mitochondrial toxicity and drug dependence (EMA, 2015b; FDA, 2015c).  
The European Medicines Agency (EMA), recently included new guidelines in 
the preclinical drug approval process, which is the local tolerance of the drug. 
The new guidelines states that the drug cytotoxicity should be tested in vitro on 
tissues that will intentionally or accidentally be in direct contact with the drug. 
Unfortunately, the new guidelines will start in May 2016 and do not include 
drugs now used globally as compounded topical treatment for patient suffering 
chronic sickness such as NP (EMA, 2015a). 
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1.8 Cell lines and tissues 
Prior to any human clinical trials, in vitro cellular investigation, with all its 
limitations and advantages, is the classical method for preclinical testing and 
prediction of the expected toxicity. The selection of in vitro monolayer cell line 
models and methods of investigations are expected to be representative of both 
the target tissue and clinical course of the drug when used clinically (Astashkina 
et al., 2012). 
Monolayer cell line testing has the benefit of reproducibility and availability 
especially if multiple tests are to be conducted at different times. The 
reproducibility of results is not otherwise always guaranteed if primary cell 
culture is used instead as the investigation model. The primary cell culture is a 
logical in vitro representative model, but its limitations have resulted in less use 
in in vitro studies. Among these limitations are: untoward biological effect of in 
vitro environment itself as opposed to the drug under test; limitation of patient 
and donor ethical requirement and passage number restriction especially when 
further studies to be conducted (Ekwall et al., 1991; Ch, 2009). 
Different human and animal cell lines were chosen in this study as 
representative of orofacial tissue. The selection was based on the tissue 
expected to be in direct prolonged, contact with topical agents. These cell lines 
have already been employed in different studies to investigate various orofacial 
reactions and cytotoxicity resonances to different materials: 
1- Mouse fibroblast, 3T3 cell line was used as representative of gingival 
fibroblast as previously employed (Geurtsen et al., 1998; Pereira et al., 
2002).  
2- Immortalized oral keratinocytes from floor of mouth OKF6-TERT1 cell 
line was selected as representative of oral keratinocytes having already 
been used in the literature in this respect (Dickson et al., 2000; Oviir et 
al., 2006; McLeod et al., 2014).  
3- Skin keratinocytes as one of the expected tissues exposed to the topical 
treatment if used extra-orally: the HaCat cell line was used as 
representative of skin keratinocytes with multiple applications in skin 
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reaction and investigations (Boukamp et al., 1988; Moharamzadeh et al., 
2007). 
4- Primary gingival fibroblast cells were used as representative of gingival 
fibroblast and implemented in the in-house 3D tissue construction. These 
cells were collected from biopsy after routine dental treatment following 
ethical approval (no. 09/ H1308/ 66) and consent (Colley et al., 2011).  
5- The keratinocyte compartment of the in-house constructed cells was 
FNB6 cell line. These normal oral keratinocytes are immortalized cells 
obtained from dysplastic biopsy (Muntoni et al., 2003).  
6- MatTek model was used in this study was bought from MatTek 
corporation as representative of oral gingival tissue, made by primary 
cells (oral keratinocytes and gingival fibroblasts) with early passages 
(MatTek, 2015). 
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1.9 Summery 
The systemic treatment of NOP is usually associated with an intolerable side 
effect profile that affects patient’s adherence to treatment. Topical management 
offers the chance to avoid such heavy burden of side effects and deliver pain 
relief in mild and moderate cases (Heir et al., 2008). This may have helped in 
evolving and progressing topical compounded treatment. In spite of the 
limitations of clinical studies that have employed topical medications in the 
orofacial region,  many studies revealed the wide acceptance and application of 
topical medication in management of NP all over the body including NOP 
(Epstein et al., 1997; Padilla et al., 2000; Sawynok, 2003; Strümper and 
Durieux, 2003; Argoff, 2004; Vidal et al., 2004; Lynch et al., 2005b; de Leon-
Casasola, 2007; Heir et al., 2008; McCleane, 2010; Jorge et al., 2011; Kopsky 
and Keppel Hesselink, 2012; Haribabu et al., 2013; Sawynok, 2014; Thompson 
and Brooks, 2015). The NMs employed in topical treatment have the approval 
for systemic administration, but have only been designed for this administration 
(FDA, 2015a). Very few studies have tested the topical effects of NMs on 
human cells. Some have suggested that there is evidence of cell death and 
limitation of cellular proliferation (Yun et al., 2005; Moreno-Fernández et al., 
2008) following topical application. This, therefore, raises important questions 
about the potential untoward local effects caused by these drugs when applied 
to the orofacial tissue which tends to have a high cellular turnover rate. This 
also becomes especially pertinent if topical administration of the NMs to the oral 
mucosa and facial skin proves effective in the short-term and is then prescribed 
as a regular long-term medication. In this study we will investigate the effects of 
selected topical drugs on cell lines and tissue relevant to oral tissue in vitro.  
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1.10 Aims and Objectives 
The aim of this study was to investigate the effect of pharmacological 
concentrations of three neuromodulatory medications (amitriptyline, 
carbamazepine and gabapentin) frequently reported to be applied topically on 
cell lines and tissue relevant to the orofacial tissue in vitro. 
The specific objectives were: 
Phase 1 Using monolayer cell culture to investigate: 
1- Both cumulative and specific time cellular viability using alamarBlue® 
assay against a range of concentrations of the three NMs. 
2- Cellular counting using CCK-8 assay against a range of concentrations 
of the three NMs using specific time exposure.  
3- Cellular morphology and attachment following 30 min exposure to the 
HPLC concentrations of the three NMs using scanning electron 
microscope. 
4- The expression of 20 different Cytokines after 30 min exposure to the 
HPLC concentrations of the three NMs. 
Phase 2 Using 3D models to investigate: 
1- The effect of amitriptyline on 3D tissue viability and cytotoxicity at 
different time points using alamarBlue® and LDH assays.  
2- Amitriptyline transport through the 3D tissue using anti-amitriptyline 
antibody in immunofluorescence technique and HPLC. 
3- The effect of amitriptyline on 3D tissue morphology and apoptosis activity 
using H&E and anti-caspase 3 antibody respectively. 
  
Phase 3 Using RNA from total human gingival tissue biopsy and SH-SY5Y cell 
line to identify the expression of receptors to the three NMs. 
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Chapter: 2 Materials and Methods 
2.1 Tissue culture techniques 
 All media and supplements were obtained from Sigma Aldrich, UK unless 
otherwise stated. Tissue culture procedures were carried out in Class II laminar 
hood (BioAir SafeFlow 1.2, Lafteck, Australia) in the tissue culture laboratory 
using aseptic techniques. An Incubator was used to maintain the tissue flask at 
37 ◦C, 95 % O2 and 5 % CO2 (Incu-Safe, Sanyo, Japan). 3T3 and HaCat cells 
were obtained from the European Collection of Authenticated Cell Cultures 
(ECACC), OKF6-TERT1 cell line was a gift from Dr. Max Robinson, Newcastle 
University. 
2.1.1 Growth and maintenance of 3T3 mouse fibroblast 
Mouse fibroblasts 3T3 cells passage 5, were propagated in Dulbecco-Modified 
Eagles Media (DMEM) with glutamine, 10 % (v/v) foetal bovine serum and 1 % 
(v/v, 100 U/100 µg) of penicillin /streptomycin. Mouse 3T3 cells were seeded in 
25 cm2 (T 25) flasks with 5ml of culture medium. The growth medium was 
replaced every day with fresh culture medium. Cells were passaged at ratio of 
1:5 every 3-4 days or when 80 % confluency was reached, which was assessed 
by light microscopy (Leica, UK). Cells were washed with phosphate buffered 
saline (PBS: 137 mM NaCl2, 2.7 mM KCl, 4.3 mM. Na2HPO4.7H2O, 1.4 mM 
KH2PO4, pH 7.3) after discarding old growth medium. Then 3 ml of 0.05 % 
trypsin/ 0.2 % Ethylenediaminetetraacetic acid (v/v, EDTA) was added and the 
flask incubated for 3-5 min, to insure cell detachment. After cell detachment, the 
trypsin was neutralized with fresh 7 ml culture medium. Cells were seeded at 
approximately 1 million cells / flask into 75 cm2 flask (T 75). 
2.1.2 Growth and maintenance of human oral keratinocyte cells (OKF6-
TERT1) 
The Keratinocyte-Serum Free Media with glutamine (K-SFM), bovine pituitary 
extract and epidermal growth factor were obtained from Life Technologies, UK. 
The growth media was prepared by adding bovine pituitary extract (30 g/ml), 
epidermal growth factor (0.1 ng/ml), calcium chloride (0.3 mM) and 5 ml 
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penicillin /streptomycin to K-SFM. A frozen stock of OKF6-TERT1 cells at 
passage 3 were initially seeded in 25 cm2 flask (T 25) with 5 ml culture medium. 
Cells were passaged 7-9 days later or when 80 % confluency was reached. 
Cells were trypsinized with 3 ml of trypsin/EDTA added to the flask for 30 
second after discarding the media, then a new 3 ml trypsin used and the flask 
kept in the incubator for 8-10 min. When the cells detached, 15 ml of DMEM 
was used to neutralize the trypsin, and it was centrifuged at 2000 rpm for 10 
min. Cells were then seeded in new flask at density of 1 million / flask with fresh 
K-SFM media.  
2.1.3 Growth and maintenance of human skin keratinocytes cells (HaCat) 
HaCat cells at passage 70 were propagated in the DMEM media (Section 2.1.1) 
and passaged after 4-5 days or after 80 % confluency was reached. After 
aspirating the culture media, the flask washed twice with EDTA, then 3 ml 
trypsin/EDTA added and the flask incubated for 5-10 min. A fresh media was 
added and the suspension centrifuged for 5 min at 1200 rpm. The media was 
then replaced with fresh culture media and the cells seeded as new passage in 
75 cm2 flask (T 75). Cells were seeded at approximately 1 million cells / flask 
into 75 cm2 flask (T 75). 
2.1.4 Growth and maintenance of primary human gingival fibroblast 
Primary human gingival fibroblasts cells at passage 3 was a gift from School of 
Clinical Dentistry/ University of Sheffield. Cells were propagated in Dulbecco-
Modified Eagles Media (DMEM) with glutamine, 10 % (v/v) foetal bovine serum 
and 1 % (v/v, 100 U/100 µg) of penicillin /streptomycin. Cells were passaged at 
ratio of 1:3 every when 80 % confluency was reached. Cells were washed with 
phosphate buffered saline then 3 ml of trypsin/ EDTA was added and the flask 
incubated for 3-5 min, to insure cell detachment. After cell detachment, the 
trypsin was neutralized with fresh 7 ml culture medium. Cells were seeded at 
approximately 1 million cells / flask into 75 cm2 flask (T 75). 
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2.2 Preparation of drugs for use in cell culture  
Amitriptyline hydrochloride, gabapentin and carbamazepine were purchased in 
pure sterilized form from Sigma-Aldrich, UK. All the preparations and dilutions 
were made in the Class II hood. Manufacturer instructions were followed in risk 
and safety measures. 
2.2.1 Amitriptyline hydrochloride 
Amitriptyline was initially dissolved in double–distilled water (dd H2O) to 
concentration of 1 % (w/v) and stored in the dark at 4 ◦C. The working 
concentrations were made by further dilution in PBS first and then culture 
media. Concentrations are shown in Table 2.1: 
 
Volume 0.07% drug solution 
(µl) 
Volume of media 
(µl) 
Concentrations 
(M) 
14 1486 20 
34 1466 50 
68 1432 100 
136 1364 200 
272 1228 400 
409 1829 600 
544 966 800 
681 819 1000 
818 682 1200 
886 614 1300 
954 540 1400 
357(0.2%) 1143 1500 
380(0.2%) 1120 1600 
404(0.2%) 1096 1700 
428(0.2%) 1072 1800 
 
Table 2.1: Amitriptyline’s range of concentrations that was used in cumulative 
cellular viability experiments in 3T3, HaCat and OKF6-TERT1 cell lines using 
alamarBlue®. 
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2.2.2 Gabapentin  
Gabapentin was dissolved in dd H2O to concentration of 0.5 % (w/v) solution 
and stored in the dark container at 4 ◦C. Further dilution was made (0.017 %, 
w/v) before the required concentrations were prepared with appropriate culture 
media according to the cell line type. Concentrations are shown in  
Table 2.2: 
 
Volume 0.017% drug solution 
(µl) 
Volume of media 
(µl) 
Concentrations 
(M) 
13.5 2236.5 6 
67.5 2182.5 30 
135 2115 60 
225 2025 100 
337.5 1912.5 150 
450 1800 200 
562.5 1687.5 250 
675 1575 300 
900 1350 400 
1125 1125 500 
1350 900 600 
1575 675 700 
1800 450 800 
2025 225 900 
380 (0.5% drug solution) 1620 5540 
 
Table 2.2: Gabapentin’s range of concentrations that was used in cumulative 
cellular viability experiments in 3T3, HaCat and OKF6-TERT1 cell lines using 
alamarBlue®. 
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2.2.3 Carbamazepine  
Carbamazepine was initially dissolved in 100 % (v/v) ethanol to concentration of 
2 % (w/v) solution and stored in the dark at room temperature. To create 
working concentrations, further dilution was made (0.07%, w/v) in culture media 
before designed concentrations were made as shown in  
Table 2.3: 
   
Volume 0.07% drug solution 
(µl) 
Volume of media 
(µl) 
Concentrations 
(M) 
5 1495 10 
15 1485 30 
30 1470 60 
50 1450 100 
75 1425 150 
100 1400 200 
150 1350 300 
200 1300 400 
250 1250 500 
300 1200 600 
350 1150 700 
400 1100 800 
500 1000 1000 
550 950 1100 
650 850 1300 
750 750 1500 
850 650 1700 
1000 500 2000 
1050 450 2100 
 
Table 2.3: Carbamazepine’s range of concentrations was employed in 
cumulative cellular viability experiments in 3T3, HaCat and OKF6-TERT1 cell 
lines using alamarBlue®. 
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2.3 Monolayer cell culture viability experiments 
AlamarBlue® (AbD Serotec, UK) was used to establish cellular viability. The 
differences in chemical reduction of an indicator (Resazurin) were measured in 
the growth media reflecting cellular viability.  
2.3.1 Cell density and incubation time 
Firstly, appropriate cell line density and appropriate incubation time were 
established for each cell line. Each cell type were seeded at density of 5000, 
10000 and 20000 (+ 25,000 for OKF6-TERT1 cell line) cells per well in 96 well 
plate and culture media was added to a final volume of 200 µl per well. After 
overnight incubation at 37 ◦C, the media was replaced with different 
concentrations of drug in addition to 10 % (v/v) alamarBlue®. Absorbance was 
measured at two wavelengths (570/600) nm using a plate reader (BioTek, 
Winooski, VT) at 30 min, 1 h, 2 h, 4 h and 24 h. The cell viability was calculated 
using the following equation:  
 
 
   
 
     
Where:
 
O1 = molar extinction coefficient (E) of oxidized alamarBlue® (Blue) at 570 nm 
O2= E of oxidized alamarBlue at 600 nm  
R1 = E of reduced alamarBlue (Red) at 570 nm  
R2= E of reduced alamarBlue at 600 nm  
A1 = absorbance of test wells at 570 nm  
A2 = absorbance of test wells at 600 nm  
N1 = absorbance of negative control well (media plus alamarBlue® but no cells) 
at 570 nm 
N2 = absorbance of negative control well (media plus alamarBlue but no cells) 
at 600 nm 
Percentage reduction of alamarBlue® =   
(O2 x A1) - (O1 x A2)        
*100                                                                                 
                              
(                                                                     (R1 x N2) - (R2 x N1)   
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2.3.2 Cumulative cell viability assay 
The information for the cell density and incubation time was found in the 
previous experiment (Section 2.3.1). The 3T3, OKF6-TERT1 and HaCat cells 
were trypsinized and seeded at 10000, 20000,10000 cells  per well respectively, 
in a 96-well plate to a final volume of 200 l per well, being incubated overnight 
at 37 ◦C. Media was then replaced by medication solution at one of the tested 
concentrations plus 10% (v/v) of alamarBlue®. The plate reader was used to 
measure absorbance at (570/600) nm at 30 min, 1 h, 2 h, 4 h and 24 h time 
points. The percentage difference in reduction between control and treated cells 
was calculated using the following equation: 
 
 
 
 
Where: 
O1 = molar extinction coefficient (E) of oxidized alamarBlue® (Blue) at 570 nm  
O2= E of oxidized alamarBlue at 600 nm 
A1 = absorbance of test wells at 570 nm  
A2 = absorbance of test wells at 600 nm  
P1 = absorbance of positive growth control well  
(cells plus alamarBlue but no test agent) at 570 nm  
P2 = absorbance of positive growth control well  
(cells plus alamarBlue but no test agent) at 600 nm 
 
The results represent the cytotoxicity effect of the drugs on cells viability. 
Percentage difference between controls 
and treated cells                                     =      
(O2 x A1) - (O1 x A2)    
*100                                                                                 
                              
(                                                                       (O2 x P1) - (O1 x P2) 
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2.3.3 Effect of NMs at specific time points  
The keratinocytes cells, HaCat and OKF6-TERT1, were used in similar culture 
and counting as in the cumulative method. The cells were seeded in final 
volume of 100 µl/well in 96 well plate. After drug exposure at 30 min and 24 h, 
cells were washed with PBS before adding fresh culture media and 10% 
alamarBlue®. High and low concentrations (Table 2.4) were used and the 
absorbance was measured 4 h after the addition of alamarBlue®, using the 
same wavelengths and calculation method (Section 2.3.2). 
 
Medications Low concentration 
(µM) 
High concentration 
(mM) 
Amitriptyline 200 1.8 
Carbamazepine 100 1.7 
Gabapentin 150 5.54 
 
Table 2.4: High and low concentrations of NMs were used to investigate viability 
change in specific time points experiment in HaCat and OKF6-TERT1 cell lines 
using alamarBlue®. 
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2.3.4 Calculation of median lethal dose (LD50) 
Two different colorimetric assays (alamarBlue®, MTT) were used to investigate 
the concentrations of NMs required to kill 50 % of the cultured cells. 
a- AlamarBlue® assay 
The LD50 values of NMs were investigated in the three cell lines (3T3, HaCat 
and OKF6-TERT1). Using both exposure methods, the cumulative and specific 
time, the cell culture method were carried out as in Section 2.3.2 and 2.3.3 
respectively. The concentration of NMs (Table 2.1, Table 2.2, Table 2.3), were 
used to conduct the experiments. The calculations were made using the 
following equations and the results were transferred to semi log graph paper to 
find the LD50 value: 
 AOLW = Absorbance of AB in media – Absorbance of media only  
 AOHW = Absorbance of AB in media – Absorbance of media only 
 R0 = AOLW/AOHW  
 Percentage difference in reduction = ALW – (AHW x R0) for test well       x 100  
                                                               
ALW – (AHW x R0) for control well  
 
Where: 
AOLW = absorbance of oxidized form at the lower wavelength  
AOHW = absorbance of oxidized form at the higher wavelength  
ALW = absorbance at lower wavelength minus the media blank  
AHW = absorbance at higher wavelength minus the media blank  
R0 = Correction factor   
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b- MTT assay 
MTT assay was used to investigate the LD50 value for amitriptyline in FNB6 cell 
line. The cells were trypsinized and seeded as 5000/ well for LD50 experiment, a 
range of concentrations of amitriptyline was prepared in FNB6 culture media 
(Table 2.1). After 24 h incubation, the old media replaced with medication 
solution at one of the amitriptyline concentrations. After incubation for 30 min 
and 24 h, the media was discarded and the wells were washed with PBS before 
adding new media + 10 % (v/v) of MTT assay. Following 2 h incubation, the 
MTT media was discarded and a solubilisation/stop Solution [10% Triton-X 100 
in acidic Isopropanol (0.1N HCl)] of 100 µl/well was added for 30 second before 
absorbance reading using plate read at 570 nm. 
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2.4 Cell counting experiments in monolayer cell culture 
Cell Counting kit-8 (CCK-8) from Dojindo Laboratories (Kumamoto, Japan), was 
used to investigate the effects of the tested three NMs on the cell counts in 
vitro. The assay mechanism is based on cellular activity, specifically 
dehydrogenases and mitochondrial activity, resulting in reduction of Tetrazolium 
salts (yellow) to Formazan (orange) that can be quantified by plate reader in 
growth media. 
HaCat and OKF6-TERT1 cells were seeded and treated as in Section 2.3.3, 
alongside a range of control cells seeded at different cell densities to establish a 
calibration curve. Calibration curves were made by seeding the cells at different 
mounting count for HaCat and OKF6-TERT1 cells, Table 2.5 . 
After incubation for 30 min and 24 h, the effect of the NM was stopped by 
washing the cells with PBS. Cells were then incubated with 100 µl fresh culture 
media plus 10 % (v/v) CCK-8 reagent. Absorbance was measured after 
incubation for 150 min using a plate reader (BioTek, Winooski, VT) at 450 nm 
wavelength. The results were drawn against the calibration curve to estimate 
the final change in cell count after NMs exposure. 
 
HaCat cells  
cell/ well 
OKF6-TERT1 cells 
cell/well 
Calibration curve counts Test count Calibration curve counts Test count 
1,000 10,000 2,000 20,000 
2,000 5,000 
5,000 10,000 
10,000 15,000 
15,000 20,000 
20,000 25,000 
Table 2.5: Cell counts in calibration curve made to estimate the effect of NMs 
exposure on HaCat and OKF6-TERT1 cells in vitro. 
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2.5 3D tissue cell culture 
Two types of 3D tissues were used in the amitriptyline investigation: a cell line 
model (in-house constructed) and a primary cell model (MatTek). Culture media 
used in tissue maintenance depended upon cell type used to construct the 3D 
model, but mainly consisted of DMEM: F-12HAM, with group of additives to 
induce tissue growth and differentiation such as 10 ng/ml epidermal growth 
factor, 0.4 µg/ml hydrocortisone and 5 µg/ml insulin. 
2.5.1 In-house constructed 3D model 
The 3D tissue was constructed and tested in the laboratories of School of 
Clinical Dentistry/ University of Sheffield. Two types of cells were implemented: 
FNB6 cell line, representing oral keratinocyte as the top layers (250, 000 cells / 
transwell plate) and the second cell type was primary human gingival fibroblast 
(250, 000 cells / transwell plate); both were seeded onto a rat-tail collagen in a 
transwell plate with 0.4 µm pore size (Corning, USA). After 21 day incubation, 
the tissue was implemented in the experiments. The media were replaced every 
day with 500 µl of culture media in the lower chamber of transwell plate. 
2.5.2 MatTek 3D tissue model 
Tissue models were bought from MatTek Corporation, USA, Figure 2.1. Tissue  
was constructed using primary gingival keratinocytes and fibroblast that seeded 
on collagen coated membrane with pore size  0.4 µm, inner diameter = 0.875 
cm. Surface area = 0.6 cm2 using MillicellTM CM microporous membrane 
tissue culture inserts (Millipore Corporation, Bedford, MA). Trans-epithelial 
electrical resistance (TEER) of each lot is measured prior to shipment (QC 
specification: GIN-100: 516 + 122 ohms*cm2).
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Figure 2.1: The cell culture of 3D tissue (A) air liquid interface tissue culture using tissue inserts (B) layers of full thickness gingival tissue 
from MatTek. 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer. Reproduced from Klausner et al. (2007) with permission, 
Appendix A.8
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2.6 3D tissue viability experiments 
AlamarBlue® was used to investigate viability in response to amitriptyline 
exposure in both 3D models. AlamarBlue® assay time was 2 h in the in-house 
constructed 3D model and 6 h in the MatTek 3D model. Amitriptyline 
concentration was 226 µM in both models and all time points. 
For in-house constructed model, two time points were used 30 min and 24 h; in 
MatTek models, tissue was exposed to amitriptyline at the following time points: 
30 min, 24 h, twice daily (B.I.D.) and three times a day (T.I.D.) for three days. 
2.6.1 Viability in both 3D models at 30 min and 24 h  
Three tissue inserts were used for test and control. Amitriptyline solution (226 
µM) was applied in 100 µl volume on the top of the tissues and media only for 
the control tissues. For the lower chamber, 1 ml of fresh media was applied for 
both test and control tissues. Either after 30 min or 24 h incubation, the tissue 
inserts were transferred for a new 6 well plate and washed twice with PBS. The 
old media was stored, and an aliquot was sent for Amitriptyline quantification by 
HPLC. The tissue inserts were then incubated with 500 ml of media plus 10 % 
(v/v) alamarBlue® on the top in new 6-well plate. The incubation time was 6 h in 
MatTek models and 2 h in in-house models. The media were then aspirated and 
placed in 96-well plate with 100 ul/well to measure absorbance by plate reader 
at (570/600) nm. 
2.6.2 Repeated exposure viability assay 
The 3D tissue models were exposed to amitriptyline as in the 30 min exposure 
but instead of adding media plus alamarBlue® after 30 min, tissue inserts were 
replaced in a new 6 well plate with 1 ml fresh media in the lower chamber after 
washing, for further exposures. These procedures were repeated twice and 
three times daily, using separated sets of tissue, for three days before the 
alamarBlue® testing were done. 
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2.7 Lactate dehydrogenase assay (LDH), cytotoxicity assay 
Culture media from viability experiments in both 3D models (The MatTek and in 
–house constructed) was stored at -20 °C and used in the LDH assay 
(CYTOTOX96®, Promega, UK). The media from 3D tissue experiments were 
thawed and transferred to 96-well plate as 50 µl per well (n=3) and then 50 
µl/well of reconstituted substrate mix was added. After 30 min incubation at 
room temperature in the dark, 50 µl of stop solution was added and absorbance 
was measured by plate reader (BioTek, Winooski, VT) at 490 nm. 
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2.8 Doubling up technique to compound medications in Orabase paste 
For these experiments, a sterile, without additives, Orabase paste (ConvaTec 
UK, Flintshire, UK), (containing: gelatin, pectin, sodium carbnoxymethyl 
cellulose, polythene and liquid paraffin) was used. The required amount of the 
pure medication and paste were weighed and placed separately on a glass tile 
in the Class II hood (Table 2.6). The Doubling up technique was used to mix 
small equal amount of powder and paste volume by spatula using the shearing 
technique. The process was repeated until all the powder was incorporated into 
the paste. The powder/paste compound was then mixed with an equal volume 
of fresh remaining paste and this step repeated until all the paste was used and 
a homogenous compound was formed. 
 
Types (w/v) Amount of Pure 
medication (mg) 
Amount of Orabase 
paste (g) 
2 % Amitriptyline 20  1  
4 % Carbamazepine 40  1  
4 % Gabapentin 40  1  
 
Table 2.6: List of drugs and Orabase paste weights, were used to compound 
NMs medications using doubling up technique. 
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2.8.1 Determining drug release from the paste 
A decided amount (2 g) of compounded paste of each medication were applied 
with a small spatula on the walls of the 6-well plate filled with 10 ml of culture 
media. The plate was incubated at 37 °C. After incubation for 30 min and 1 h, 2 
ml media was aspirated for each time points. The media was sent to Cardiff 
toxicology laboratories to measure drug release from the Orabase paste by 
HPLC at different time points, the experiments done in replicate. 
Conditions used in HPLC investigation are shown in Table 2.7. 
Instrument Perkin Elmer Flexar 
Column  Spherisorb CNRP 5µ, 25cm (Column Position :1) 
Column Temperature Ambient 
Flow rate 2 ml/min 
Mobile Phase Acetonitrile: 10 mM phosphate buffer,pH 3.0 (30:70)  
Detector  PerkinElmer Flexar PDA  Analytical Wavelength : 210 nm 
 
Table 2.7: The conditions of HPLC used by Cardiff toxicology laboratories to 
investigate NMs concentrations in the culture media during drug release 
experiments and in the amitriptyline passage experiments in the 3D tissue cell 
culture. 
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2.9 Scanning electron microscopy 
Cells were seeded onto glass cover slips at density of 100,000 per well for 3T3 
cells and HaCat cells; and 200,000 per well for OKF6-TERT1 cells. After 
overnight incubation, media was replaced with media containing drug 
concentrations at a level dictated by the HPLC results. After 30 min incubation, 
the spent media were stored at -20 °C freezer for use with Human Inflammation 
Antibody Array experiment. The wells were then washed with PBS and left at 4 
◦C fridge with 2 % (v/v) Glutaraldehyde in Sorenson’s phosphate buffer for 
fixation. Twenty four hours later, this was replaced by the following dehydration 
steps: 25 % ethanol for 30 min, 50 % ethanol for 30 min, 75 % ethanol for 30 
min and finally the cover slips were immersed with 100 % ethanol for 1 h and 
complete drying was carried out by the Baltec Critical Point Dryer at Electron 
Microscopy Research Services at Newcastle University. After mounting, the 
coverslips were coated with 15 nm of gold using a SEM unit (Polaron 
Equipment Limited, Watford, UK). 
2.10 Human Inflammation Antibody Array 
All buffers and membranes were purchased from RayBiotch®, Norcross, USA. 
The buffers were prepared and stored according to the manufacturer’s 
instructions. All the incubation steps were made at room temperature with 
rocking at 0.5 cycle/sec except the overnight incubations in which the samples 
stored at 4 ˚C in the fridge. The membranes were then incubated with 2 ml 
blocking buffer, supplied in the kit, for 30 min. The membranes were then 
incubated with 2 ml of conditioned media (spent media from Section 2.9) 
overnight at 4 °C. The media was discarded and the membranes were washed 
three times with wash buffer before further washes with buffer II. After washing, 
1 ml of pre-prepared Biotinylated Antibody Cocktail was added to each 
membrane and incubated for a further 2 h. The washing steps were then 
repeated after discarding the Biotinylated Antibody Cocktail. A second wash 
was carried out before incubating the membranes with 1 X HRP-Streptavidin 
overnight at 4 ˚C. Final washes were made and the membranes were placed on 
tissue paper for drying and then transferred to a plastic sheet with printed side 
up. Detection buffer mix (500 µl/ membrane, 250 µl detection buffer C + 250 µl 
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detection buffer D) was added and another plastic sheet placed over the 
membranes with slight rolling to avoid air bubbles. The membranes were 
exposed to x-ray film within 10-20 min of detection buffer application and the 
best representive pictures were recorded at 1-2 min exposure time using highly 
sensitive Amersham Hyperfilm ECL, UK. The twenty different target cytokines 
are arranged in the array membrane as shown in Table 2.8. 
Data analysis was made after subtraction the background values from reported 
spot. The final values were calculated using the following equation:  
X(Ny) = X(y) * P1/P(y) 
P1 = mean signal density of Positive Control spots on reference array 
P(y) = mean signal density of Positive Control spots on Array "y" 
X(y) = mean signal density for spot "X" on Array for sample "y" 
X(Ny)= normalized signal intensity for spot "X" on Array "y" 
Reference array= it is positive control spots to which the other arrays are 
normalized. 
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 A B C D E F G H 
1 POS POS NEG NEG Eotaxin-
1 
Eotaxin-
2 
G-
CSF 
GM-
CSF 
2 POS POS NEG NEG Eotaxin-
1 
Eotaxin-
2 
G-
CSF 
GM-
CSF 
3 IFN 
gamma 
IL-1 
alpha 
IL-1 
beta 
IL-2 IL-3 IL-4 IL-6 IL-7 
4 IFN 
gamma 
IL-1 
alpha 
IL-1 
beta 
IL-2 IL-3 IL-4 IL-6 IL-7 
5 IL-8 IL-10 IL-11 IL-12 
p40 
IL-12 
p70 
IL-13 I-309 TIMP-2 
6 IL-8 IL-10 IL-11 IL-12 
p40 
IL-12 
p70 
IL-13 I-309 TIMP-2 
7 BLANK BLANK BLANK BLANK BLANK BLANK NEG POS 
8 BLANK BLANK BLANK BLANK BLANK BLANK NEG POS 
POS = Positive Control Spot, NEG = Negative Control Spot, BLANK = Blank Spot 
 
Table 2.8: The type and arrangement of inflammatory cytokines in RayBioteck 
array membrane. 
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2.11 Immunohistochemistry analysis 
After alamarBlue® was applied, the tissue inserts from in-house constructed and 
MatTek models were transferred to new 6 well plate for washing with PBS, 
before 24 h fixation with 10 % (w/v) formalin. Tissue embedding and slide 
preparation was then carried out to prepare slides for further 
immunohistochemistry and immunofluorescence studies.  
2.11.1 Haematoxylin and Eosin (H&E):  
Staining with H&E was carried out for the in-house constructed and MatTek 
tissue models in the school of clinical dentistry/ the university of Sheffield and 
Royal Victoria Infirmary pathology laboratory/Newcastle Hospitals NHS 
Foundation Trust respectively using automated system (Ventana Benchmark 
Autostainer, Ventana Medical Systems Inc, USA). Slide examination was carried 
out by light microscope to investigate any morphological changes after 
amitriptyline exposure at all time points. 
2.11.2 Apoptotic activity: 
 Two types of apoptosis antibody (anti-caspase 3 antibody) were used to 
investigate apoptosis throughout the 3D tissue model in response to 
amitriptyline exposure: Menapath polyclonal Caspase 3 antibody (Biocare LLC, 
California, USA) and a rabbit monoclonal caspase 3 antibody from R&D 
systems 269518 (R&D Systems, Inc., USA).  
Using the aforementioned anti-caspase 3 antibodies, tissue slides were treated 
in the Royal Victoria Infirmary pathology laboratory/Newcastle Hospitals NHS 
Foundation Trust.  
The immunohistochemistry was carried out in the department of Cellular 
Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust. The 
sections of formalin-fixed-paraffin-embedded 3D cell models (4 µm thickness) 
were immunohistochemically stained on a Ventana Benchmark Autostainer 
(Ventana Medical Systems Inc, USA). The primary antibodies for 
caspase 3 were used at 1:1000 and 1:300 dilution for rabbit monoclonal and 
menapath polyclonal respectively. The sections were subject to heat retrieval 
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with pH 9 buffer (Ventana Benchmark Autostainer protocol CC1) and staining 
was generated using ultraView detection reagent (Ventana Medical Systems 
Inc, USA).  Sections of tonsil were used as positive controls, negative controls 
omitted the primary antibody. 
Slides examination and counting was carried out using light microscope and the 
counting was made at 20 X magnification before it further calibrated by another 
researcher. 
2.12 Immunofluorescences investigation of amitriptyline passage through 
3D models 
Both 3D model types were fixed with 10 % (v/v) formalin for 24 h after viability 
studies were carried out. Immunohistochemistry experiment was carried out 
investigating the presence of amitriptyline within the tissue using the primary 
antibody, mouse monoclonal anti-amitriptyline antibody (AbCam®, UK). Slides 
were washed with TBS-1 (20 µM), TBS-T (TBS-1+ 1% (v/v) Tween) and TBS-1 
for 10 min for each step. Slides were incubated with primary antibody with 1:100 
dilution in Triton™ (Sigma, UK) in humidifier containers for 24 h at 4 °C. After 
incubation, slides were washed before adding 250 µl of the secondary antibody 
(anti-mouse, Alexa Flour 488, from Molecular Probes®, Invitrogen, UK) in 1:500 
dilutions in PBS. After 1 h incubation in the dark at room temperature, the 
washing was repeated; these steps were carried out in the dark. After washing, 
slides were mounted in medium of nuclei staining (Vectashield® HardSet™ 
mounting medium with DAPI, Vector laboratories, UK) plus glycerol before 
placing the cover slip. Examination was carried out using an Olympus BX61 
microscope, Japan. 
TBS-1: Tris Buffered-Saline 1X 
TBS-T: Tris Buffered-Saline 1X-Tween 
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2.13 RNA extraction 
RNA was extracted from monolayer cell lines (OKF6-TERT1) and human 
gingival tissue biopsy. 
2.13.1 Monolayer cell culture 
Trizol® reagent (Invitrogen, UK) was used to extract RNA, DNA and protein from 
monolayer cell culture. 1 ml of Trizol reagent was added to a T75 flask after 
discarding the culture media and the cell was washed with PBS.  A cell scraper 
was used in the fume hood until the chalky homogenous mixture result was 
obtained. The homogenised sample was then incubated at room temperature 
for 5 min before addition of 0.27 ml of chloroform with vigorous shaking for 15 
seconds. After 15 min incubation at room temperature, the sample then was 
centrifuged at 12,000  g for 15 min at 4 ◦C in order to complete phase 
separation. 
The aqueous phase supernatant, after centrifuging, was transferred to new 
tube, then precipitated by adding 0.625 ml of 100 % (v/v) isopropanol and 
incubated for 10 min at room temperature. The aqueous phase was then 
centrifuged at 12,000  g for 10 min at 4 ◦C.  
The supernatant was removed and the RNA pellet was washed by 1.25 ml of 75 
% (v/v) ethanol and centrifuged at 7,500  g for 5 min at 4 ◦C. The supernatant 
was removed and the tube left open at room temperature to dry for 5 min. The 
RNA was re-suspended with 20 l of RNase-free water. RNA concentration was 
assessed using the Nano-drop spectrophotometer (Thermo scientific, UK) and 
the 280/260 ratio was recorded and RNA stored at -80 °C freezer, for 
downstream applications. 
2.13.2 Gingival tissue 
Trizol® reagent from Invitrogen, UK was used to extract RNA. Gingival tissue 
was kept in RNAlater® (Ambion®, Paisley, UK) at -80 °C after surgery and 
before use. After thawing, the tissue was weighed and collected in 1.5 ml micro-
centrifuge tube before the addition of 0.75 ml of Trizol Reagent/50-100 mg 
tissue and pounded with pellet pestles for 5-10 min at room temperature to 
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homogenize the sample. Samples were then vigorously shaken for 15 seconds, 
after addition of 0.2 ml of chloroform. Before centrifuging, samples were 
incubated for 5-15 min at room temperature. Samples were then centrifuged at 
12,000 × g for 15 min at 4 ˚C to complete separation. 
The aqueous colourless upper phase, containing the RNA, was removed and 
employed in isolation, washing and re-suspension RNA extraction procedure. 
Intermediate and lower phenol phase was kept for future protein and DNA 
extraction procedures. 
At new tube, aqueous phased was mixed with 0.5 ml of 100 % isopropanol. 
After 10 min incubation at room temperature, then it was centrifuged at 12,000-
× g for 10 min at 4 ˚C to precipitated RNA as a gel like pellet. 
Isopropanol supernatant and the pellet were washed with 1 ml of 75 % (v/v) 
ethanol. Samples were centrifuged at 7500 × g for 5 min at 4 ˚C. RNA pellet 
were air dried for 5-10 min and dissolved with 20 µl of sterile distilled water. 
Before RNA was stored at -80 ˚C, concentrations were checked by Nano-drop 
spectrophotometer (Thermo scientific, UK) by measuring the absorbance on 
Nano drop and 260/280 ratios were recorded. 
2.14 RNA procedure  
2.14.1 cDNA first strands synthesis 
First strand of cDNA were prepared from RNA using reactions consisting of 1 
µg of RNA, 1 µl Oligo (dt) (VH Bio Ltd, 50 µM) with RNase free water until a 
final of 12.5 µl. The samples were then incubated in thermostat reactions at 65 
˚C for 5 min, followed by 1 min incubation in ice before addition of 1 µl of 
reverse transcriptase enzyme (Promega, UK Ltd), 2 µl dNTP, and 5 µl of 5 x 
First Stand Buffer and 4 µl water. The whole volume then incubated at 50 ˚C for 
60 min then at 70 ˚C for 15 min. For negative reaction, water was used in place 
of reverse transcriptase enzyme. 
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2.14.2 Polymerase chain reaction 
A PCR reaction containing 1 µl template cDNA, 0.2 µM forward primer, 0.2 µM 
reverse primer, 12.5 µl Taq master mix (New England Biolabs, UK) and 10.5 µl 
water were used for cDNA amplification. PCR reaction cycle started at 94 ˚C for 
denaturation for 30 sec, extension at 72 ˚C for 60 sec over a course of 30 
cycles. Annealing temperature was depending on primer design options but 
mainly ran between 50-62 ˚C for 30 s. 
2.14.3 Agarose gel electrophoresis 
Agarose gel was used to analyse PCR products. Agarose powder (Melford 
biolaboratories, UK) 1.5 % (w/v), dissolved in 50 ml of 1× TBE buffer (89 mM 
Tris base, 89 mM Boric Acid, 2 mM EDTA) and heated for 3-5 min avoiding 
excessive boiling. Gel red 10 % (v/v) was added to the cooled solution but 
before gelling and then poured into trays to set with gel combes in place. Eight 
microliters of PCR products were mixed with 2 µl of gel loading dye before 
placement in the gel slots. 5 µl of 100 bp DNA ladder was used to assess bands 
size were judged by 5 µl of 100 bp DNA ladder (Hyper ladder IV, Bioline, UK). 
Gels were run at 80 V for 1 h, and results were analysed and quantified by: 
G:BOX Chemi XL viewer;  gene snap and gene tools software (SYNGENE, 
Frederik, USA). 
2.14.4 Primer designs 
Oligonucleotides primers were designed using Blast/NCBI data base web site or 
ordered directly from commercially available oligonucleotide options (Life 
Technologies Ltd, UK), Table 2.9. Primers were selected to contain 20-23 base 
pairs, 50-60 °C (annealing) temperatures and to span intron-to-intron junctions. 
Primers with G and C nucleotide at the 3 and 5 ends were preferred and GC 
content was not less than 50%. All primers were produced in Integrated DNA 
Technologies (IDT). Blast/NCBI data base web site: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHom. 
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Table 2.9: Primers, sequences for all investigated receptors and ion channels. 
Subscript numbering refers to position of the primer on the gene. NCBI 
accession numbers included. * refers to commercial primers. 
 
 
Name and 
accession no. 
Primer sequence Length 
(bp) 
Annealing 
temp (°C) 
ADORA2A 
NM_001278497.1 
5’-809TCCCCTTTGCCATCACCATC828-‘3 
5’-1414AGTCGGGGCAGAAGAAAGTG1395-‘3 
606  58/60 
GRIN1 
NM_000832.6 
 
5’-1495AAGCCTCGAGGGTACCAGAT1511-‘3 
5’-1708TGCAAAAGCCGTAGCAACAC1689-‘3 
217 50, 51.9, 53.8, 
58 & 60 
GRIN1* 
NM_000832.6 
GGTCTGCAGGCTTCGCTCTAG 
GGCCCGGTCTTCCAGATGTT 
490 52.3 & 54.8 
GRIN2A 
NM_001134407.1 
5’-1123 GACAACAGCTTTGTGGGCTG1141-‘3 
5’-1337 TTGGGATGAGCTCCGTGTTC1356-‘3 
235 50, 51.9, 53.8, 
58 & 60 
GRIN2B* 
NM_000834.3 
5’-271 CTCTTCTGAGAACGAGCTCTGCT249-‘3 
5’-777 CTCACTTTGTCTGGCCTTGCTTTC753-‘3 
504 52.8 & 54.8 
GRIN2C* 
NM_000835.4 
CTCCAAGACCCAAGGCTGCTG 
ATGTGGCTCTCAGATGCCCTCTAG 
510 54.9 
GRIN2D 
NM_000836.2 
5’-643GTCCTTTGTAGCCGTGACCA662-‘3 
5’-1277TCCTGTCTCTGGTGAGGGAG1259-‘3 
635 50, 53.8, 56.1 
& 58 
GRIN1 
NM_000832.6 
 
5’-1495AAGCCTCGAGGGTACCAGAT1511-‘3 
5’-1708TGCAAAAGCCGTAGCAACAC1689-‘3 
217 50, 51.9, 53.8, 
58 & 60 
SCN3A 
NM_006922 
5’-3174 CATTTTTGCTGTGGTCGGCA 3193-‘3 
5’-3957 AGCTTGTTCACCTTCTCGGG3938-‘3 
784 54, 56.4/53.1 
SCN9A 
NM_002977.3 
5’-635 CCGTTTCAATGCCACACCTG645-‘3 
5’-1399GCTAAGAAGGCCCAGCTGAA1379-‘3 
758 51.1 
SCN11A 
NM_001287223.1 
5’-5824GCATCTTTGCCCTGGTAGGT834-‘3 
5’-1466GGCTGGTCTTTCCCAGACTC1447-‘3 
643 53.1 & 51.1 
CACNA2D1 
NM_000722.2 
 
5’-671AGGCAGCCAGAGGATAAAACC 692-‘3 
5’-991GATGTACCATGGTCTTCTGCG 970-‘3 
320 51.5/53.3 
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2.15 Purified PCR reaction from agarose gel 
QIAquick Gel Extraction Kit (Qiagen, UK) was employed to prepare purified 
PCR reaction if multiple bands were found in agarose gel run. Bands of interest 
were excised using sterile scalpel blade with ultraviolet screen guide. According 
to the excised gel-piece weight, 3 volumes of Buffer QG were added to 1 gel 
volume as per manufacturer’s instructions. It was then incubated at 50 ˚C for 10 
min with intermittent mix by vortex until been dissolved. After gel completely 
dissolved, 1 gel volume of isopropanol (100 mg = 100 ul) was added, then the 
mixture was transferred to QIAquick spin column in 2 ml collection tube and 
centrifuged for 1 min at room temperature at 17,000 × g. After discarding the 
flow – throw a series of washing and centrifuge were made by adding 0.5 ml of 
Buffer QG, 0.75 ml of was added to column and centrifuged as previously. 
Further centrifuging was made before putting the spin column in new 1.5 ml 
micro-centrifuge tube. For DNA eluting, 50 µl of EB Buffer was added with 
further centrifuging to collecting DNA was sent for sequencing to confirm PCR 
product (Eurofins Genomics, UK). 
 
2.16 Statistical analysis: Simple descriptive statistics, one-way ANOVA 
followed by Bonferroni post hoc tests, parametric independent sample t test and 
non-parametric two independent samples were conducted in SPSS version 22 
(SPSS Inc., Chicago, IL).  
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Chapter: 3 Monolayer Cell Culture Experiments 
 
3.1 Introduction 
The journey to drug approval passes through several standard steps beginning 
with molecular planning which includes identifying the route of administration, 
target tissue and receptors. Following molecular planning the drug approval 
process continues through serial phases of safety and specificity where the 
drug under development will be tested regarding its function, metabolism and 
excretion (EMA, 2015b; FDA, 2015b). The drugs of interest in this study 
(amitriptyline, carbamazepine and gabapentin), are already approved as 
systemic medication, however, dose limits, changing the route of administration, 
and target tissue suggest different pharmacodynamics and pharmacokinetics. 
The drug regulatory authorities, like the FDA, is then not responsible for the 
safety of any compounded version of the drug for instance in a topical form for 
orofacial tissues (FDA). In any topical treatment, peripheral tissue and receptors 
are the sites of action for the drug with minimal to no systemic absorption. This 
means, therefore that cytotoxicity testing for the systemic administration of the 
drug may be misleading for the topical administration. In topical administration, 
cytotoxicity is mainly linked to tissue that is in direct contact with the applied 
medication and not to the systemic absorption process. It is therefore important 
to assess safety of topically applied medications at the level of the tissue they 
are in direct contact with, taking in consideration the use of high concentrations, 
that are usually implemented topically and the variation in tissue exposure 
times.  
In this chapter, a group of investigations were carried out to assess the 
cytotoxicity of three neuromodulatory medications (NMs): amitriptyline, 
carbamazepine and gabapentin. These NMs were chosen as the initial drugs of 
interest as they have been identified as potentially helpful when applied topically 
in managing different neuropathic orofacial pain conditions (Padilla et al., 2000). 
These NMs have been applied in various concentrations using varying 
application vehicles or carrier media such cream and Orabase paste (ConvaTec 
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UK, Flintshire, UK), (Padilla et al., 2000; Sawynok, 2003; Heir et al., 2008). 
None of these medications have, however, had their effects on cellular viability 
or attachment examined when applied topically to orofacial tissues. Cellular 
viability (including cell counting) and attachment is a crucial first step in decision 
making about drug safety  (Niles et al., 2008).  
Safety and cytotoxicity testing in a monolayer cell line has been found to be 
convenient, cost effective, and reproducible when compared with animal or 
primary cell options, in both the drug industry and in dental material testing 
(Lovschall et al., 2002). Using a monolayer cell line also helps to reduce, refine 
and modify animal involvement in drug discovery during preclinical testing 
(EMA, 1997). The types of cell line used in this chapter, were matched as 
closely as possible to the first cells in long-term contact with topical treatment in 
the orofacial region. Oral and skin keratinocyte, HaCat and OKF6-TERT cells 
respectively were used as relevant models to human skin and oral mucosa 
epithelial cells. These are immortalized non cancer cell lines. According to 
clinically prescribed topical treatments from the literature (Padilla et al., 2000; 
Heir et al., 2008), high concentrations of NMs were implemented in this chapter 
comparing with concentrations used previously in cytotoxicity studies 
investigating cytotoxicity of NMs. 
Different types of cell based assays can be used to investigate cellular viability 
and cytotoxicity in testing drug safety. In the pharmaceutical industry, the 
biological and biochemical effect of drugs are submitted to automated cell 
based assay, in so-called “high throughput” screening. In this type of high 
throughput screening various assays are used to examine cellular viability 
including alamarBlue®, which is based upon biochemical cellular activity to 
reduce a chemical indicator (Resazurin) (Niles et al., 2008). The investigation of 
cellular viability at different time points is helpful in deciding maximum exposure 
times and concentration safety. We utilised alamarBlue® in the experiments 
described in this chapter alongside a further reagent CCK-8 in a cell counting 
experiment. The reason we took two approaches to investigating the effect of 
NMs on cellular viability is that alamarBlue® may not actually reflect the number 
of viable cells as a few remaining viable cells may produce overlapping colour 
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change and the reverse is also true (Ramirez et al., 2010). Cell-counting, 
therefore, serves as a useful cross-check of the results obtained from 
alamarBlue® testing.  
To find concentrations of NMs to be released from the topical treatment carrying 
agent in clinical treatment, a clinical orabase paste was prepared in the 
laboratory with desired concentrations of NMs and high-performance liquid 
chromatography (HPLC) was used to find how much concentrations will release 
from topical NM and to be used in the morphology and cytokine expression 
studies later. The NMs employed may also impact upon cellular integrity 
through membrane integrity and cellular attachment, so this was examined 
through the use of a scanning electron microscope to scrutinise any changes in 
cellular attachment and shape. To explore the changes in the inflammatory 
status after NM exposure, a Human Inflammatory Antibody Array was 
implemented serving this goal.  
 
 
 
 
 
 
 
 
 
83 
 
3.2 Cellular viability after exposure to NMs 
To optimize the viability methods to be used, several experiments with different 
concentrations were setup. The main objective was to apply the same high 
concentrations used clinically as topical treatment. However, problems were 
observed in dissolving the NMs in culture media using high concentrations, 
even when a low pH was induced. Carbamazepine solution preparations were 
associated with crystallization, which then interfered with the accuracy of plate 
reader readings. 
Further methods were designed, trialled and modified including the application 
of high concentrations of NMs mixed with rat collagen gel, which was then used 
to coat the bottom of well plates, but this resulted in a turbid solution and 
interfered with viability measurement.  
Clinical concentrations of NM containing paste were also prepared in the lab 
using Orabase paste from ConvaTec, Flintshire, UK, (containing: gelatin, pectin, 
sodium carbnoxymethyl cellulose, polythene and liquid paraffin). These 
preparations showed that it was impossible to apply the paste directly on the 
monolayer cell culture or grow cells on top of the paste as complete cell death 
was expected.  
As an alternative to coat the bottom of wells with paste, the walls of wells were 
coated with the desired concentrations of NM in the paste prior to seeding the 
cells in the wells. The problems experienced after using this method were that: 
It was difficult to control the constant volume of media as it was absorbed by the 
paste; the long incubation at 37 °C caused disintegration of the paste which 
disturbed the culture media.  
Following the experiences outlined above, a pragmatic decision was made to 
use a range of concentrations, diluted in media using the highest concentrations 
possible of the NM that still allowed full dilution and did not interfere with viability 
assessment. The cellular viability was measured using alamarBlue® as a 
colorimetric reaction, using two exposure methods which utilised two 
concentrations of NM (designated as high and low concentration) on three types 
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of cell line (3T3 mouse fibroblast cells, OKF6-TERT1 oral keratinocytes cells 
and HaCat skin keratinocytes cells).  
The two exposure methods used were:  
a)  Cumulative NMS effect.  
b) Specific time interval effect of NM. 
3.2.1 Experimental results from exposure of cell lines to a cumulative 
NMs effect.  
The three cell lines, 3T3, HaCat and OKF6-TERT1 were exposed to range of 
concentrations of the three NMs drugs. Ascending time points were 
implemented in this exposure method in an attempt to simulate the effect of 
continual cumulative exposure to NMs over time. The following results are for 
two sets of concentrations (high and low concentrations), the results of 
complete range of concentrations for the all NMs are presented in the Appendix 
B (Figure B.1, Figure B.2, Figure B.3, Figure B.4, Figure B.5, Figure B.6, Figure 
B.7, Figure B.8 and Figure B.9). 
In the mouse fibroblast, 3T3 cells, exposure to amitriptyline in high 
concentration (1.8 mM) was associated with a significant reduction in cellular 
viability at all time points measured compared with untreated control cells 
(p<0.05, one-way ANOVA followed by Bonferroni’s post hoc test). Low 
concentration of the same drug (200 µM) reduced cellular viability significantly 
after only 24 h exposure. At both concentrations of carbamazepine (100 µM 
low; 1.7 mM high) cellular viability was not affected at any time point (p>0.05). 
Both concentrations of gabapentin (150 µM low; 5.54 mM high) reduced cellular 
viability in the 3T3 cells: low concentration induced a significant reduction in 
cellular viability at all time points; high concentration was associated with a 
significant decrease in cellular viability reduction after 2 h exposure (p<0.05). 
The reduction in cellular viability with gabapentin was not as marked as seen in 
the amitriptyline exposure, especially at the higher concentration (1.8 mM) and 
it changed or reduced over time indicating possible cellular adaptation         
Figure 3.1).
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Figure 3.1: Cumulative cellular viability of 3T3 cells exposed to two different concentrations of amitriptyline (AMI), carbamazepine (CBZ) 
and gabapentin (GAB), measured using alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated 
control cells by one-way ANOVA followed by Bonferroni’s post hoc test, * p<0.05.
* 
* 
* * 
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The cellular viability results for skin keratinocytes, HaCat cells, following 
exposure to the three NMs are shown in Figure 3.2. In these experiments, 
amitriptyline exposure produced a significant decrease in cellular viability in 
HaCat cells at high (1.8 mM) concentrations at all time points compared with 
untreated control cells (p<0.05). Low (200 µM) amitriptyline concentration 
induced a significant decrease in viability at 30 min, 1 h and 4 h exposure time 
points. The reduction in cellular viability observed with low concentration of 
amitriptyline was, however, smaller in magnitude compared with the difference 
observed between control and high amitriptyline concentration exposure.  
A significant reduction in cellular viability in HaCat cells exposed to 
carbamazepine only occurred at high (1.7 mM) concentrations after 2 h of 
exposure (p<0.05). Gabapentin produced a significant reduction in viability at 
high (5.54 mM) concentrations at all time points compared to control (p<0.05). 
Non-significant changes in viability were found when HaCat cells were exposed 
to low concentrations of carbamazepine and gabapentin at nearly all time 
points, with the exception of 4 h exposure time point with low carbamazepine 
(100 µM) concentration (p>0.05). 
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Figure 3.2: Cumulative cellular viability of HaCat cells exposed to two different concentrations of amitriptyline (AMI), carbamazepine 
(CBZ) and gabapentin (GAB), (indicated) measured using alamarBlue®. Mean values + SE (n=8) are shown for each experiment. 
Compared with untreated control cells by one-way ANOVA followed by Bonferroni’s post hoc test, * p<0.05. 
* * * 
* 
* 
* 
* 
* * 
* 
* 
* 
* 
* 
* * 
* 
* 
* 
* 
* 
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In oral keratinocyte cells, OKF6-TERT1, significant decreases in cellular viability 
(p<0.05) were only demonstrated after 4 h exposure to NMs, except for 
amitriptyline where high concentrations (1.8 mM) exposure revealed a 
significant decrease in cellular viability after 2 h exposure (p<0.05) comparing to 
control. A low concentration of amitriptyline (200 µM) caused significant 
reduction of viability after 4 h of exposure (p<0.05).  
A significant decrease in cellular viability occurred after carbamazepine high 
concentrations (1.7 mM) exposure after 4 h compared to control (p<0.05), while 
low carbamazepine concentration (100 µM) exposure did not associate with 
significant decrease of cellular viability at all time points (p>0.05). 
The only exception was gabapentin, where both high and low concentrations of 
gabapentin did not significantly affect cellular viability at all time points (p>0.05), 
the results are presented in Figure 3.3. 
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Figure 3.3: Cumulative cellular viability of OKF6-TERT1 cells exposed to two different concentrations of amitriptyline (AMI), 
carbamazepine (CBZ) and gabapentin (GAB), (indicated) measured using alamarBlue®. Mean values + SE (n=8) are shown for each 
experiment. Compared with untreated control cells by one-way ANOVA followed by Bonferroni’s post hoc test, * p<0.05.
* 
* 
* 
* 
* * 
* 
* 
* 
* 
* * 
* 
* 
* 
* 
* 
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The viability results for the three NMs in all three cell lines treated demonstrated 
an extreme effect of amitriptyline on cellular viability which began after 30 min 
exposure time, and was especially marked with high concentrations (1.8 mM). 
Carbamazepine and gabapentin appeared to disrupt cellular viability less and 
even their reported significant reductions, may not be as meaningful clinically as 
the response of the cells to exposure of amitriptyline at both low and high 
concentrations.  
Median lethal values were calculated at both 30 min and 24 h cumulative time 
points for each cell line and for each NM they were exposed to (Figure 3.4). 
Amitriptyline exposure was associated with a median lethal dose effect in all cell 
lines. The median lethal dose (LD50) of amitriptyline in 3T3 cells was 1 mM at 30 
min exposure and 158 µM at 24 h exposure time point. In HaCat cells, 
amitriptyline LD50 values were 512 µM and 186 µM at 30 min and 24 h time 
points respectively whilst in OKF6-TERT1, the only LD50 for amitriptyline was 
after 24 h exposure in which LD50 was 630 µM. 
For the other NMs, the only LD50 value recorded was for carbamazepine in 
HaCat cells, and this was 398 µM after 24 h exposure time (Figure 3.5). 
Gabapentin did not demonstrate any LD50 effect in any cell line used at either of 
the two time points examined (Figure 3.6). 
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Figure 3.4: Median lethal dose (LD50) calculation for amitriptyline (AMI) 
cumulative exposure at 30 min and 24 h in (A) 3T3 cells, (B) HaCat cells and 
(C) OKF6-TERT1 cells (n=8).   
 
Figure 3.5: Median lethal dose (LD50) calculation for carbamazepine (CBZ) 
cumulative exposure at 30 min and 24 h in (A) 3T3 cells, (B) HaCat cells and 
(C) OKF6-TERT1 cells (n=8). 
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Figure 3.6: Median lethal dose (LD50) calculation for gabapentin (GAB) 
cumulative exposure at 30 min and 24 h in (A) 3T3 cells, (B) HaCat cells and 
(C) OKF6-TERT1 cells (n=8). 
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3.2.2 Experimental results from exposure of cell lines to NMs for a 
specific time interval: 
The same concentrations and viability assay were used in this method as in the 
previous section (3.2.1). Regarding the cell lines, only the oral keratinocyte 
(OKF6-TERT1) and skin keratinocytes (HaCat) cell lines were investigated, 
reflecting target peripheral orofacial tissue for topical treatment. In this method, 
only two time intervals for exposure to NMs were employed: 30 min exposure to 
NM, as this was felt to be as close as possible to the likely substantively of the 
NMs topical application in the oral cavity.  A second, longer exposure time of 24 
h, was used to represent the maximum possible exposure time of topical 
treatments.  
A significant decrease in cellular viability in HaCat compared to untreated 
control cells was demonstrated at both time points (30 min and 24 h) and both 
concentrations (200 µM and 1.8 mM) of amitriptyline (p<0.05). In HaCat cells 
exposed to carbamazepine, a significant decrease in viability was only 
demonstrated at high concentrations of carbamazepine (1.7 mM) at the longer 
exposure time (24 h, p<0.05; Figure 3.7). Gabapentin showed less untoward 
biological effect in term of cellular viability with viability reduction reported as 
non-significant (p>0.05) compared to control at both time points and both 
concentrations. 
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Figure 3.7: Specific time cellular viability of HaCat cells exposed to two different concentrations of amitriptyline (AMI), carbamazepine 
(CBZ) and gabapentin (GAB) at 30 min and 24 h time points, (indicated) measured using alamarBlue®. Mean values + SE (n=6) are 
shown for each experiment. Compared with untreated control cells (dotted black line) by one-way ANOVA followed by Bonferroni’s post 
hoc test, * p<0.05.
* 
* 
* * 
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In OKF6-TERT1, as in HaCat cells, short and long exposure to amitriptyline at 
both low (200 µM) and high (1.8 mM) concentrations, resulted in a significant 
decreases in cellular viability compared with untreated control (p<0.05, Figure 
8).  
Carbamazepine and gabapentin induced a significant reduction in cellular 
viability (p<0.05) at low concentrations compared to untreated control at the 
short exposure time (30 min), whilst reduction in cellular viability was non-
significant (p>0.05) at the long exposure time (24 h). Cells exposed to the high 
concentrations of carbamazepine and gabapentin demonstrated a significant 
reduction in viability at both time points (Figure 3.8). 
The median lethal dose (LD50) was calculated for 30 min exposure time only. 
The only LD50 value was 141 µM for amitriptyline in OKF6-TERT1 cells 
exposure (Figure 3.9). The other medications, carbamazepine and gabapentin, 
did not demonstrate any LD50 effect even at high concentrations (Figure 3.10, 
Figure 3.11). 
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Figure 3.8: Specific time cellular viability of OKF6-TERT1 cells exposed to two different concentrations of amitriptyline (AMI), 
carbamazepine (CBZ) and gabapentin (GAB) at 30 min and 24 h time points, (indicated) measured using alamarBlue®. Mean values + 
SE (n=6) are shown for each experiment. Compared with untreated control cells (dotted black line) by one-way ANOVA followed by 
Bonferroni’s post hoc test, * p<0.05.
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Figure 3.9: Median lethal dose (LD50) calculation for amitriptyline (AMI) specific 
time exposure at 30 min in (A) HaCat cells and (B) OKF6-TERT1 cells (n=6). 
 
Figure 3.10: Median lethal dose (LD50) calculation for carbamazepine (CBZ) 
specific time exposure at 30 min in (A) HaCat cells and (B) OKF6-TERT1 cells 
(n=6). 
Figure 3.11: Median lethal dose (LD50) calculation for gabapentin (GAB) specific 
time exposure at 30 min in (A) HaCat cells and (B) OKF6-TERT1 cells (n=6).  
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3.3 Cell counting assay:  
Investigating cell counts in addition to examining cellular viability is essential in 
order to give a complete picture of the in vitro effect of NMs on target cells. This 
is due to the fact that chemical indicator changes measured in viability 
assessments using alamarBlue® occur due to a chemical reduction, which is 
affected by cellular activity and not necessarily number of cells. This can also 
change with exposure time and drug concentration. Cell counting in this group 
of experiments was carried out using Cell Counting Kit-8 assay (CCK-8). Only 
the keratinocyte cell lines, HaCat and OKF6-TERT1 were used for cell counting. 
A standard ascending serial count of untreated cells were seeded into a well 
plate and used to plot a calibration curve. The calibration curve was used as a 
reference point to estimate post NMs exposure cell count. 
Compared to the calibration curve as a reference, the estimation of the number 
of HaCat cells was 2000 cells, after 30 min exposure to low (200 µM) and high 
(1.8 mM) concentrations of amitriptyline, about 20% of original seeding count 
(10,000 cells). A greater decline in the cell count occurred at the 24 h time point, 
where the number of cells counted was less than 1000 (10 % of original seeding 
count) for both concentrations of amitriptyline (200 µM, 1.8 mM); (Figure 3.12). 
Exposure to the low and high concentration of carbamazepine (100 µM, 1.7 
mM) also demonstrated a decrease in the cell count after 30 min exposure 
(4000, 40 % of original seeding count). At 24 h of exposure to low concentration 
of carbamazepine, however, the cell count was similar to control cells. The high 
concentration of carbamazepine (1.7 mM) resulted in a drop in the cell count to 
less than 1000 cells (10 % of original seeding count); (Figure 3.13). Gabapentin 
exposure showed the least effect on the cell count with the main decline in cell 
count at 24 h exposure to the low concentration (150 µM) of gabapentin (9000, 
90 % of original seeding count), (Figure 3.14). 
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Figure 3.12: HaCat cell count after exposure to two different concentrations of amitriptyline at (A) 30 min and (B) 24 h time points. Cell 
counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 assay). The calibration curve shows 
untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment. 
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Figure 3.13: HaCat cell count after exposure to two different concentrations of carbamazepine at (A) 30 min and (B) 24 h time points. Cell 
counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 assay). The calibration curve shows 
untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment. 
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Figure 3.14: HaCat cell count after exposure to two different concentrations of gabapentin at (A) 30 min and (B) 24 h time points. Cell 
counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 assay). The calibration curve shows 
untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment. 
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In OKF6-TERT1 cells, amitriptyline decreased the cell count at both low and 
high concentrations (200 µM, 1.8 mM) and both time points (Figure 3.15). After 
30 min of exposure to low concentration amitriptyline (200 µM), the cell count 
decreased to 10,000, 50% of the original seeding count (20,000), whereas after 
thirty minutes exposure to the higher concentration (1.8 mM), the cell count 
decreased to less than 2000 cells, 10 % of the original seeding count. After 24 h 
of exposure, both concentrations of amitriptyline employed caused the cell 
count to decrease to less than 200 cells, 1 % of the original seeding count.  
The short time exposure (30 min) to carbamazepine at high and low 
concentrations (150 µM, 1.7 mM) showed a slight effect on cell count, the 
estimated numbers were 18,000 (90 % of the original seeding count). After 24 h 
exposure, the cell count dropped to 10,000 cells (50 % of the original seeding 
count) for both high and low concentration solutions (150 µM, 1.7 mM), (Figure 
3.16). Exposure to gabapentin did not cause a major reduction in the cell count 
(19,000, 95 % of the original seeding count) in comparison with the controls at 
either high or low concentrations (150 µM, 5.45 mM) at either time points 
(Figure 3.17). 
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Figure 3.15: OKF6-TERT1 cell count after exposure to two different concentrations of amitriptyline at (A) 30 min and (B) 24 h time points. 
Cell counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 assay).  The calibration curve 
shows untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment. 
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Figure 3.16: OKF6-TERT1 cell count after exposure to two different concentrations of carbamazepine at (A) 30 min and (B) 24 h time 
points. Cell counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 assay). The calibration 
curve shows untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment. 
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Figure 3.17: OKF6-TERT1 cell count after exposure to two different concentrations of gabapentin at (A) 30 min and (B) 24 h time points. 
Cell counts were measured at an absorbance of 450 nm in the presence of tetrazolium salts (CCK- 8 Assay). The calibration curve 
shows untreated cell counts at different densities of seeding. Mean values + SE (n=6) are shown for each experiment.
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3.4 Experiment to estimate the dosage of drug released from a standard 
topical paste. 
Differing NM concentrations were tested in relation to their effects on cellular 
viability, but the concentrations employed in this chapter may not necessarily 
reflect the actual concentrations released from high concentrations of topical 
treatment which may be lower than the actual concentration in the topical 
carrying agent. As mentioned earlier in the chapter, I examined and explored a 
number of different options (Section 3.2), to directly test both higher 
concentrations of the pure drugs, and also carrier agent with clinical 
concentrations of the NMs, with cell-line models. Unfortunately, these differing 
options failed either through turbidity, crystallization, or immediate cell death 
thereby preventing accurate measurement of viability and cell count. The 
approach taken was therefore instead of merging both gel and cell culture at the 
same time, the paste was left in culture media for 30 min and 1 h respectively 
and the media were then examined to give an indication of the concentrations 
that may be released clinically (Hanasono et al., 2004).  
Clinical treatment in Orabase paste (PCP Direct online pharmacy, UK) was 
prepared in the laboratory, applying the most common clinical concentrations of 
NMs have been prescribed for orofacial neuropathic pain (Padilla et al., 2000; 
Heir et al., 2008; Haribabu et al., 2013). The amounts released from these gels 
into the aspirated media were then investigated by HPLC analysis. Table 3.1, 
demonstrates the concentrations detected in the aspirated media of each NM 
after 30 min and 1 h. We then utilised the concentrations detected after 30 min 
in the aspirated media in the cellular morphology and cytokine expression 
experiments.  These were thought to provide a closer representation of the 
likely clinical treatment application time. 
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Medications Orabase paste 
concentrations 
% (w/w) 
Released 
Concentration 
after 30 min 
Released 
Concentration after 
1 h 
Amitriptyline 2 %  (63 mM)  0.007 % (226 µM) 0.014 % (449.5 µM) 
Carbamazepine 4 % (169 mM)  0.003 % (123.9 µM) 0.011 % (476 µM) 
Gabapentin 4 % (233 mM)  0.09 % (5.54 mM) 0.18 % (10.5 mM) 
 
Table 3.1: Orabase paste and released concentrations of amitriptyline, 
carbamazepine and gabapentin (w/w) are given along with molars 
concentrations. For released concentrations, results were determined by HPLC 
(n=2).  
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3.5 Cellular morphology and cytokine expression experiments  
Using the short exposure time (30 min), two types of experiments were carried 
out to investigate the effect of NMs exposure on cellular morphology and 
cytokine expression: 
3.5.1 Scanning Electron Microscope (SEM)   
Prior to SEM 3T3, HaCat and OKF6-TERT1 cells were exposed to 30 min of the 
three respective NMs at the concentrations determined in Table 1 (AMI 226 µM; 
CARB 123.9 µM; GABA 5.54 mM). Cells were then prepared for SEM 
investigation as described in section 2.9. SEM images were made at two 
magnifications, 100 X and 1000 X, to investigate morphological and attachment 
changes. Careful examination of these images, revealed that exposure to 
amitriptyline for 30 min affected cellular attachment and morphology and 
resulted in rounding of both HaCat and OKF6-TERT1 cells indicating cell death 
and detachment (Figure 3.18, Figure 3.19). The amitriptyline exposure images 
were the only images from all three NMs to suggest extensive changes in the 
cellular attachment and morphology when compared with the control cell 
images. Mouse fibroblast (3T3) image results are presented in Appendix (Figure 
C.1), and confirm the same response to amitriptyline exposure. The exposure of 
HaCat cells to carbamazepine was associated with slight changes in 
morphology when compared to the control images and the OKF6-TERT1 cells 
response. Gabapentin exposure did not result in any obvious changes in 
morphology and attachment. 
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Figure 3.18: SEM images at 100 X magnification of OKF6-TERT1 and HaCat 
cells after 30 min exposure to amitriptyline (AMI), carbamazepine (CBZ) and 
gabapentin (GAB) at concentrations determined by HPLC. The top first panel of 
two images represents the normal morphology of control cells. The other 
images showing the changes after NMs exposure.  
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Figure 3.19: SEM images at 1000 X magnification of OKF6-TERT1 and HaCat 
cells after 30 min exposure to amitriptyline (AMI), carbamazepine (CBZ) and 
gabapentin (GAB) at concentrations determined by HPLC. The top first panel of 
two images represents the normal morphology of control cells. The other 
images showing the changes after NMs exposure.  
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3.5.2 Inflammatory cytokine release in response to NMs exposure 
The expressions of twenty different inflammatory cytokines were investigated in 
HaCat and OKF6-TERT1 cell lines after exposure to the NMs at the 
concentrations determined by the drug release experiment that were also 
utilised in the SEM examination (Section 3.4 & 3.5). The exposure time of the 
cells to the NM was 30 min. The results of membrane experiments are shown in 
Figure 3.20 and Figure 3.21. The inconsistency of cytokine expression between 
the replicate experimental results indicated that there was no significant 
differences in cytokine expression between tested and control cells in both cell 
lines, however the main cytokine expressed was IL-8. 
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Figure 3.20: Cytokine expression after 30 min exposure of Skin keratinocytes, 
HaCat cells, to amitriptyline (AMI), carbamazepine (CBZ) and gabapentin (GAB) 
at concentrations determined by (HPLC). 
 
 
 
 
 
Figure 3.21: Cytokine expression after 30 min exposure of oral keratinocytes, 
OKF6-TERT1, cells to amitriptyline (AMI), carbamazepine (CBZ) and 
gabapentin (GAB) at concentrations determined by (HPLC). 
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3.6 Discussion and summary 
Prior to commencing any Phase I clinical trial for a new drug, the U.S. Food and 
Drug Administration (FDA) requires detailed preclinical data regarding drug 
cytotoxicity investigation (FDA, 2015c). In these in vitro cytotoxicity studies, 
typical target tissues for systemically administered drugs have been examined 
including hepatic and neuronal tissues. In the case of topical compounded NMs 
used on orofacial tissues, given that the route of administration has changed 
from systemic use to topical, and the concentrations used have increased, 
these FDA previous approvals for safety and efficacy may no longer be valid in 
this context, so it is necessary to examine their toxic effects on orofacial 
epithelial tissues (Ahuja and Sharma, 2014; FDA, 2015a).  
This in vitro study tested the effect of three commonly prescribed NMs, 
amitriptyline, carbamazepine and gabapentin, on cell lines culture. AlamarBlue® 
is a non-toxic colorimetric assay, it is reduced by mitochondrial processes 
making it a suitable assay for testing drugs known to cause mitochondrial 
dysfunction such as amitriptyline (Bopp and Lettieri, 2008). In addition, the 
alamarBlue® assay provides an accurate interpretation of cellular viability 
without killing the cells during analysis, and therefore allows for further studies 
and examinations to be conducted on the cells in question (Miret et al., 2006; 
Al-Nasiry et al., 2007).  
The time points and exposure methods used, were designed to replicate, as far 
as possible the clinical course of topical treatment using NMs. Two exposure 
methods were employed: cumulative and specific time interval effects. The 
former method was designed to explore the different effects of exposure time of 
the target NMs. This is especially important as the topical treatment route is 
hypothetically combined with absorption into the tissues it is applied to.  
Depending upon the method of topical application, the time periods of exposure 
of these tissues to the NM may be increased. This is especially true in the 
clinical use of these types of topical NMs in the orofacial region as patients are 
often instructed to repeatedly apply them to the target tissue two to three times 
daily, perhaps even with a custom made appliance. The specific time-intervals 
examined incorporated a short exposure time (30 min), in order to demonstrate 
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the early effect of the applied medication on the surface cellular layer. The long 
specific time interval exposure time (24 h), was chosen to represent the longest 
possible exposure time or repeated application time that might be used by a 
patient. The change in viability as measured by alamarBlue® does not 
necessarily reflect the change in cell count, which is a known limitation of 
colorimetric assays. To ensure that cell count was taken into account, the 
change in cell count was assessed using the Cell Counting Kit-8 (CCK8;  
Dojindo Laboratories, Kumamoto, Japan) where the chemical indicator is 
different to that used in alamarBlue®  that give comparable results and more 
confident in the reliability of the assays used than using the same test to find 
various parameters (Rampersad, 2012). The cell lines employed in these 
methods were: mouse fibroblast (3T3), in addition to skin keratinocytes (HaCat) 
and oral keratinocytes (OKF6-TERT1) as representative of orofacial tissue. Cell 
line application in toxicity investigations offers the first stages in cytotoxicity 
analysis, allowing multiple reproducible results with in minimal time, with 
reduced expense and time prior to experimentation with animal and primary cell 
studies (Barile et al., 1994). 
Amitriptyline cytotoxicity has been attributed to different mechanisms including: 
mitochondrial dysfunction; increased production of reactive oxygen species 
leading to alteration in cellular metabolism and permeability and elevated 
intracellular oxidative stress (Moreno-Fernández et al., 2008; Cordero et al., 
2009). The in vitro cytotoxicity of amitriptyline has been investigated and 
reported previously in different human and animal cell lines, mainly constituting 
neuronal cell lines and hepatocytes as shown in Table 2. The most frequently 
used concentration of amitriptyline  employed in these studies was the 
concentration measured at plasma level, where ingestion of a 100 mg tablet 
leads to approximately 0.15 µM - 0.7 µM plasma concentrations up to a 
maximum dose of 2.8 µM – 18.3 µM in the case of over dose and toxicity 
(Waller and Renwick, 1994b; Obuchowicz et al., 2006). Higher concentrations 
were previously employed to study the apoptotic effect of amitriptyline on a 
cancer cell line, where Pula et al. (2013) found that 50 µM exposure after 24 h 
is enough to decrease cellular viability, with IC50 values of 4 µM after 48 h 
incubation. These studies illustrate the potential toxicity of amitriptyline in 
115 
 
different tissues and low LD50 value that jeopardize monolayer cell culture 
integrity.  
In the current study, both concentrations of amitriptyline (200 µM, 1.8 mM) 
caused a significant reduction in the cellular viability in all cell lines even after a 
short exposure time. Exposure to amitriptyline decreased the cell count to less 
than 20 % and 10 % of the original seeding count in skin keratinocytes (HaCat) 
cell line at short and long time exposures, whilst in oral keratinocytes (OKF6-
TERT), the cell count decreased to 50 % and 10 %  of the original seeding 
count at short exposure time in low and high concentrations respectively before 
further deteriorating to <1 % of the original seeding count after 24 h. Scanning 
electron microscopy (SEM) confirmed these findings with obvious cellular 
changes in morphology indicating cellular death in all cell lines analysed. The 
cytotoxicity of amitriptyline was also demonstrated in its LD50 values, which 
were low compared with clinical concentrations used, in both cell lines and 
occurred at short exposure times.  
The apoptotic and anti-proliferative effects of carbamazepine have been 
investigated and reported mainly in neuronal and glial cell culture, but also in 
blood cells, using plasma level concentrations up to 500 µM (Gao et al., 1995; 
Awara et al., 1998; Pavone and Cardile, 2003; Araújo et al., 2004; Suwalsky et 
al., 2006; Dambach et al., 2014). Plasma levels of carbamazepine (13 µM- 50 
µM) caused no effect on the viability of cancer cell lines (Ständer et al., 1998). 
Compared with amitriptyline exposure, carbamazepine is reported to be non-
cytotoxic except at higher concentrations, where the cytotoxic effect on cell 
culture was still less than that seen with amitriptyline exposure, using the same 
time points and cell lines (Mannerström et al., 2006); (Table 2). Even IC50 value 
was not reported in most carbamazepine exposure in the same previous study, 
thereby corroborating our findings in these orally relevant cell lines, where 
carbamazepine exposure was found to be less cytotoxic compared with 
amitriptyline. Cytotoxicity was investigated on different cell types with higher 
concentrations (1.7 mM). In contrast to amitriptyline, carbamazepine was less 
cytotoxic in both cell lines, and the major changes in viability measured, only 
occurred at high concentrations and longer exposure times. The SEM findings 
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did not reveal any major changes in morphology and attachment compared with 
untreated control cells and compared with the gross changes found with 
amitriptyline exposure. The LD50 values were also confirmatory in this respect, 
as they were only calculable after a cumulative total of 24 h exposure which is 
not commonly applicable for the topical application of a gel in the intra or extra-
oral treatment. The LD50 was 398 µM in HaCat cells after 24 h exposure. 
Gabapentin appeared to be the least cytotoxic drug among the three NMs 
examined in this study. The previous studies found similar findings; in spite of 
the low concentrations they employed (          Table 3.2). Even when significant 
viability changes occurred, they were mostly associated with high concentration 
and a long exposure time (24 h) and the amount of reduction in cellular viability 
and cell count was small compared with amitriptyline. There was also no LD50 
calculable with SEM findings are not showing any recognizable cellular death 
signs. 
Exposure of amitriptyline and carbamazepine at different time points and 
concentrations was associated with high plate reader readings and colour 
change of alamarBlue® compared with control (Figure 3.3 & Figure 3.7), which 
could either indicate an increase in cell number or an increase in ATP 
production by the viable cells. By using two different methodologies, and cell 
count using CCK-8 we were able to show that there was a decrease in cell 
counts at these time points and therefore we hypothesise that the result seen 
with alamarBlue® are indicative of increased cellular activity, which has been 
reported by Mannerström et al. (2006), in different cell lines after exposure to 
amitriptyline and carbamazepine. 
OKF6-TERT1 exposure to carbamazepine and gabapentin showed change 
from a significant reduction at the 30 min time point to a non-significant change 
after 24 h time point. This could be explained as cellular adaptation to these 
drugs especially as the cell count did not change in the case of gabapentin at 
both time points and there was reduction in cell count after 24 h compared to 
the 30 min cell count. 
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The effect of NMs exposure on cytokine expression has been investigated 
previously in clinical studies and in vitro experiments. The exposure or 
treatment has previously been associated with a suppression of specific pro-
inflammatory cytokines (IL-1  and TNF-α), in addition to over expression of 
anti-inflammatory cytokine (IL-10). Carbamazepine exposure and treatment has 
been associated with the over expression of the following groups of cytokines:  
(IL-2, IL-5, IL-6 and IL-10),  (Obuchowicz et al., 2006; Hashioka et al., 2007; 
Backonja et al., 2008; Mathieu et al., 2011; Lee et al., 2013). In our 
experiments, there was a very low level of detected cytokine expression with all 
NMs, and the cytokine expressions did not differ to untreated cells. This could 
be due to the short exposure time (30 min) used and the fact that a very crude 
method of measuring cytokine expression was employed. It allowed multiple 
cytokines to be analysed at the same time, however more sensitive measures, 
such as RT-qPCR or ELISA may have revealed different results. Amitriptyline 
cytotoxicity was reported in such short exposure as in the viability studies in this 
chapter, however, amitriptyline was found to induce apoptosis and cell death 
through its effect on mitochondria, subsequent release of caspase activating 
protein that causes activation of caspase 3 pathway and apoptosis (Moreno-
Fernández et al., 2008). 
In summary, viability results, in both cumulative and specific time points, and 
cell count investigations gave consistently similar results for each NM tested. 
Amitriptyline exposure was associated with a reduction in cellular viability and 
cell count; carbamazepine and gabapentin exposure disturbed cellular viability 
and cell counts less, even at high concentrations. The SEM findings were 
consistent with the viability results with only slight changes and rounding cells in 
case of carbamazepine exposure. 
Amitriptyline is well-documented as a topical treatment, and has been employed 
in many clinical trials, however, amitriptyline associated cytotoxicity has not 
been reported in any clinical trials relating to orofacial neuropathic pain or even 
in neuropathic pain affecting other parts of the body.  
Before a decision to exclude amitriptyline from topical management of 
neuropathic orofacial pains can be made on the basis of safety, further 
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investigations using more sophisticated cell culture techniques is required. In 
the next chapter, we employ the use of a 3D tissue cell culture model, to carry 
out further experiments to strengthen the in vitro findings reported in this 
chapter.
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Medications Studies Cell or tissue type Exposure 
time 
Concentrations Viability % Cell count % LD50 or IC50 µM 
%  µM 
 
 
 
 
 
 
Amitriptyline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Mannerström et al., 
2006) 
HepG21  
SH-SY5Y2     
U-373 MG3 
Primary mouse hepatocyte 
24 h 0-0.003 0–100  <2% 
<3%            100 µM 
<65% 
<20 
 29.6 ± 4.3 
48.1 ± 4.2 
28.4 ± 3.1 
7.2 ± 26.4 
(Dahlin et al., 1999) Primary endothelial  
Smooth muscle cells 
(Human) 
0-2 h 0.0001-0.01 3-330 <90% 100 µM 4 
<20%  330 µM  
 
  
(Pula et al., 2013) HTB1145 1-7 days 0.00001-
0.03 
0.5-
1000 
<2% after 48 h at 
100 µM 
 4 µM after 48 h 
(Lirk et al., 2006b) Primary dorsal root 
ganglion cells (Rat) 
24 h 0.001-
0.0047 
50-150  <60 at 100 µM  
(Moreno-Fernández et 
al., 2008) 
 Primary skin fibroblast 
(Human) 
48 h 0.0006-
0.003 
20-100  <6.5 at 100 µM  
(Barile and Cardona, 
1998) 
HFL16 
Detroit 5517 
WS18 
24 h     90 
51 
67 
(Boelsterli et al., 1987) Erythrocyte (Rat) 1 h     140 (HC50)9 
(Yang et al., 2002) HFL1 24 h     89 +1.27 
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Medications Studies Cell or tissue type Exposure 
time 
Concentrations Viability % Cell count % LD50 or IC50 µM 
Carbamazepine 
 
 
(Mannerström et al., 
2006) 
HepG2  
SH-SY5Y     
U-373 MG 
Primary Mouse hepatocyte 
24 h 0-0.1 0–420  N 
<82   420 µM 
N 
<40 
 36.8±0.04 in 
mouse 
hepatocyte 
(Boelsterli et al., 
1987) 
Erythrocyte (Rat) 1 h     140 (HC50) 
(Gao et al., 1995) Primary Cerebellar granule 
cells (Rat) 
3 days 0.002 100 <40%    
(Pérez Martín et al., 
2008) 
Vero cells 4 h-24 h 0.0002-
0.011 
10-500 Sig at 100 µM after 
24 h 
(Proliferation) 
 406.2 (Half 
maximal 
inhibition) 
(Valentine et al., 
1996) 
cHol10 
h3A4v211 
67 H 0.005-0.02  211-
846 
 <12.5     200 µM                    
<28 
(Pavone and 
Cardile, 2003) 
Astrocyte primary cultures 
(Rat) 
48 h 0.0001-0.01 0.42-
42.3 
<50 at 42.3 µM   
(Regan et al., 1990) Neuroblastoma (neuro-2A) 
glioma (C6) 
48 h 0.011-0.014 50-60 N   
(Ständer et al., 1998) LN-22912, LN-30813, T98G14  
U87MG15, U251MG16, 
D247MG17 
72 h 0.0003-
0.00035 
13-15 N   
Gabapentin (Pavone and Cardile, 
2003) 
Astrocyte primary cultures 
(Rat) 
48 h 0.0001-0.01 5.8-
584 
<72 at 584 µM   
(Dambach et al., 2014) Primary glial cell culture 
(Rat) 
24 h 0.001-0.01 85.4-
584 
N   
1 hepatocellular carcinoma cell line, 2 neuroblastoma cell line, 3 malignant gliomas cell line, 4 after 2 h, 5 mesodermal tumour (mixed) cell line, 6 human lung fibroblast cell line, 7 Skin 
fibroblast cell line, 8 skin fibroblast, 9 drug concentration causing 50% haemolysis, 10 B lymphoblastoid cell line, 11 B lymphoblastoid cell line, 12,13,14,15,16,17 glioma cell lines.          
Table 3.2: In vitro studies, showing the cytotoxic effects of amitriptyline, carbamazepine and gabapentin on different cell types.
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Chapter: 4 Three-dimensional (3D) tissue 
experiments 
4.1 Introduction 
The effect of amitriptyline exposure on monolayer cell culture (Chapter 3), 
revealed high amitriptyline cytotoxicity even at low concentration and short 
exposure time with a measured reduction in cell count and morphological 
changes. However, clinical studies using amitriptyline as topical treatments did 
not report any tissue damage even when using high concentrations on skin and 
oral mucosa (Padilla et al., 2000; Lynch et al., 2005b). For further experiments 
of viability and cytotoxicity, two separate 3D tissue culture models were used to 
be more representative of oral mucosa and to compare with monolayer cell 
culture. In addition, immunohistochemistry investigations were also employed to 
reveal amitriptyline toxicity.  
The two dimensional cell culture (2D) model is the conventional in vitro model 
used in drug discovery processes. However, the difference in cellular 
morphology and physiological activity, dictate the evolution of more 
representative in vitro models (Maltman and Przyborski, 2010; Edmondson et 
al., 2014). The 3D cell culture microenvironment is thought to resemble in vivo 
tissue more accurately, where cells are arranged in a 3D spatial structure and 
are subject to inter-cellular and extracellular matrix interaction. All these 
biological interactions affect cellular, biological and physiological activity, 
including the response to external signalling or stimuli at the level of viability, 
multiplication and expression of various receptors. The development and 
implementation of 3D tissue cell culture in drug discovery and cytotoxicity 
assessments, including biocompatibility of dental materials gives more 
credibility to decisions based on in vitro data, helping to limit clinical 
complications, and the need for further, often costly, experiments (Klausner et 
al., 2007; Cantòn et al., 2010; Maltman and Przyborski, 2010; Edmondson et 
al., 2014). 
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In this chapter, two models representing full thickness gingival tissue were 
used. These models, a commercial available and in–house constructed model, 
were both constructed of epithelial cells (keratinocytes) and gingival fibroblasts 
on collagen scaffolds (Section 2.5). The two types of 3D model used were: 
commercial MatTek model, which is constructed from primary human gingival 
cells, keratinocytes and fibroblast cells (EpiOral™ and EpiGingival ™, MatTek 
Corporation, USA); the in-house constructed model constructed from 
keratinocytes cell line (FNB6 cell line from human oral dysplasia) and primary 
gingival fibroblasts. Both models were constructed on collagen scaffolds in 
tissue culture inserts and transwell plates respectively, (ethical approval number 
09/H1308/66), (Klausner et al., 2007; Colley et al., 2011), (Section 2.5).  
In this chapter, alamarBlue® was used to investigate viability using short and 
long exposure time of amitriptyline. Repeated exposure time points were used 
to simulate repeated clinical application as well as periods of recovery with the 
aim to investigate the possibility of reversible damage that could occur with 
chronic use.  
The cytotoxicity effect was investigated using the Lactate dehydrogenase assay 
(LDH); (CYTOTOX96®, Promega, UK), using the same time points as those 
used in the viability study (using conditioned culture media from both MatTek 
and in-house constructed models). In this chapter, two types of anti-caspase 3 
antibodies were used to investigate the apoptotic effect of amitriptyline in both 
3D models and at all time points as previous studies reported an apoptotic 
effect of amitriptyline on cell culture models through activation of the caspase 3 
pathway (Lirk et al., 2006a). 
Employing 3D tissue with air–liquid interphase culture environment was used to 
simulate and measure actual drug absorption. The percentage of amitriptyline 
passage through epithelial tissue to the expected target nerve endings was 
investigated using both chemical and immunofluorescence studies, through 
HPLC and immunofluorescent microscope (Section 2.8.1 & 2.12). 
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4.2 Viability of 3D models 
The alamarBlue® assay (Section 2.6) was used to investigate the changes in 3D 
tissues viability after amitriptyline exposure. The exposure time points were 
limited to the expected clinical course and the amitriptyline concentration used 
was the concentration found in HPLC results presented in Chapter 3 (Section 
3.4), (226 µM). 
4.2.1 Viability of MatTek 3D tissue  
Viability was measured after the commercially available MatTek model was 
exposed to amitriptyline at a concentration of 226 µM applied to the apical 
service of the tissue inserts. Four time points were measured in the MatTek 
model: 30 min, 24 h and repeated exposure for three days: where amitriptyline 
was applied twice a day (B.I.D.) and three times a day (T.I.D.).  
The results showed a reduction in viability after the two repeated exposure time 
points (B.I.D. and T.I.D.); however, this change in viability was only significant 
with B.I.D. exposure time point (p<0.05). The 30 min and 24 h exposure did not 
show any reduction in viability, Figure 4.1. 
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Figure 4.1: Cellular viability of the MatTek 3D tissue models exposed to 
amitriptyline (226 µM) for 30 min, 24 h, twice a day (B.I.D.) and three times a 
day (T.I.D.) for three days. Mean values + SE (n=3) are shown for each 
experiment compared with untreated control tissue shown as 100 % viable 
(black dotted line) by one-way ANOVA followed by Bonferroni’s post hoc test, * 
p<0.05. 
 
 
 
 
 
 
 
 
*  
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4.2.2 Viability of in-house constructed 3D tissue  
a- Viability of cells were used to construct the in-house 3D model 
The median lethal dose (LD50) of amitriptyline was investigated in the cell line 
(FNB6) and primary cells (primary human gingival fibroblast cells, passage 9) 
used to construct the in-house 3D models. The experiments were carried out 
separately from the tissue used to construct, at short and long time points (30 
min, 24 h) of amitriptyline exposure. 
The results of amitriptyline exposure on FNB6 were investigated using a MTT 
assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide), (Figure 
4.2). In gingival fibroblasts, LD50 values were investigated using alamarBlue® at 
30 min and 24 h time points, (Figure 4.3). The results of amitriptyline exposure 
showed high cytotoxicity of amitriptyline even at low concentrations. The 
calculation of LD50 was made without subtracting the media absorption to draw 
the curve above zero. The LD50 values for both cell lines are shown in Table 
4.1. 
Although two different methods were used to calculate the median lethal dose 
of amitriptyline (MTT, alamarBlue®), changed due to convenience in 
laboratories (Sheffield and Newcastle Universities), the results are almost 
identical, Table 4.1. 
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 Cell types 30 min  (µM) 24 h  (µM) 
A FNB6 cell line 
(using MTT assay) 
204 50 
B Fibroblast cell 
(using alamarBlue®) 
204 52.4 
 
Table 4.1: Median Lethal dose values for amitriptyline were investigated in: (A) 
FNB6 cell line at 30 min and 24 h exposure time points using MTT assay. (B) 
Human gingival fibroblast cells at 30 min and 24 h exposure time points using 
alamarBlue® assay, n=6. 
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Figure 4.2: Amitriptyline (AMI) median lethal dose values were calculated using 
MTT assay in FNB6 cell line after (A) 30 min and (B) 24 h exposure time points. 
Mean values + SE (n=6) are shown for each experiment.   
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Figure 4.3: Amitriptyline (AMI) median lethal dose values were calculated using 
alamarBlue® assay in human gingival fibroblast cells after (A) 30 min and (B) 24 
h exposure time points. Mean values + SE (n=6) are shown for each 
experiment.   
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b- Viability results of the in-house constructed 3D tissue 
The in-house constructed 3D models were exposed to amitriptyline at 30 min 
and 24 h time points only. The repeated exposure time points (B.I.D. and T.I.D.) 
were not employed in this model as the 3D model was not robust for repeated 
exposure experiments, in addition to the restriction of the laboratory procedure 
at Sheffield University, UK.   
The exposure of the in-house constructed model to amitriptyline at 30 min and 
24 h, showed similar results to that found in the commercial MatTek model 
experiments, Figure 4.4. There was a reduction after 24 h amitriptyline 
exposure, but both time points differences were non-significant comparing with 
control untreated tissues (p>0.05).  
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Figure 4.4: Cellular viability of the in-house constructed 3D tissue models was 
measured using alamarBlue®, exposed to amitriptyline (226 µM) at 30 min, 24 h 
time points. Mean values + SE (n=3) are shown for each experiment compared 
with untreated control cells by parametric independent t- test, *p>0.05. 
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4.3 Cytotoxicity results 
The cytotoxicity of amitriptyline was also investigated using LDH assay on 
conditioned media (media bathing tissue models after treatment) collected after 
amitriptyline exposure. The time points used for cytotoxicity assay were the 
same as in the viability experiment (30 min, 24 h, B.I.D. and T.I.D.). 
4.3.1 Cytotoxicity of amitriptyline in the MatTek model  
Conditioned media were collected after each exposure to amitriptyline in the 3D 
tissue model. For repeated exposure, the culture media were collected at the 
end of experiment day and was submitted to LDH assay to investigate also if 
repeated exposure affects the cytotoxicity profile differently to single exposure.  
Absorbance was measured at 490 nm, a higher reading indicates an increase in 
LDH activity and cell death. The only significant difference observed was at 24 h 
exposure time point where increase in LDH level was measured in both control 
and treated tissue models, (Figure 4.5). 
 
4.3.2 Cytotoxicity of amitriptyline in the in-house constructed model 
The in-house constructed model was exposed to amitriptyline for 30 min and 24 
h and showed significant level of LDH at both time points comparing with control 
tissue samples (p<0.05). The higher change was after 24 h of exposure as 
shown in Figure 4.6. 
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Figure 4.5: Cytotoxicity results of the MatTek 3D tissue models were exposed to amitriptyline (AMI), (226 µM) for 30 min, 24 h, twice a 
day (B.I.D.) and there times a day (T.I.D.) for three days. Mean values + SE (n=3) are shown for each experiment after were normalised 
to control results. Compared with control results (black dotted line) at the same time points by parametric independent t-test, * p<0.05. 
* 
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Figure 4.6: Cytotoxicity results of the in-house constructed 3D tissue models 
were exposed to amitriptyline (AMI), (226 µM) at 30 min, 24 h time points. Mean 
values + SE (n=3) are shown for each experiment after normalised to control 
results at the same time points. Compared with untreated control cells (black 
dotted line) by parametric independent t-test, *p<0.05. 
 
 
  
 
 
 
* * 
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4.4 H&E immunohistochemistry study to investigate tissue integrity 
To explore the amitriptyline effect on 3D models cellular and tissue integrity, 
H&E staining was employed. After viability experiments were conducted, the 3D 
tissues were fixed using 10 % formalin and tissue were embedded in wax 
before slides were prepared. Sections were stained with H&E and visualized by 
light microscope. The slides were examined in blind way regarding the 
exposure time points, groups and the tissue types. 
4.4.1 Tissue integrity of MatTek model by H&E 
After 30 min and 24 h exposure of amitriptyline, careful examination of the H&E 
slides at 20 x and 40 x magnification, did not reveal any visual changes within 
tissues including keratin and cellular layers comparing with control tissues, 30 
min and 24 h exposure time points are shown in Figure 4.7 and Figure 4.8 
respectively. Three slides for each time points were examined for each time 
point. 
Repeated exposure to amitriptyline for 3 days with B.I.D. and T.I.D. exposure 
time points, did not produce major changes, however, slight rounding and 
shrinkage in the cellular layer was observed in the case of treatment group, 
which was more pronounced with T.I.D. exposure.  
B.I.D. and T.I.D. exposure time points are shown in Figure 4.9 and Figure 4.10 
respectively.  
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Figure 4.7: Representative H&E stained slides from MatTek tissue after 30 min 
exposure to amitriptyline (226 µM), n=3. A: control tissue images at  (i) 20 X and 
(ii) 40 X, B: amitriptyline exposed tissue images at (i) 20 X and (ii) 40 X. Layers 
indicated: 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer. 
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Figure 4.8: Representative H&E stained slides from MatTek tissue after 24 h 
exposure to amitriptyline (226 µM), n=3. A: control tissue images at  (i) 20 X and 
(ii) 40 X, B: amitriptyline exposed tissue at (i) 20 X and (ii) 40 X. Layers 
indicated: 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
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Figure 4.9: Representative H&E stained slides for MatTek tissue after twice a 
day (B.I.D.) exposure for three days to amitriptyline (226 µM), n=3. A: control 
tissue images at (i) 20 X and (ii) 40 X, B: amitriptyline exposed tissue at (i) 20 X 
and (ii) 40 X. Layers indicated: 1: keratin layer, 2: cellular layer, 3: basal layer, 
4: collagen layer. 
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Figure 4.10: Representative H&E stained slides for MatTek tissue after three 
times a day (T.I.D.) exposure for three days to amitriptyline (226 µM), n=3. A: 
control tissue images at (i) 20 X and (ii) 40 X, B: amitriptyline exposed tissue at 
(i) 20 X and (ii) 40 X. Layers indicated: 1: keratin layer, 2: cellular layer, 3: basal 
layer, 4: submucosa layer collagen layer). 
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4.4.2 In-house Constructed 3D tissue results 
The in-house constructed model was exposed to amitriptyline at 30 min and 24 
h. The results of H&E experiment for both time points expressed slight changes 
of cells including rounding and shrinkage between treated tissues compared 
with control untreated tissues at the same time points investigated.  
Figure 4.11 and Figure 4.12 are shown 30 min and 24 h results respectively. 
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Figure 4.11: Representative H&E stained slides for the in-house constructed 
tissue after 30 min exposure to amitriptyline (226 µM), n=1. A: control tissue 
images at (i) 20 X and (ii) 40 X, B: amitriptyline exposed tissue at (i) 20 X and 
(ii) 40 X. Layers indicated: 1: keratin layer, 2: cellular layer, 3: basal layer, 4: 
submucosa layer collagen layer. 
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Figure 4.12: Representative H&E stained slides for the in-house constructed 
tissue after 24 h exposure to amitriptyline (226 µM), n=1. A: control tissue 
images at (i) 20 X and (ii) 40 X, B: amitriptyline exposed tissue at (i) 20 X and 
(ii) 40 X. (1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
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4.5 Investigation of the apoptotic effect of amitriptyline in 3D model 
The cytotoxic effect of amitriptyline is expected to be associated with apoptotic 
activity even at low concentrations, to investigate this probability, two types of 
apoptosis antibody were used to investigate cellular apoptosis throughout the 
3D tissue model in response to amitriptyline exposure: Menapath polyclonal 
Caspase 3 antibody (Biocare LLC, California, USA) and a rabbit monoclonal 
caspase 3 antibody from R&D systems 269518 (R&D Systems, Inc., USA). 
4.5.1 Caspase 3 level in MatTek 3D model  
Immunohistochemistry results are presented as microscopic images for all time 
points, with usual counting of positively expressed anti-caspase 3 antibody 
results from 9 images representing 3 tissues for each group, compared with the 
same numbers of images and tissues from control slides results. The counting 
was carried out using light microscope and 50 % of results were calibrated by 
another researcher independently.  
a: Menapath polyclonal Caspase 3 in the MatTek model: 
Short time exposure of 30 min, showed less apoptotic cells in both control and 
treatment groups when compared with the other exposure time points. The 
counting of expressed antibody, apoptotic cells, was not significant when 
compared with control results (p>0.05), (Figure 4.13, Figure 4.17).  
 
Long time exposure time point (24 h), was associated with a significant 
difference of expressed apoptotic activity when compared with control (p<0.05). 
The slides images present with high expression of anti-caspase 3 antibody 
positive results (    
Figure 4.14, Figure 4.17). 
Repeated exposure time points (B.I.D., T.I.D.) were associated with a higher 
numbers of apoptotic cells when compared with controls at the same time 
points. The counting of expressed antibody was significant at both time points 
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when compared with control (p<0.05); Figure 4.15, shows B.I.D. time point 
results and  Figure 4.16 shows T.I.D. time points results. Results for all 
apoptotic counting experiments are amalgamated in Figure 4.17. 
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Figure 4.13: Menapath polyclonal Caspase 3 immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 µM) for 
30 min, n=3. Images shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: amitriptyline, 1: keratin layer, 2: 
cellular layer, 3: basal layer, 4: collagen layer). 
C                                 AMI   
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Figure 4.14: Menapath polyclonal Caspase 3 immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 µM) for 
24 h, n=3. Images shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: amitriptyline, 1: keratin layer, 2: 
cellular layer, 3: basal layer, 4: collagen layer). 
C                                 AMI  
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Figure 4.15: Menapath polyclonal Caspase 3 immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 µM) twice 
a day (B.I.D.) for three days, n=3. Images shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: amitriptyline, 
1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
AMI C                      
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Figure 4.16: Menapath polyclonal Caspase 3 immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 µM) 
Three times a day (T.I.D.) for three days, n=3. Images shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: 
amitriptyline 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
C AMI 
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Figure 4.17: The results of Menapath polyclonal Caspase 3 immunohistochemistry study of the MatTek tissue was exposed to 
amitriptyline (AMI), (226 µM) at 30 min, 24 h, B.I.D. and T.I.D., the results are mean + SE (n=3 tissues, n=9 images analysed and 
presented), the results were compared with control using parametric and nonparametric independent t-test, *p<0.05.
 
 
149 
 
 
b: Rabbit monoclonal from R&D systems in the MatTek model: 
The second antibody investigation showed less overall apoptotic expression in 
both treated and control tissues at all time points. Significant differences 
between treated and control tissues were similar to those seen in the Menapath 
polyclonal Caspase 3 experiment. 
Short exposure time (30 min) showed non-significant difference in numbers of 
apoptotic cells between control and treated cells, (p>0.05), (Figure 4.18, Figure 
4.22). Long exposure time point (24 h) was associated with a higher number of 
apoptotic cells even more than the repeated exposure and the results were 
significant comparing with control (p<0.05) (Figure 4.19, Figure 4.22).  
Repeated exposure time points (B.I.D., T.I.D.) were associated with higher 
numbers of apoptosis and significantly different when were compared with 
control tissue results at both time points (B.I.D., T.I.D.), (B.I.D. results: Figure 
4.20, Figure 4.22 ; T.I.D. results : Figure 4.21, Figure 4.22 ). 
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Figure 4.18: Rabbit monoclonal from R&D systems immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 
µM) for 30 min, n=3. Images shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: amitriptyline, 1: keratin 
layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
C AMI 
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Figure 4.19: Rabbit monoclonal from R&D systems immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 
µM) for 24 h, n=3. Images are shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: amitriptyline, 1: keratin 
layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
C AMI 
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Figure 4.20: Rabbit monoclonal from R&D systems immunohistochemistry study of MatTek tissue after exposure to Amitriptyline (226 
µM) twice a day (B.I.D.) for three days, n=3. Images are shown at 20 X magnification. Apoptotic cells are stained brown. (C: control, AMI: 
amitriptyline, 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
C AMI 
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Figure 4.21: Rabbit monoclonal from R&D systems immunohistochemistry study of MatTek tissue after exposure to amitriptyline (226 
µM) three times a day (T.I.D.) for three days, n=3. Images are shown at 20 X magnification. Apoptotic cells are stained brown (C: control, 
AMI: amitriptyline, 1: keratin layer, 2: cellular layer, 3: basal layer, 4: collagen layer). 
C AMI 
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Figure 4.22: The results of the Rabbit monoclonal from R&D systems immunohistochemistry experiment of MatTek tissue exposed to 
amitriptyline (AMI), (226 µM) at 30 min, 24 h, B.I.D., T.I.D. Mean + SE (n=3 tissue, n=9 images analysed and presented), the results were 
compared with control using parametric and nonparametric independent t-test, *p<0.05. 
 
 
 
* 
* 
* 
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4.5.2 Caspase 3 level in the in-house constructed 3D model 
The in-house constructed tissue models showed more apoptotic activity than 
MatTek model in response to amitriptyline exposure at both time points (30 min, 
24 h), in general the final count was less for the second antibody compared to 
the first one. The count was made on 3 pictures of different parts of one tissue 
sample. 
 a: Menapath polyclonal Caspase 3 in the in-house constructed model: 
In first anti-caspase 3 antibody experiments, the results of 30 min exposure of 
amitriptyline, showed high apoptosis count and was significant compared with 
control tissue (p<0.05) and the microscopic images showed obvious destruction 
in tissue layers (Figure 4.23, Figure 4.25). 
 When the in-house constructed tissue was exposed at the longest exposure 
time point (24 h) for  amitriptyline,  counting results were non-significant 
compared with control (p<0.05). The positive apoptotic activity a part from the 
main tissue strip was neglected as it may be related to the tissue preparation 
procedure (Figure 4.24, Figure 4.25).  
 
 
 
 
 
 
156 
 
 
Figure 4.23: Menapath polyclonal Caspase 3 immunohistochemistry study of the in-house constructed tissue after exposure to 
amitriptyline (226 µM) for 30 min, n=1. Images shown at 20 X magnification.(C: control, AMI: amitriptyline, 1: keratin layer, 2: cellular 
layer, 3: basal layer, 4: collagen layer). 
 
C AMI 
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Figure 4.24: Menapath polyclonal Caspase 3 immunohistochemistry study of the in-house constructed tissue after exposure to 
amitriptyline (226 µM) for 24 h, n=1. Images shown at 20 X magnification. (C: control, AMI: amitriptyline, 1: keratin layer, 2: cellular layer, 
3: basal layer, 4: collagen layer). 
 
C AMI 
158 
 
 
Figure 4.25: The results of Menapath polyclonal Caspase 3 antibody immunohistochemistry experiment of the in-house constructed 
tissue was exposed to amitriptyline (AMI) at 30 min, 24 h. Mean + SE (n=1 tissue, n=3 images analysed and presented), the results were 
compared with control using nonparametric independent t-test (Mann-Whitney), *p<0.05. 
 
* 
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b: Rabbit monoclonal from R&D systems in in-house constructed model 
The same time points of exposure (30 min , 24 h) were employed for the 
second antibody experiments and both time points (30 min , 24 h) results were 
significant comparing with control tissue results (p<0.05); Figure 4.26, Figure 
4.28 are shown 30 min time point results, Figure 4.27, Figure 4.28 are shown 
24 h time point results.  
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Figure 4.26: Rabbit monoclonal from R&D systems immunohistochemistry study of in-house constructed tissue after exposure to 
amitriptyline (226 µM) for 30 min, n=1. Images shown at 20 X magnification. (C: control, AMI: amitriptyline, 1: keratin layer, 2: cellular 
layer, 3: basal layer, 4: collagen layer). 
AMI C 
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Figure 4.27: Rabbit monoclonal from R&D systems immunohistochemistry study of the in-house constructed tissue after exposure to 
amitriptyline (226 µM) for 24 h, n=1. Images shown at 20 X magnification.  (C: control, AMI: amitriptyline, 1: keratin layer, 2: cellular layer, 
3: basal layer, 4: collagen layer). 
AMI C 
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Figure 4.28: The results of Rabbit monoclonal from R&D systems antibody immunohistochemistry experiment of the in-house constructed 
tissue was exposed to amitriptyline (AMI), (226 µM) at 30 min, 24 h. Mean + SE (n=1 tissue, n=3 images analysed and presented), the 
results were compared with control using nonparametric independent T test (Mann-Whitney), *p<0.05. 
* 
* 
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4.6 Amitriptyline penetration through the tissue 
These experiments were designed to investigate whether topical treatment of 
amitriptyline has the ability to penetrate the mechanical barriers in the oral 
mucosa, as it is crucial for the drug to provoke the required effect on peripheral 
receptor target. Two types of experiments were conducted to examine 
amitriptyline drug passage through both 3D tissue models, MatTek and in-
house constructed models: an immunofluorescence study using an anti-
amitriptyline antibody and HPLC chemical analysis of the conditioned media 
collected from the lower chamber of the tissue inserts and transwell plates. 
4.6.1 Immunohistochemistry study to look at amitriptyline passage 
through 3D tissue 
Immunofluorescence studies of the presence of amitriptyline within the 3D 
tissue models were made using anti-amitriptyline antibody (mouse monoclonal 
anti-amitriptyline antibody, AbCam®, UK). Image analysis of both models 
revealed the presence of amitriptyline (green dots) within the tissue layers at all-
time points, with the exception of 30 min exposure time in the in-house 
constructed model. The results of MatTek model are shown in Figure 4.29, 
Figure 4.30, the results of the in-house constructed model are shown in Figure 
4.31.  
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Figure 4.29: Representative images showing immunofluorescent results in the MatTek tissue exposed to amitriptyline (226 µM) for 30 
min and 24h and fixed and stained with anti-amitriptyline antibody followed by secondary fluorescent antibody (anti-mouse, Alexa Flour 
488) showed in green and visualized at 20 X using florescent microscope. Blue stain is DAPI (nuclei staining), Green colour is for 
amitriptyline, n=2. 
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Figure 4.30: Representative images showing immunofluorescent results in the MatTek tissue exposed to amitriptyline (AMI), (226 µM) 
twice a day (B.I.D.) and three times a day (T.I.D.) for three days and fixed and stained with anti-amitriptyline antibody followed by 
secondary fluorescent antibody (anti-mouse, Alexa Flour 488) showed in green and visualized at 20 X using florescent microscope. Blue 
stain is DAPI (nuclei staining), Green colour is amitriptyline, n=2. 
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Figure 4.31: Representative image showing immunofluorescent results in the in-house constructed tissue exposed to amitriptyline (226 
µM) for 30 min and 24 h and fixed and stained with anti-amitriptyline antibody followed by secondary fluorescent antibody (anti-mouse, 
Alexa Flour 488) showed in green and visualized at 20 X using florescent microscope. Blue stain is DAPI (nuclei staining), Green colour 
is amitriptyline, n=1.
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4.6.2 Measurement of amitriptyline infiltration through tissue by 
Chemical analysis (HPLC)  
The conditioned media were collected from the lower chamber of the 3D model 
after all exposure times and analysed by HPLC to find how much drug is able to 
pass through the tissue.  
The MatTek model tissue barrier was more developed. After short exposure 
time of 30 min, the levels of amitriptyline measured in the media were similar to 
control, where undetected concentration of the tested drug was the results of 
the HPLC. The results of the remainder time points are shown in Table 4.2 and 
Figure 4.32.  
Higher detected concentrations of amitriptyline were reported after 24 h 
exposure time in the MatTek model, which is reasonable with such long 
exposure time. The repeated exposure (B.I.D. and T.I.D.) results are actually 30 
min exposure results after 3 days of continual exposure, and these were lower 
than 24 h but considerably higher than single 30 min exposure. 
The chemical analysis of the in-house constructed tissue model, showed how 
the differences in tissue construction affects tissue barrier integrity and that had 
an obvious effect on the drug passage, when the final concentrations were 
nearly the same in all time points results except the control. Table 4.3 and 
Figure 4.33, show HPLC results of the in-house 3D model. 
 
 
 
 
 
 
 
168 
 
 
 
Time 
points 
Amitriptyline concentration 
measured by HPLC µM 
Relative to applied 
concentration % 
30 min 0.085 0.26 
24 h 6.65 20.6 
B.I.D. 0.6 1.86 
T.I.D. 0.89 2.75 
 
Table 4.2: The results of HPLC (chemical analysis) of the MatTek tissue 
exposed to amitriptyline concentration (226 µm) for 30 min, 24 h, B.I.D. and 
T.I.D. time points, (n=3). 
 
 
 
 
Figure 4.32: HPLC results of MatTek tissue exposed to amitriptyline for 30 min, 
24 h, B.I.D. and T.I.D. time points, (n=3). 
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Time 
points 
Amitriptyline concentration 
measured by HPLC µM 
Relative to applied   
concentration % 
30 min 40.46 89.5 
24 h 40.14 88.8 
 
Table 4.3: The results of HPLC (chemical analysis) of the in-house constructed 
tissue exposed to amitriptyline concentration (226 µm) for 30 min and 24 h time 
points, (n=2). 
 
 
 
 
 
Figure 4.33: HPLC findings of the in-house constructed model exposed to 
amitriptyline for 30 min and 24 h time points , n=2. 
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4.7 Discussion 
As a preclinical testing pathway for the drug development process, monolayer 
cell culture (2D) and its cellular assays are relatively inexpensive, fast and an 
accessible representation of the in vivo environment (Zou et al., 2007). 
Recently, however, concern has been expressed regarding the limitations of 2D 
cell culture as a model for the in vivo tissue environment. The introduction of a 
3D tissue model has, therefore, been suggested to be an appropriate, more 
sophisticated physiological substitute for both human in vivo environment and 
animal studies. This type of model gives advantage such as the possibility to 
study pathophysiology, treatment safety and prognosis with better in vivo 
expectations and less chance of misleading data as in 2D studies (Griffith and 
Naughton, 2002; Maltman and Przyborski, 2010). The introduction of the 3D 
tissue model to study the biocompatibility of many dental materials have found 
to be promising with an in vitro response found close to in vivo biological 
responses using 3D cell culture (Klausner et al., 2007; Moharamzadeh et al., 
2012). 
Unlike monolayer cell studies, 3D in vitro studies are more representative and 
realistic as a model for the in vivo environment, particularly regarding the inter-
cellular and cellular-matrix orientation and interaction (Maltman and Przyborski, 
2010). Different viability measures showed that the response of 3D cell culture 
is less negative when compared to 2D cell culture results. Viability reduction 
was about 50 % different and inflammatory cytokines levels were under 
expressed when same stimuli applied on 3D tissue models (Sun et al., 2006; 
Moharamzadeh et al., 2012). 
The viability assay used in this chapter is alamarBlue®, it demonstrates the 
cellular viability through chemical reduction of Resazurin. Using alamarBlue® 
has many advantages especially for the expensive, time consuming, type of cell 
culture as it did not affect the tissue or cellular integrity and this helps the 
researcher in being able to conduct further research and investigation on the 
same cell culture. This fact informed our decision to use alamarBlue® rather 
than a MTT assay, as we would lose the tissue for further downstream 
applications and just produce the viability measurement without having the 
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possibility of using the tissue for further designed investigations such as H&E 
staining, immunohistochemistry or immunofluorescence studies (Colley et al. 
2013).   
In the monolayer cell culture viability study, there is a pre-estimation experiment 
for exposure time and cell count to be employed for the viability study 
(Serotec®, 2015). However, that was difficult to apply in 3D tissue as using a 
group of tissues for estimation is rather expensive and time consuming, in 
addition, the seeding cell count at  the time of 3D tissue construction is the 
same but it is not necessary the same eventually, after the model completion. 
Accordingly, after amitriptyline exposure, 3D tissue was submitted for 
alamarBlue® test for 2 h and 6 h in in-house constructed and MatTek models 
respectively according to observation and previous studies (Colley et al. 2013). 
The amitriptyline concentration used was as determined by the research 
presented in Section 3.4. Time points implemented were 30 min and 24 h in 
both models (MatTek and in-house constructed) and repeated exposure [twice 
a day (B.I.D.) and three times a day (T.I.D.) for three days] in MatTek models 
only. The application of repeated exposure was designed to reflect the effect of 
repeated toxicity and to explore if there is a reversal toxicity as recommended in  
toxicity guidelines (EMA, 2010). The experiment time (3 days) was shorter than 
classic clinical course for neuropathic pain topical treatment (Lynch et al., 
2005b), but is limited to the expected 3D model shelf life according to  
manufacturer’s instructions (MatTek, 2015). The incorporation of repeated 
exposure time points was a key factor to build a better understanding of 
amitriptyline’s apoptotic effect, as high apoptotic activity was found compared 
with single time exposure.  
In the MatTek model, the tissue barrier integrity was investigated and approved 
using trans-epithelial electrical resistance (Klausner et al., 2007; MatTek, 2015). 
From the amitriptyline exposure observations, culture media did not pass readily 
through the tissue surface, so alamarBlue® solution needed more time to 
penetrate through the tissue superficial keratin layer and cellular layer to 
measure cellular viability. After amitriptyline exposure, the MatTek tissue 
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models were exposed to alamarBlue® for 6 h before plate reading and this was 
still within an optimum alamarBlue® protocol (4 h-8 h), (Serotec®, 2015).  
For the in-house constructed model, the alamarBlue® was exposed for 2 h as 
this was long enough to penetrate the whole tissue thickness (Colley et al., 
2013). The chemical barrier is less developed in the in-house constructed tissue 
and there was some shrinkage in the supporting collagen that affected the 
mechanical barrier integrity of the constructed tissue and eventually simplify 
media and amitriptyline passage through the tissue from tissue apical surface to 
lower chamber. 
Viability results for both tissues models showed a reduction in viability after 
repeated time points and 24 h time points in MatTek and in-house constructed 
models respectively, but these reductions were still non-significant compared 
with control. The results of 3D model constructed in Newcastle oral biology 
laboratory were non-significant for 30 min and 24h exposure time points similar 
to the results of MatTek model (Figure D.1). However, there was a significant 
difference in the B.I.D. time point in MatTek model but it this was a small 
reduction in viability compared to the control. This could be related to the type of 
assay which may be reduced by any part of tissue covering up the difference in 
viability especially if we are talking about short exposure; however, we still can 
find as in Figure 4.1, that reduction in viability occurred after repeated 
exposures (B.I.D. and T.I.D.) indicating that this may occur in the in vivo 
situation.  
Amitriptyline cytotoxicity was measured using LDH assay, which measures 
lactate dehydrogenase enzyme as representative of cell lysis. Cytotoxicity 
results in the conditioned media showed only a significant difference between 
treatment and control tissues at 24 h exposure time for the MatTek models. The 
results of in-house constructed model, showed a significant difference when 
compared to control at both time points (30 min and 24 h). The results of model 
constructed in Newcastle revealed significant difference at 30 min time point 
only (Figure D.2). LDH experiments did not reveal high toxicity may be due to 
the repeated washing after each exposure in the case of repeated time points of 
exposure might affect the expression of lactate dehydrogenase eventually in the 
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conditioned media. It does, however, appear that amitriptyline has a cytotoxic 
effect in both models.  
The variations in the readings between time points and tissues and between 
different colorimetric assays, dictate the need for further research with more 
robust findings in order to confirm or deny the risk to oral mucosa that 
amitriptyline represents when applied topically. The results also raise a question 
about the suitability of colorimetric assay for 3D tissue culture. Both methods 
do, however, indicate an effect of amitriptyline on 3D tissue culture and that it is 
potentially a negative effect. 
Amitriptyline’s effect on 3D tissue cellular construction was further investigated 
using H&E slides. Except for slight findings in the MatTek model at T.I.D. time 
point, H&E immunohistochemistry did not show any gross morphological 
changes, or severe damage through the treatment groups compared to the 
control images for both tissue types and all exposure time points.  
Amitriptyline has been found to cause disruption in mitochondrial membrane 
potential following increase of production of reactive oxygen species. The 
resulted activation of caspase 3 pathway is through release of cytochrome c 
that leads to mitochondrial mediated apoptosis (Green and Reed, 1998; Lirk et 
al., 2006a; Bautista-Ferrufino et al., 2011). Two types of anti-caspase 3 
antibody were used to investigate apoptotic activity resulting from amitriptyline 
exposure. The results showed an obvious apoptotic effect in the slide images. 
The amount of apoptotic activity in treated group in long exposure (24 h) and 
long-term exposure (B.I.D. and T.I.D.) was significantly higher compared to the 
control. These results demonstrate that the number of dead cells through 
apoptosis is increased with repeated exposure to the target drug. This is 
important as this process mirrors the clinical application procedure of the drug 
for chronic pain, requiring repeated exposure topical treatment. The results 
were significant in both tissue types in most exposure time and highest in the 
repeated exposure (B.I.D., T.I.D.) and long-time exposure (24 h).  
The MatTek model results were more consistent and potentially reliable through 
the investigations in this chapter. This may be related to the type of cells used 
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which were primary cells from healthy volunteers made using first or second 
passage. The cell line models used to construct the in-house model were from 
dysplastic samples where the cells behave in a more dysplastic way losing 
some of the normal gingival development and characteristics. In addition, the 
type of gingival cells (fibroblast cells) representing the supporting submucosa 
fibrous tissue, was less viable, causing slow reproducing and further shrinkage 
of the supported collagen.  
Previous studies that investigated post-amitriptyline exposure related nerve 
damage, were thoroughly approved using animal studies. In these studies, 
amitriptyline was applied directly onto the nerve trunk and using concentrations 
similar to those applied clinically in NP treatment course (Estebe and Myers, 
2004; Barnet et al., 2005; Lirk et al., 2006b). While many clinical trials have 
used higher concentrations, they did not report any epithelial or nerve damage. 
This raises the question about how amitriptyline is able to pass through the 
tissue, particularly with short exposure time points and how much of the drug is 
expected to reach the target nerve endings. Estebe and Myers (2004) reported 
that the detergent effect of amitriptyline caused irreversible nerve degeneration 
at concentrations higher than 0.3 %, (10 mM). However, clinical studies which 
applied amitriptyline topically with high concentration [1.5-10 %, (50-300 mM)] 
on skin and mucosa reported no signs of nerve degeneration; the only reported 
effect was a temporary inflammatory response (Padilla et al., 2000; Lynch et al., 
2005a; Dualé et al., 2008; Kopsky and Keppel Hesselink, 2012). 
Amitriptyline passage through the tissue was investigated in this work using 
chemical analysis (HPLC) and immunofluorescence investigation. The results 
showed the presence of the amitriptyline within the tissue at most of the time 
points using the anti-amitriptyline antibody, while results of chemical analysis of 
lower chamber amitriptyline concentrations were varied between MatTek and in-
house model.  
The in-house constructed tissue suffered a collagen shrinkage that affected the 
barrier characteristics of the tissue which is shown in the results, where 30 min 
and 24 h exposure results were the same. For the MatTek model, the HPLC 
results varied according to exposure time, negligible concentrations of 
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Amitriptyline were calculated after 30 min exposure while the 24 h exposure 
showed a higher rate of drug passage through the tissue, with the repeated 
exposure (B.I.D. and T.I.D.) results showing that the repeated exposure for 30 
min affected the tissue integrity and there may even be cellular death disrupting 
the barrier characteristics and integrity. The results show that there were no 
measurable changes in tissue and cellular morphology, but that amitriptyline still 
has the ability to penetrate through epithelial surface. More investigations are 
needed to disclose if the increase in penetration ability of amitriptyline is due to 
cellular death, change in the intercellular junction characteristics or both of 
them. 
The lipophilic affinity and para-cellular penetration characteristic of its tertiary 
amine structure (Sudoh et al., 2003) give the amitriptyline an adjuvant 
penetrative capacity. However this is not completely accurate, as amitriptyline 
passage after 30 min was negligible, but with more tissue integrity disruption as 
happened after repeated application, a higher concentration was found in the 
lower chamber. 
Dahlin et al. (1999) found that amitriptyline exposure affects cytoskeletal 
orientation and increases para-cellular permeability even at low amitriptyline 
concentrations, resulting in disruption of tight intercellular junction structure and 
function. In addition, we found (in Chapter 3) that amitriptyline exposure affects 
cellular morphology and attachment, and the collective cytoskeleton orientation 
of the monolayer cell culture. Further, in this chapter, repeated exposure of low 
concentrations (226 µM) at short time point (30 min) affected the intercellular 
tight junctions and increased tissue permeability, which may explain the 
increase in tissue permeability to amitriptyline at repeated exposure time points 
of exposure as found by HPLC.  
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Chapter: 5 The expression of peripheral 
receptors in human gingival tissue  
5.1 Introduction 
The complexity and the role of peripheral receptors in the pathophysiology of 
neuropathic pain has become of more importance given the recent expansion in 
research concerning topical management strategies in NOP (Padilla et al., 
2000; Merrill, 2004; Cairns, 2009b). Animal, in vitro and human functional 
studies (Doak and Sawynok, 1995; Sawynok and Liu, 2003; Hirai and Hama, 
2014), have been designed to decode the peripheral process of pain and to find 
possible changes in receptor expression and excitability to understand their role 
in pain pathophysiology. The studies examining receptor expression and 
excitability in chronic pain have revealed the function of a group of receptors 
and/or ion channels that are involved in orchestrating peripheral persistent pain 
and also other sensation changes such as hyperalgesia and allodynia. These 
sensory changes have been identified to associate with over and under 
excitation or expression of specific receptors, during different types of 
neuropathic pain (Sawynok, 2003; Sawynok et al., 2005; McGivern, 2009; 
Sawynok, 2009; Sessle, 2009). Topical administration of NMs in NOP, offers 
the opportunity to target these receptors, achieving a fast response and 
avoiding systemic route complications (Heir et al., 2008; McDougall, 2011; 
Haribabu et al., 2013; Casale and Mattia, 2014).  
For this preliminary study and as representative of trigeminal innervation, a 
single anonymous sample of human gingival tissue was analysed for genetic 
investigations of peripheral receptors. Ethical approval (Newcastle & North 
Tyneside 2 Ref 7/Q1003/41) and written consent was obtained before a gingival 
tissue biopsy was excised from the palatal area as part of a routine treatment 
plan for canine exposure for orthodontic treatment purposes. The tissue was 
kept directly in the RNAlater® (Ambion®, Paisley, UK), solution before further 
storage at -80 °C until the RNA extraction procedure (Section 2.13.2). The 
gingival tissue sample was used to investigate the expression at the mRNA 
level, of a group of receptors and ion channels identified as the most expected 
targets for the three investigated NMs in his study: amitriptyline, carbamazepine 
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and gabapentin. The expression of these receptors was also investigated in 
parallel mRNA extracted from a neuroblastoma cell line (SH-SY5Y). The results 
were further investigated in RNA extracted from an oral keratinocyte cell line 
model (OKF6-TERT1), to investigate whether there is cross expression 
between trigeminal nerve endings in the gingival biopsy and oral keratinocyte 
cells. 
The receptors of interest were identified after thorough literature search 
(Section 1.6). Oligonucleotide primers were designed using NCBI Blast package 
(Section 2.14.4) or ordered directly from commercially available oligonucleotide 
options (Life Technologies Ltd, UK). 
Standard reverse transcriptase (RT) procedure (Section 2.14) was used to 
prepare the complementary DNA (cDNA) samples from the gingival and SH-
SY5Y RNA samples. Expression of the target receptors’ genes was investigated 
using polymerase chain reaction (PCR) and specified primers. The results were 
visualised by gel electrophoresis (2.14.3) and all positive results were confirmed 
by sequencing services (Eurofins Genomics, UK). The selected targets for 
genetic investigations are shown in Table 5.1. 
A housekeeping gene (GAPDH) primer was also used to investigate the 
integrity of the cDNA samples and to ensure quality. The band expression was 
strong for the all samples indicating the cDNA was adequate. 
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Receptor type Gene  Phenotype Drug in action References supporting 
receptors’ inclusion 
Adenosine receptor ADORA2A Adenosine A2 receptor Amitriptyline 
 
Carbamazepine 
(Sawynok et al., 2005) 
 
(Lee and Abrahams, 2008) 
Glutamate receptors 
(NMDA channel) 
GRIN1 Glutamate ionotropic receptor NMDA type 
subunit 1 
Amitriptyline  
 
 
Carbamazepine 
(Cairns, 2009) 
 
 
(Hough et al., 1996) 
GRIN2A Glutamate ionotropic receptor NMDA type 
subunit 2A 
GRIN2B Glutamate ionotropic receptor NMDA type 
subunit 2B 
GRIN2C Glutamate ionotropic receptor NMDA type 
subunit 2C 
GRIN2D Glutamate ionotropic receptor NMDA type 
subunit 2D 
Sodium channels SCN3A Sodium channel, voltage-gated, type III, 
alpha subunit (Nav 1.3) 
Amitriptyline  
 
 
Carbamazepine 
 
(Esser and Sawynok, 1999) 
 
 
(Lee and Abrahams, 2008) 
SCN9A Sodium Channel, Voltage-Gated, Type IX, 
Alpha Subunit (Nav. 1.7) 
SCN11A Sodium Channel, Voltage-Gated, Type XI, 
Alpha Subunit (Nav 1.9) 
Calcium channels CACNA2D1 Calcium voltage-gated channel auxiliary 
subunit alpha2delta 1 
Gabapentin (Maneuf et al., 2006) 
 
Table 5.1: List of peripheral analgesic receptors for amitriptyline, carbamazepine and gabapentin were investigated in the gingival 
tissue and SH-SY5Y cell line samples at mRNA level using PCR standard technique.
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Table 5.2: Primers, sequences for all investigated receptors and ion channels. 
Subscript numbering refers to position of the primer on the gene. NCBI 
accession numbers included. * refers to commercial primers. 
 
Name and 
accession no. 
Primer sequence Length 
(bp) 
Annealing 
temp (°C) 
ADORA2A 
NM_001278497.1 
5’-809TCCCCTTTGCCATCACCATC828-‘3 
5’-1414AGTCGGGGCAGAAGAAAGTG1395-‘3 
606  58/60 
GRIN1 
NM_000832.6 
 
5’-1495AAGCCTCGAGGGTACCAGAT1511-‘3 
5’-1708TGCAAAAGCCGTAGCAACAC1689-‘3 
217 50, 51.9, 53.8, 
58 & 60 
GRIN1* 
NM_000832.6 
GGTCTGCAGGCTTCGCTCTAG 
GGCCCGGTCTTCCAGATGTT 
490 52.3 & 54.8 
GRIN2A 
NM_001134407.1 
5’-1123 GACAACAGCTTTGTGGGCTG1141-‘3 
5’-1337 TTGGGATGAGCTCCGTGTTC1356-‘3 
235 50, 51.9, 53.8, 
58 & 60 
GRIN2B* 
NM_000834.3 
5’-271 CTCTTCTGAGAACGAGCTCTGCT249-‘3 
5’-777 CTCACTTTGTCTGGCCTTGCTTTC753-‘3 
504 52.8 & 54.8 
GRIN2C* 
NM_000835.4 
CTCCAAGACCCAAGGCTGCTG 
ATGTGGCTCTCAGATGCCCTCTAG 
510 54.9 
GRIN2D 
NM_000836.2 
5’-643GTCCTTTGTAGCCGTGACCA662-‘3 
5’-1277TCCTGTCTCTGGTGAGGGAG1259-‘3 
635 50, 53.8, 56.1 
& 58 
GRIN1 
NM_000832.6 
 
5’-1495AAGCCTCGAGGGTACCAGAT1511-‘3 
5’-1708TGCAAAAGCCGTAGCAACAC1689-‘3 
217 50, 51.9, 53.8, 
58 & 60 
SCN3A 
NM_006922 
5’-3174 CATTTTTGCTGTGGTCGGCA 3193-‘3 
5’-3957 AGCTTGTTCACCTTCTCGGG3938-‘3 
784 54, 56.4/53.1 
SCN9A 
NM_002977.3 
5’-635 CCGTTTCAATGCCACACCTG645-‘3 
5’-1399GCTAAGAAGGCCCAGCTGAA1379-‘3 
758 51.1 
SCN11A 
NM_001287223.1 
5’-5824GCATCTTTGCCCTGGTAGGT834-‘3 
5’-1466GGCTGGTCTTTCCCAGACTC1447-‘3 
643 53.1 & 51.1 
CACNA2D1 
NM_000722.2 
 
5’-671AGGCAGCCAGAGGATAAAACC 692-‘3 
5’-991GATGTACCATGGTCTTCTGCG 970-‘3 
320 51.5/53.3 
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5.2 The results of genetic investigation 
Using the primers in Table 5.2, human gingival tissue and appropriate cell line 
(SH-SY5Y) were screened for the presence of the selected gene receptors by 
PCR at the mRNA level, results are discussed for each gene below. 
5.2.1 Adenosine receptors 
The expression of adenosine receptor, ADORA2A, at the mRNA level was 
investigated in the RNA extracted from human gingival tissue and SH-SY5Y cell 
line. Primers specific for adenosine A2A receptor were designed using NCBI 
Blast package, Table 5.2. A standard PCR (Section 2.14) was carried out at 
different annealing temperatures.  
Gel electrophoresis showed distinct bands representing PCR products of the 
receptors generated from both the gingival and SH-SY5Y samples of RNA, 
Figure 5.1. The PCR products identities were confirmed by sequencing services 
(Eurofins Genomics, UK) as Adenosine receptor A2A (ADORA2A, 
NM_001278497.1).  
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Figure 5.1: PCR products showing the presences of adenosine receptor 
(ADORA2A) in cDNA prepared from (A) Gingival tissue samples was observed 
at (58 and 60) °C only (lane 3&4), product was weakly expressed. (B) SH-SY5Y 
samples at a range of annealing temperatures investigated (50, 51.9, 53.8, 58 
and 60) °C shown in lane 1 to 5. In M, hyper ladder IV (Bioline, UK), sizes 
indicated. 
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5.2.2 N-methyl D-aspartate (NMDA) channel  
The NMDA ionotropic channel is the main ionotropic glutamate receptor. The 
NMDA1 and NMDA2 (A, B, C & D) subunits of NMDA channel were 
investigated as the most related NMDA channel subunits to peripheral 
analgesics in trigeminal area (Marvizon et al., 2002; Cairns, 2009a). The 
expression of NMDA1 subunit (GRIN1) and four types of NMDA2 subunit 
(GRIN2A, GRIN2B, GRIN2C and GRIN2D,Table 5.2) were investigated in the 
RNA extracted from gingival tissue and SH-SY5Y cell line. As cDNA was 
prepared from the gingival sample was at lower concentration than that from 
SH-SY5Y, thus further primers were purchased for GRIN1, GRIN2B, GRIN2C 
and GRIN2D from life technologies. 
GRIN1 
The primer designed in–house found to be useful in the SH-SY5Y sample only, 
Figure 5.2. Using the commercial primer revealed distinct bands in the gingival 
sample and weak expression in SH-SY5Y sample using standard gel 
electrophoresis procedure, (Figure 5.3). PCR products were confirmed by 
sequencing services (Eurofins Genomics, UK) for all results as GRIN1 
(NM_000832.6). 
GRIN2A 
Primer specific for NMDA subunit type 2A (GRIN2A) was designed and used in 
a standard RT-PCR procedure to prepare the cDNA for gel electrophoresis. 
A standard gel electrophoresis procedure showed distinct bands in gingival 
tissue sample only, without expression in the RNA from SH-SY5Y sample, 
Figure 5.4. The PCR products were further confirmed by sequencing services 
(Eurofins Genomics, UK) as GRIN2A (NM_001134407.1). 
GRIN2B 
The primer for NMDA subunit type 2B (GRIN2B) was purchased from Life 
Technologies Ltd, UK; Table 5.2. A standard PCR procedure was used to 
prepare the cDNA for gel electrophoresis. 
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The results of gel electrophoresis revealed expression of a distinct band in the 
gingival tissue sample only, Figure 5.5, and the results were further confirmed 
by Eurofins sequencing services as GRIN2B (NM_0.000834). 
GRIN2C 
The primer for NMDA subunit type 2C (GRIN2C) was purchased from Life 
Technologies Ltd, UK. A standard PCR procedure was used to prepare the 
cDNA for gel electrophoresis. 
Gel electrophoresis results identify band with gingival tissue sample only, Figure 
5.6. The result was confirmed as GRIN2C (NM_000835.4) using Eurofins 
sequencing service (Eurofins Genomics, UK). 
GRIN2D 
The primer for NMDA subunit type 2D (GRIN2D) was designed in-house and a 
cDNA was prepared using standard PCR technique. 
Gel electrophoresis results showed weak bands in SH-SY5Y samples only 
(Figure 5.7) and the results were confirmed by Eurofins sequencing services as 
GRIN2D (NM_000836.2). 
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Figure 5.2: PCR products showing the presences of NMDA1 subunit (GRIN1) in 
cDNA prepared from SH-SY5Y samples at all annealing temperatures 
investigated (50, 51.9, 53.8, 58 and 60 °C) shown in lane 1 to 5. In M, hyper 
ladder IV (Bioline, UK), sizes indicated. No expression was detected in gingival 
tissue sample. 
 
 
 
Figure 5.3: PCR products showing the presences of NMDA1 subunit (GRIN1) 
using commercial primer in cDNA prepared from human gingival tissue (lane 1: 
52.3 °C, lane 2: 54. 8 °C) and SH-SY5Y cell line (lane 3: 52.3 °C, lane 4: 54.8 
°C). In M, hyper ladder IV (Bioline, UK), sizes indicated. 
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Figure 5.4: PCR products showing the presences of NMDA 2A subunit 
(GRIN2A) in cDNA prepared from gingival tissue samples only at all annealing 
temperatures investigated (50, 51.9, 53.8, 58 and 60) °C shown in lane 1 to 5. 
In M, hyper ladder IV (Bioline, UK), sizes indicated. 
 
 
 
 
Figure 5.5: PCR products showing the presences of NMDA 2B subunit 
(GRIN2B) in cDNA prepared from gingival tissue samples only at annealing 
temperatures investigated (52.8 & 54.8) °C. In M, hyper ladder IV (Bioline, UK), 
sizes indicated. 
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Figure 5.6: PCR products showing weak expression of NMDA2 C subunit 
(GRIN2C, NM_000835.4) in cDNA prepared from gingival tissue samples only 
at annealing temperature investigated (54.9) °C. Housekeeping gene (GAPDH) 
observed at annealing temperature (58) °C. In M, hyper ladder IV (Bioline, UK), 
sizes indicated. 
 
 
 
Figure 5.7: PCR products showing weak expression of NMDA2 D subunit 
(GRIN2D, NM_000836.2) in cDNA prepared from SH-SY5Y cell line samples 
only at annealing temperature investigated (50, 53.8, 56.1 & 58) °C shown in 
lane 1 to 4. M, hyper ladder IV (Bioline, UK), sizes indicated. No expression was 
detected in gingival tissue sample. 
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5.2.3 Sodium channels 
Sodium channels are the main peripheral ion channel involved in pain 
transduction and are therefore a highly desirable target for topical NMs such as 
amitriptyline and carbamazepine in order to produce an analgesic effect. Among 
nine recognised types of sodium channels (Nav 1.1 to Nav 1.9), four only have 
been found to be connected to peripheral pain pathophysiology (Nav 1.3, Nav 
1.7 to Nav 1.9), (Cummins, 2009). The investigated sodium channels in this 
study were: Nav 1.3, Nav 1.7 and Nav 1.9. The primers were prepared using 
NCBI Blast package (Section 2.14.4), the resultant sequence, product size and 
annealing temperature are shown in Table 5.2. 
The expression of the Nav 1.3, 1.7 and 1.9 sodium channels (SCN3A, SCN9A 
and SCN11A respectively) were investigated in gingival tissue and SH-SY5Y 
RNA samples. Gel electrophoresis results showed distinct bands in both RNA 
extracted from gingival tissue (Figure 5.8) and SH-SY5Y cell line (Figure 5.9) for 
SCN3A products and the results identity were identified by Eurofins sequencing 
service (Eurofins Genomics, UK) as SCN3A (NM_006922). SCN9A was only 
expressed in SH-SY5Y sample (Figure 5.9) and for SCN11A, the expression at 
very low level was detected in SH-SY5Y samples only. Both results were 
identified as SCN9A (NM_002976.3) and SCN11A (NM_002976.3) using 
sequencing service. 
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Figure 5.8: PCR products showing the expression of Nav 1.3 sodium channel 
(SCN3A) in cDNA prepared from gingival tissue samples at annealing 
temperature investigated (54) °C. The housekeeping gene (GAPDH) expressed 
at annealing temperature (58) °C. In M, hyper ladder IV (Bioline, UK), sizes 
indicated. 
 
 
 
 
Figure 5.9: PCR products in cDNA prepared from SH-SY5Y samples showing 
the expression of Nav 1.3 (SCN3A) at annealing temperatures (56.4/53.1) °C 
shown in lane 1&2, Nav 1.7 (SCN9A) at annealing temperature (51.1) °C shown 
in lane 3 and weak expression of Nav 1.9 (SCN11A) at annealing temperatures 
(53.1/51.1) °C shown in lane 4&5. In M, hyper ladder IV (Bioline, UK), sizes 
indicated. 
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5.2.4 Calcium channel 
The analgesic action of the anticonvulsant gabapentin is ligand to the blocking 
of calcium channel subunit α2δ-1. The primer of the calcium channel auxiliary 
subunit α2δ-1 (CACNA2D1) was designed in-house, Table 5.2. A standard PCR 
procedure was used to prepare the cDNA for gel electrophoresis.  
The gel electrophoresis results showed distinct bands in both the RNA from 
gingival tissue samples and SH-SY5Y samples, Figure 5.10. The results were 
confirmed by sequencing services as CACNA2D1 (NM_000722.2). 
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Figure 5.10: PCR products showing the expression of Ca α2δ-1 (CACNA2D1) in 
cDNA prepared from (A) Gingival tissue samples at annealing temperatures 
investigated (51.5 & 53.3) °C. The Housekeeping gene (GAPDH) expressed at 
annealing temperature (58) °C shown in lane 3. (B) SH-SY5Y samples at 
annealing temperatures (51.5) °C. The Housekeeping gene (GAPDH) 
expressed at annealing temperature (58) °C. In M, hyper ladder IV (Bioline, 
UK), sizes indicated 
 
 
 
 
B 
B 
A 
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5.3 Semi-quantification of receptors expressed in human gingival RNA 
The expression level of genes found to be expressed in the gingival tissue 
samples were semi-quantitatively assessed in relation to the housekeeping 
gene (GAPDH) expression in gingival tissue RNA. Although these results are 
from one biological sample, for semi-quantities analysis, three technical 
replicates were analysed using gene tools software (SYNGENE, Frederik, 
USA). The results showed a high level of expression of the glutamate receptor 
NMDA2A (GRIN2A) and the lower levels of expression for NMDA1 (GRIN1) 
Figure 5.11, but with wide standard errors. 
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Figure 5.11: Relative expression level of receptors (ADORA2A, GRIN1, 
GRIN2A, GRIN2B, GTGRIN2C, SCN3A and CACNA2D1)  in gingival tissue 
sample results to the housekeeping gene (GAPDH) expression in the same 
sample using gene tools software (SYNGENE, Frederik, USA), (SE+ mean, n=3 
replicate).  
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5.4 Expression of receptors identified in human gingival tissue RNA in 
oral keratinocyte cells  
The set of genes found to be expressed in gingival tissue sample were also 
investigated at the mRNA level in oral keratinocyte cells (OKF6-TERT1), (Table 
5.3). The gel electrophoresis results revealed the expression of the NMDA 
subunits genes (GRIN1, GRIN2A, GRIN2B & GRIN2C) in the OKF6-TERT1 
sample, but no expression of ADORA2A, SCN3A, and CACNA2D1 receptors 
were identified, Figure 5.12. The results were confirmed by sequencing service. 
 
 
Investigated 
genes 
Human gingival 
tissue 
Neuroblastoma 
cell line (SH-
SY5Y)  
Oral keratinocyte 
cell line (OKF6-
TERT1) 
ADORA2A × ×  
GRIN1 × × × 
GRIN2A ×  × 
GRIN2B ×  × 
GRIN2C ×  × 
GRIN2D  × Not tested 
SCN3A × ×  
SCN9A  × Not tested 
SCN11A  × Not tested 
CACNA2D1 × ×  
    
Table 5.3: List of the all investigated and expressed genes in the three samples: 
Human gingival tissue, SH-SY5Y neuroblastoma cell line and OKF6-TER1 oral 
keratinocyte cell line. 
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Figure 5.12: PCR products showing the expression of the all investigated genes 
in (A): cDNA prepared from OKF6-TER1 cell line, at annealing temperatures 
investigated 53.4 °C for: 1: GRIN2A, 4: GRIN1, 5: GRIN2B, 6: GRIN2C. With 
housekeeping gene expression shown at lane 8 (GAPDH, 58 °C). (B) cDNA 
prepared from gingival tissue sample, at annealing temperatures investigated 
53.4 °C for: 1: GRIN2A, 2: ADORA2A, 3: CAA2D, 4: GRIN1, 5: GRIN2B, 6: 
GRIN2C, 7: SCM3A, and 8: housekeeping gene (GAPDH) at 58 °C annealing 
temperature.  In M, hyper ladder IV (Bioline, UK), sizes indicated. 
A 
B 
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5.5 DISCUSSION 
The apparent safety of topical treatment along with the concept of the presence 
of key peripheral nervous system receptors has escalated the prescription and 
compounding of the topical neuromodulatory treatments (Sawynok, 2003; 
Baron, 2006; Mick et al., 2011). The crucial role of peripheral receptors and ion 
channels in the pathophysiology of neuropathic pain have been investigated 
and reported in many in vitro, animal and human functional studies (Hirai and 
Hama, 2014). However, these studies have their limitations for example: these 
studies used an acute model of pain as a representative model of chronic in 
vivo human conditions; and in functional studies there is great subjectivity 
(Blackburn-Munro, 2004; Mogil, 2009). This results in knowledge shortages and 
necessitate more advance human based studies to fulfil the need of a greater 
understanding of neuropathic pain pathophysiology, for better treatment choices 
(Micó et al., 2006).  
This study was designed as a preliminary investigation into the types of 
peripheral receptor expressed in the human gingival tissue, as a human tissue 
that is likely to be representative of peripheral trigeminal sensory innervation. 
These preliminary results should help in designing longer and more thorough 
molecular studies, investigating the expression and the role of these receptors 
in NOP and the most suitable topical medication for the management of PNP. 
The selection of receptors was based upon the three NMs (amitriptyline, 
carbamazepine and gabapentin) used and their peripheral analgesic pathway. 
This was a targeted approach, using only one human gingival sample, and not 
all receptors and ion channels were represented.  
The Adenosine receptors are expected to be a typical target for the peripheral 
acting NMs, such as amitriptyline and carbamazepine (Sawynok et al., 1999; 
Sawynok et al., 2005; Micó et al., 2006; Lee and Abrahams, 2008). Two types 
of adenosine receptors (A1, A2A) are suggested to be expressed peripherally 
on both type of nerve endings: the myelinated (Aδ–fibers) and unmyelinated (C-
fibers) (Sawynok, 2009). This genetic expression investigation showed the 
expression of A2A receptor (ADORA2A) at mRNA level in both gingival tissue 
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and SH-SY5Y samples. However, the investigations did not reveal adenosine 
receptor A1 expression in both gingival tissue and (SH-SY5Y) samples. The 
results of this exploring investigation indicate that ADORA2A might be involved 
in adenosine mediated analgesic process induced by NMs topical action. 
The prevention of glutamate action, the main excitatory amino acid, would 
induce analgesic action in the target site; the limitations of glutamate receptor 
(NMDA channel) antagonists did not limit the clinical and animal trials using 
different medications such as amitriptyline (Ushida et al., 2002; Lynch et al., 
2005b; Cairns, 2009a; Mercadante, 2015). The expression of NMDA ionotropic 
channel subunits (NMDA 1, NMDA 2 A, B, C& D) subunits was investigated in 
both the gingival tissue and SH-SY5Y samples. With exception of the NMDA2D 
(GRIN2D) subunit, the results showed the expression of three subunits 
(GRIN2A, GRIN2B & GRIN2C) in gingival tissue samples only, while NMDA1 
(GRIN1) was expressed in both. The expression of NMDA receptor subunits 
may justify the topical analgesic action of NMs such as amitriptyline and 
carbamazepine. 
Sodium channels are typical targets for the peripheral analgesic agents such as 
local anaesthetics, in addition to the affinity of tricyclic antidepressants 
(amitriptyline) and anticonvulsants (carbamazepine) for sodium channels. The 
levels of expression of sodium channels investigated in this Chapter (Nav 1.3, 7 
& 9) were relatively low or not detected in the gingival tissue sample. Their 
expression might have been affected by the local anaesthetics which was used 
in the surgical excision procedure to obtain the sample. Conversely, in SH-
SY5Y samples, the levels of expression of all the sodium channels were 
relatively high. This area needs further examination and it may be possible to 
obtain samples where general, rather than local, anaesthesia has been used 
thereby removing the potential confounding influence of local anaesthesia. Our 
preliminary results for receptor expression should therefore be subject cautious 
interpretation and require further confirmation from a wider selection and 
number of samples including unattached and attached gingiva from elsewhere 
in the oral cavity. 
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The increased evidence of correlation between expression and upregulation of 
the calcium channel α2δ-1 subunit during neuropathic pain, makes it as a good 
target for the peripheral analgesic effect (Maneuf et al., 2006; Li et al., 2014). 
Anticonvulsants such as gabapentin have affinity for calcium channel α2δ-1 
subunit, inducing the analgesic by blocking pain perception, propagation and 
decreasing neurotransmitter release (McGivern, 2009). The gel electrophoresis 
and gene sequencing showed the expression of the calcium channel α2δ-1 
(CACNA2D1) subunit in gingival tissue as well as cell line sample (SH-SY5Y), 
indicating this could be the site of action for gabapentin topical treatments. 
The semi-quantitative assessment of the expressed genes comparing to the 
house keeping gene (GAPDH) expression, showed the higher expression was 
belong to the glutamate receptor subunit (GRIN2A). This is the results of one 
sample, it could be a recognised possibility, but further work may be by 
including more samples and/or growing cells in vitro to measure how the 
expression of these receptors would be affected by topical treatment exposure.  
The full thickness gingival tissue sample is not merely representative of 
trigeminal nerve ending, as the main histological component is epithelial 
keratinocyte cells. To identify if there is a cross expression in non-neuronal cells 
such as oral keratinocytes cells, the genes found to be expressed in the gingival 
biopsy samples were also investigated in the oral keratinocyte cell line (OKF6-
TERT1) RNA. The results of gel electrophoresis and sequencing showed the 
expression of the all glutamate receptor (NMDA) subunit in the OKF6-TERT1 
samples (GRIN1, GRIN2A, GRIN2B & GRIN2C). This may indicate that the 
expressed NMDA receptors are related to the keratinocytes’ part of the gingival 
tissue. The expression of NMDA channel subunits on keratinocyte cell lines 
were previously reported, however, investigation of the glutamate receptors and 
all other expressed genes would need more thorough immunohistochemistry 
studies to recognise the expression site of these receptors and their role as 
possible targets in peripheral analgesic modality (Skerry and Genever, 2001; 
Nahm et al., 2004).  
The results from one human gingival biopsy using a target gene expression 
approach, showed the expression of most peripheral targets for topical NMs 
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analgesics investigated in this study. This was a preliminary study using a 
human sample with genetic investigation. The results would help in designing a 
thorough study and employing more human samples. The possibility of 
employing a patient samples may be limited by the nature of the disease and 
the difficulty of surgical intervention in patients already suffering with chances of 
more nerve damage, however, skin biopsy employment is approved in 
peripheral neuropathy studies with possibility of various investigations to be 
applied (Cruccu et al., 2010; Brouwer et al., 2015). 
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Chapter 6: Summary, conclusions and future work 
6.1 Summary 
The use of topical NMs is off-label treatment; that is compounded and 
prescribed “outside of the terms of their licence” (GMC, 2015) according to 
patient needs (FDA, 2015a). The topical NMs are already approved as systemic 
medications, but no topical route has been licenced. Interest has increased in 
topical NMs, because they potentially offer relief of NOP with less side effects 
which hopefully improves patient adherence and satisfaction. This study was 
designed to investigate the safety of these drugs applied topically modality and 
the existence of essential receptors that justify their topical application and 
analgesic action. 
In the first group of investigations, the effects of three commonly prescribed 
NMs (amitriptyline, carbamazepine and gabapentin) were tested on a two-
dimensional (2D) monolayer cell culture. Four assays were carried out: cellular 
viability, count, morphology and inflammatory cytokine expression. The in vivo 
clinical application and regimen for these topical treatments was considered in 
the design of the monolayer studies. Specifically we sought to emulate the 
dosing regimen and exposure times likely to be realistic in the clinical 
application of the drug.  
Both amitriptyline concentrations (200 µM, 1.8 mM), caused a significant 
reduction in the cellular viability and cell counts were less than 10 % of the 
original seeding count after the long time point exposure (24 h) in the 2D model. 
Alongside the findings from SEM, which included shrinkage and loss of 
attachment, these viability and cell count results helped confirmed that 
amitriptyline was cytotoxic in 2D monolayer cell culture.  
The two anti-convulsants (carbamazepine and gabapentin) were less cytotoxic 
than amitriptyline in the 2D monolayer cell culture. The cytotoxicity and anti-
proliferative effects of carbamazepine occurred at high concentrations (1.7 mM) 
and long exposure time (24 h) with minor morphological changes. Gabapentin 
appeared to be the least cytotoxic of all three agents and no changes were 
apparent on SEM either. All three NMs tested appeared not to significantly 
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affect cytokine expression, but this result may be related to the short exposure 
time (30 min) and examination method used. The key finding of the monolayer 
cell culture study is that amitriptyline was cytotoxic even with low concentration 
and short exposure time. The cells used in this chapter are relevant to the 
orofacial tissue of interest, however, the in vivo environment is more 
complicated to be fairly represented by monolayer cell culture.  
So Despite these seemingly definitive findings it was necessary to examine 
them further and see if they were validated in a model that was more 
representative of the in vivo tissue, a 3D tissue model (Maltman and Przyborski, 
2010). The cells used in both models are primary cells as in MatTek model and 
cell line as in in-house constructed model. 
The type of 3D tissue culture gave the opportunity to investigate viability and to 
design more robust and representative experiments as in apoptosis 
investigation using anti-caspase 3 antibodies and inspect amitriptyline passage 
through the tissue. 
The same viability assay was used in 3D model investigations (alamarBlue®) as 
in the monolayer cell culture. In addition, however, a different colorimetric assay 
to measure cytotoxicity parameter (LDH) was also employed. The type of 
culture in a 3D model (liquid air interface) also gave the opportunity for 
additional investigations and the employment of different time points (repeated 
exposure time points: B.I.D. and T.I.D.) in addition to those time points 
previously tested in the 2D monolayer cell culture (30 min and 24 h). The 
application of these repeated exposure time points facilitated the examination of 
any possible reversible toxicity and allowed for a better simulation of the clinical 
environment (EMA, 2010). 
Both colorimetric results in the 3D model showed reduced viability and 
increased toxicity after amitriptyline exposure. The effect of amitriptyline on the 
3D model was further investigated using H&E staining and two types of anti-
caspase 3 antibodies to investigate any apoptotic activity of amitriptyline (Green 
and Reed, 1998; Lirk et al., 2006a; Bautista-Ferrufino et al., 2011). H&E 
investigations did not demonstrate any gross structural changes following 
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Amitriptyline exposure. Apoptotic investigations showed that amitriptyline 
exposure was associated with an increase in apoptotic activity, especially with 
repeated exposure (B.I.D. and T.I.D.) in MatTek model and long time exposure 
(24 h) in both MatTek and in-house constructed models. 
Despite it was only repeated short exposure (30 min) of low concentration of 
amitriptyline (226 µM), the apoptosis incidence gave a strong evidence of 
amitriptyline toxicity, and clinical avoidance is advisable especially with long 
term clinical application. 
Given the expected short (30 min) clinical exposure of topical amitriptyline to 
oral tissues, its passage through such tissue was also questionable. 3D tissue 
culture was used to investigate the passage of amitriptyline using chemical 
analysis (HPLC) and immunofluorescence investigation (anti-amitriptyline anti 
body). The results of both assays revealed the presence and passage of 
amitriptyline through tissue after short application time.  
The results of 3D model revealed that: amitriptyline has strong apoptotic activity 
even though only short repeated exposure times were employed; amitriptyline 
does move through the tissues after short periods of repeated application and 
this is related to amitriptyline’s apoptotic activity and chemical structure. 
However, the 3D model used in this study is representing oral gingival tissue 
only, and investigating amitriptyline’s apoptotic effect on skin 3D tissue is 
necessary.  
Developing the 3D model and using it in this study gave more representative 
and robust results regarding in vivo environment reproduction. This type of 
culture will help to decrease expenses of commercial model and could be 
modified to perform different type of in vivo investigations. 
The presence of specific peripheral receptors and ion channels, as therapeutic 
targets for any of the topically applied NMs, is essential for them to exert any 
non-placebo analgesic mechanism. The goal of using a human gingival biopsy 
was to investigate the expression of these receptors and ion channels in 
orofacial tissue. The preliminary genetic investigation in this thesis 
demonstrated the expression of most of the desired receptors in relation to the 
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analgesic mechanism of the investigated NMs. In spite of the limitation of a 
single sample, the preliminary results in this thesis are encouraging and future 
studies using more sophisticated examination modalities are required to further 
investigate this. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
203 
 
6.2 Conclusions 
This in vitro study was designed to define the responses of range of cells and 
tissue to pharmacological concentrations of a group of medications (NMs) 
frequently reported to be applied topically for neuropathic pain treatment. The 
medications are: amitriptyline, carbamazepine and gabapentin. 
The first objective of this thesis was to define the effect of the tested NMs on 
monolayer cell culture viability, count and morphology with inflammatory 
cytokine profile investigation. The results showed a high toxic effect of 
amitriptyline on cellular viability, count and morphology in all cell lines.  
Carbamazepine showed minor morphological changes. Reduction in viability 
and count associated mainly with high concentrations of carbamazepine. 
Gabapentin presented lesser toxic effect without morphological and major cell 
count negative effects. The inflammatory cytokine expression did not change 
significantly in response to the exposure of the three NMs. 
The second objective was to use 3D model cell culture to investigate the effect 
of amitriptyline on viability, cytotoxicity, tissue morphological changes and 
apoptosis activity, in addition to examining the passage of amitriptyline through 
3D tissue. The results of viability, cytotoxicity and morphological changes in the 
3D model revealed the cytotoxic effect of amitriptyline, but these results were 
not definitive. The investigation of apoptosis in the 3D model showed a high 
apoptotic activity through 3D tissue layers in response to repeated exposure of 
amitriptyline. The results of 3D tissue showed the ability of the topical 
amitriptyline to infiltrate through tissue barriers. 
The final objective was a preliminary genetic study, designed to explore the 
expression of the peripheral receptors in the orofacial tissue. The results of the 
genetic investigation revealed the expression of the most investigated genes 
related to the suggested analgesic pathway of the three NMs.  
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6.3 Future work 
6.3.1 For in vitro studies: 
1- Examining the cytotoxicity of more known compounded topical 
treatments used such as baclofen, clonidine and clonazepam. 
2- Using neuronal tissue such as SH-SY5Y to investigate the effect of three 
NMs on the expression of peripheral receptors. 
3- Using the 3D tissue model to study the passage of the NMs that have 
been identified as less cytotoxic (carbamazepine and gabapentin) in 2D 
models.  
4- Investing more time in constructing a 3D model using human primary 
cells and implanting a neuron cell within full thickness 3D tissue. This 
model would help to understand at short term, what types of changes 
would occur after the application of NMs. 
5- Examining the change in inflammatory cytokine profile in response to 
NMs exposure using a different and more sensitive method such as 
ELISA. 
6- Using skin 3D tissue model to investigate the apoptotic effect of 
amitriptyline. 
6.3.2 For animal studies: 
1- Animal models could be used to study the cytotoxicity of low 
concentration of carbamazepine and amitriptyline, before suggesting a 
clinical study. 
2- Topical application of NMs in animal model will give the opportunity to 
study the change in expression of peripheral receptors using 
immunohistochemistry and genetic investigations. NOP might be induced 
in the animal model to study the differences in expression by using 
different pain models and application types (including: before and after 
treatment and control models). 
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6.3.3 For human studies 
Human samples could also be used to investigate the changes in expression 
and structure of the peripheral receptors in relation to the pathophysiology of 
NOP, but despite other areas receiving ethical approval (for example 
dermatological samples for peripheral neuropathy (Cruccu et al., 2010; Nolano 
et al., 2013)) this raises some difficult ethical problems such as the need for 
invasive surgery to obtain the samples in patients whose nervous systems are 
already at least peripherally sensitised. It may be that with advances in less 
invasive techniques such as brush biopsies and advances in 
immunohistochemical techniques this may become possible in future years 
without the need to subject patients to surgery. If advances are made it would 
offer the opportunity for various investigations and the results are likely to be 
more representative than animal and in vitro findings.  
The other possible method of getting human samples is the human post mortem 
tissue and fluids related to the orofacial pain. These samples would offer an 
opportunity to investigate the effect of the prescribed treatment on the 
pathophysiology of NOP especially with the availability of clinical records.  
6.3.4 For clinical studies 
The results of this in vitro study revealed the safety of gabapentin as a topical 
treatment that may help to design a clinical trial using gabapentin as a 
compounded topical treatment in management of NOP. The anticonvulsant 
gabapentin was found useful in management of different NP such as PHN and 
posttraumatic neuropathic pain. A low cost double blind N-of-1 trial for patient 
with localised NOP pain could be designed. It is helpful to compare topical 
gabapentin effect with placebo or other treatment, in which treatment effect 
could be easily validated by visual analog scale (VAS) or quantitative sensory 
testing (QST). 
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Appendix B: Cumulative viability results in 3T3, HaCat and OKF6-TERT1 cell lines 
 
Figure B.1: Cellular viability of HaCat cells exposed to different concentrations of carbamazepine (CBZ), measured using 
alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.2: Cellular viability of HaCat cells exposed to different concentrations of gabapentin (GAB), measured using alamarBlue®. 
Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.3: Cellular viability of HaCat cells exposed to different concentrations of amitriptyline (AMI), measured using alamarBlue®. 
Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.4: Cellular viability of OKF6-TERT1 cells exposed to different concentrations of carbamazepine (CBZ), measured using 
alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.5: Cellular viability of OKF6-TERT1 cells exposed to different concentrations of gabapentin (GAB), measured using 
alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.6: Cellular viability of OKF6-TERT1 cells exposed to different concentrations of amitriptyline (AMI), measured using 
alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.7: Cellular viability of 3T3 cells exposed to different concentrations of carbamazepine (CBZ), measured using 
alamarBlue®. Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.8: Cellular viability of 3T3 cells exposed to different concentrations of gabapentin (GAB), measured using alamarBlue®. 
Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Figure B.9: Cellular viability of 3T3 cells exposed to different concentrations of amitriptyline (AMI), measured using alamarBlue®. 
Mean values + SE (n=8) are shown for each experiment. Compared with untreated control cells (black dotted line). 
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Appendix C: SEM results of 3T3 cells were exposed to NMs 
 
 
Figure C.1: SEM images at 100 X AND 1000 X magnification of 3T3 cells after 30 
min exposure to amitriptyline (AMI), carbamazepine (CBZ) and gabapentin (GAB) at 
concentrations determined by HPLC.
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Appendix D: Viability and cytotoxicity results of in-house constructed (Newcastle) 3D model  
 
Figure D.1: Cellular viability of the in-house constructed 3D tissue (Newcastle models) was measured using alamarBlue®, exposed 
to amitriptyline (226 µM) at 30 min, 24 h time points. Mean values + SE (n=3) are shown for each experiment compared with 
untreated control cells (black dotted line) by parametric independent t- test, *p>0.05. 
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Figure D.2: Cytotoxicity results of the in-house constructed 3D tissue (Newcastle models) were exposed to AMI (amitriptyline), (226 
µM) for 30 min, 24 h. Mean values + SE (n=3) are shown for each experiment after were normalised to control results. Compared 
with control results at the same time points by non-parametric independent t-test, * p<0.05. 
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Appendix E : Publications and conference participations 
 
1- Paper in press: 
 
Al-Musawi, M., Durham, J., Whitworth, J.M., Stone, S.J., Nixdorf, D.R. 
and Valentine, R.A. (2016) 'Effect of topical neuromodulatory 
medications on oral and skin keratinocytes', J Oral Pathol Med. 
 
2- Conference poster presentation/ ICOT 2013 
 
Al-Musawi, M., Durham, J., Whitworth, J.M., Stone, S.J. and Valentine, 
R.A.: In vitro toxicity of Amitriptyline used as a topical agent in 
neuropathic orofacial pain. 
 
3- Conference poster presentation/ IADR Boston 2015 
 
Al-Musawi, M., Durham, J., Whitworth, J.M., Stone, S.J. and Valentine, 
R.A: In Vitro Effects of Topical Neuromodulatory Medication on Orofacial 
Tissue. Published abstract. 
 
4- Conference poster presentation/ IADR Seoul 2016 
 
Al-Musawi, M., Durham, J., Whitworth, J.M., Stone, S.J., Nixdorf, D.R. 
and Valentine, R.A.: Is Amitriptyline Safe as Topical Treatment for 
Neuropathic Orofacial Pain? In Press. 
Prizes: 
1- Poster prize at the quadrennial International Conference for Orofacial 
Pain and Temporomandibular disorders, ICOT/AAOP 2013. 
 
2- 3rd Wiley-Blackwell Young Investigator Award in Neuroscience, IADR 
Boston 2015. 
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